[{"question_number":"6","question":"In the same scenario as the previous question, but with a computed tomography (CT) angiogram not attached, what is the best treatment to achieve full recanalization?","options":["IV tPA","IV heparin","Aspirin and Plavix","IV tPA followed by mechanical thrombectomy ## Page 6"],"correct_answer":"D","correct_answer_text":"IV tPA followed by mechanical thrombectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is D: IV tPA (alteplase) followed by mechanical thrombectomy. Randomized trials (MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME) demonstrated that combining IV alteplase with endovascular thrombectomy in large vessel occlusion (LVO) yields highest rates of complete recanalization (modified TICI 2b/3 in >80% vs ~60% with thrombectomy alone) and improved functional outcomes (90-day mRS 0-2 improved by absolute 20\u201325%, NNT \u2248 4). Option A (IV tPA alone) achieves recanalization rates of only 30\u201340% in LVO. Option B (IV heparin) is not recommended in acute ischemic stroke due to increased hemorrhage risk and no benefit (TOAST guidelines class III). Option C (dual antiplatelet therapy) is for minor non-cardioembolic strokes (CHANCE, POINT trials), not acute LVO. Thus, D is the evidence-based best approach for full recanalization in LVO.","conceptual_foundation":"Acute ischemic stroke classification is based on TOAST criteria: large artery atherosclerosis causing LVO falls under the first category. Embryologically, large cerebral vessels derive from neural crest\u2013associated mesenchyme and branchial arch arteries. The arterial supply to the anterior circulation involves the internal carotid and its branches (M1, M2 segments), while collateral flow arises from leptomeningeal anastomoses. Alteplase is a serine protease that catalyzes plasminogen to plasmin, dissolving fibrin. Mechanical thrombectomy engages stent retrievers or aspiration catheters directly at the clot. The molecular target of alteplase is fibrin-bound plasminogen with higher affinity than circulating plasminogen, reducing systemic bleeding risk.  ","pathophysiology":"Normal hemostasis balances clot formation and fibrinolysis. In LVO, plaque rupture or embolism occludes large cerebral arteries, causing focal ischemia. Without reperfusion, intracellular calcium overload triggers excitotoxicity, free radical generation, BBB breakdown, and infarction. IV alteplase accelerates clot dissolution by converting plasminogen to plasmin, restoring microvascular flow. Mechanical thrombectomy physically removes the thrombus from the arterial lumen, rapidly reestablishing perfusion to ischemic penumbra, halting infarct progression. Compared to tPA alone, combined therapy addresses both fibrin-rich thrombi (tPA) and platelet-rich clots or those resistant to lysis (thrombectomy).","clinical_manifestation":"Patients present with acute focal deficits: hemiparesis, hemisensory loss, aphasia (dominant hemisphere), or hemineglect (non-dominant). LVO typically has NIHSS \u2265 8\u201315. Time window for IV tPA is 4.5 hours; for thrombectomy up to 6 hours (DAWN, DEFUSE-3 extend to 16\u201324 hours with imaging selection). Incomplete recanalization results in persistent deficits; timely dual therapy improves functional independence at 90 days (mRS 0\u20132 in 46% vs 26% with medical therapy alone).","diagnostic_approach":"Immediate noncontrast CT to exclude hemorrhage (sensitivity ~99%, specificity ~90%). CT angiography confirms LVO with sensitivity 95% and specificity 93%. CT perfusion identifies penumbra/core mismatch. Pre-tPA laboratories include glucose, platelets, INR. Post-imaging door-to-needle \u226460 minutes (AHA/ASA Class I, Level B-R).","management_principles":"Administer IV alteplase 0.9 mg/kg (max 90 mg) with 10% bolus then infusion over 1 hour. Initiate thrombectomy if CTA shows proximal anterior circulation occlusion within window and NIHSS \u22656 (Class I, Level A). Monitor BP <180/105 mmHg. Avoid antithrombotics for 24 hours post-tPA.","follow_up_guidelines":"Neurochecks every 15 min \u00d72h, every 30 min \u00d76h, hourly until 24h. Repeat CT if neurological deterioration. Initiate secondary prevention: high-intensity statin, manage BP, diabetes. Rehabilitation planning begins early.","clinical_pearls":"1. In LVO, combined IV tPA + thrombectomy yields best outcomes (NNT=2\u20134). 2. Door-to-needle \u226460 min improves functional recovery. 3. CT perfusion can safely extend thrombectomy window to 24h in selected patients. 4. Avoid heparin in acute stroke\u2014no benefit, increased hemorrhage. 5. Persistent hemiplegia despite reperfusion may reflect malignant edema\u2014monitor and manage ICP.","references":"1. Berkhemer OA et al. MR CLEAN Investigators. N Engl J Med. 2015;372(1):11-20. doi:10.1056/NEJMoa1411587\n2. Goyal M et al. ESCAPE Trial Investigators. N Engl J Med. 2015;372(24):2326-36. doi:10.1056/NEJMoa1414888\n3. Campbell BC et al. EXTEND-IA Investigators. N Engl J Med. 2015;372(11):1009-18. doi:10.1056/NEJMoa1414792\n4. Saver JL et al. SWIFT PRIME Investigators. N Engl J Med. 2015;372(24):2285-95. doi:10.1056/NEJMoa1415120\n5. Powers WJ et al. 2018 Guidelines. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A patient had head trauma and developed spontaneous perimesencephalic subarachnoid hemorrhage (SAH) 10 days later. After two digital subtraction imaging studies two weeks apart, which were unremarkable, what is the appropriate management?","options":["Send him home with follow-up in the clinic","Repeat digital subtraction imaging","MR angiography","CT angiography"],"correct_answer":"A","correct_answer_text":"Send him home with follow-up in the clinic","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Perimesencephalic SAH with two negative digital subtraction angiographies (DSAs) has a benign course. International series (Rinkel et al. 1991; van Gijn et al. 2006) show <1% rebleed risk and no underlying aneurysm. After two negative DSAs, no further vascular imaging is required; outpatient follow-up suffices (AHA/ASA 2012). Repeating DSA (Option B) or advanced imaging (C, D) exposes patients to procedural risks without benefit.","conceptual_foundation":"Perimesencephalic SAH is classified under non\u2010aneurysmal SAH in ICD-11. Blood localizes around the midbrain cisterns without intraparenchymal extension. Embryologically, the perimesencephalic cistern derives from the basal part of the subarachnoid space. Epidemiologically, 5\u201310% of all SAH. Differential includes aneurysmal SAH, venous sinus thrombosis, cavernous malformation bleeding.","pathophysiology":"Venous hemorrhage from small perforators around the mesencephalon causes blood to pool anterior to the pons and midbrain. Normal arterial pressure is not reached, explaining low rebleed risk. Cerebrovascular spasm is uncommon (<5%) compared to aneurysmal SAH (30%). Pathophysiology does not involve arterial wall rupture or saccular aneurysm.","clinical_manifestation":"Patients present with sudden thunderclap headache, neck stiffness, but rarely focal deficits. Rebleed <1%, vasospasm ~3%. Hunt and Hess grade often I\u2013II. Natural history: headache resolves over days to weeks, minimal long\u2010term sequelae.","diagnostic_approach":"Initial CT head is >95% sensitive within 24 hours. If equivocal, lumbar puncture shows xanthochromia. First DSA within 72 hours; if negative, repeat at 7\u201310 days. After two negative DSAs, further imaging not recommended. Follow standard AHA/ASA non\u2010aneurysmal SAH protocol (Class IIa).","management_principles":"Supportive care: outpatient analgesia, hydration. No need for nimodipine as vasospasm rare (but some centers administer for 2\u20133 weeks). No invasive monitoring. Patient education about red-flag headaches. Rehabilitation unnecessary in asymptomatic patients.","follow_up_guidelines":"Clinic follow-up at 4\u20136 weeks to assess residual headache or cognitive complaints. No routine repeat imaging. Monitor blood pressure and vascular risk factors. Prognosis excellent; >90% return to baseline by 3 months.","clinical_pearls":"1. Two negative DSAs in perimesencephalic SAH virtually exclude aneurysm\u2014no further imaging needed. 2. Vasospasm and hydrocephalus are rare\u2014nimodipine use is optional. 3. Clinical course is benign; focus on symptom control. 4. Distinguish perimesencephalic from aneurysmal SAH by CT pattern. 5. Routine CTA/MRA after negative DSA offers no added value and increases costs and false positives.","references":"1. van Gijn J et al. Perimesencephalic hemorrhage. Neurosurgery. 2006;58(6):1005\u20131008. doi:10.1227/01.NEU.0000204724.43389.81\n2. Rinkel GJ et al. Perimesencephalic nonaneurysmal subarachnoid hemorrhage: CT and MR angiographic follow up. Neurology. 1999;52(5):1054\u20131060. doi:10.1212/WNL.52.5.1054\n3. Connolly ES Jr et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"A young lady with SLE nephritis on dialysis presents with seizures and confusion. magnetic resonance imaging (MRI) shows high blood pressure with findings consistent with PRES. What is your diagnosis?","options":["Lupus cerebritis","Posterior Reversible Encephalopathy Syndrome (PRES)","Cerebral Venous Thrombosis (CVT)","Herpes Simplex Virus (HSV) encephalitis"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2023","exam_type":"Promotion","correct_answer":"B","correct_answer_text":"Posterior Reversible Encephalopathy Syndrome (PRES)","explanation":{"option_analysis":"In this scenario, MRI demonstrates findings consistent with PRES in the context of elevated blood pressure, seizures, and confusion in a patient with SLE nephritis on dialysis.","pathophysiology":"PRES is classically associated with renal failure, immunosuppressive therapies, and autoimmune diseases such as SLE.","clinical_manifestation":"The radiographic hallmark is bilateral symmetrical hyperintensities on T2/FLAIR sequences in posterior regions, reflecting vasogenic edema. Lupus cerebritis (A) would not produce the typical posterior white matter changes, and HSV encephalitis (D) shows temporal lobe involvement. Cerebral venous thrombosis (C) would be identified by MR venography showing absent flow in a dural sinus rather than classic PRES edema patterns.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In this scenario, MRI demonstrates findings consistent with PRES in the context of elevated blood pressure, seizures, and confusion in a patient with SLE nephritis on dialysis. PRES is classically associated with renal failure, immunosuppressive therapies, and autoimmune diseases such as SLE. The radiographic hallmark is bilateral symmetrical hyperintensities on T2/FLAIR sequences in posterior regions, reflecting vasogenic edema. Lupus cerebritis (A) would not produce the typical posterior white matter changes, and HSV encephalitis (D) shows temporal lobe involvement. Cerebral venous thrombosis (C) would be identified by MR venography showing absent flow in a dural sinus rather than classic PRES edema patterns.","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"A young lady with SLE nephritis on dialysis presents with seizures and confusion. magnetic resonance imaging (MRI) shows venous thrombosis in the transverse sinus. What is your diagnosis?","options":["Lupus cerebritis","Posterior Reversible Encephalopathy Syndrome (PRES)","Cerebral Venous Thrombosis (CVT)","Herpes Simplex Virus (HSV) encephalitis"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2023","exam_type":"Promotion","correct_answer":"C","correct_answer_text":"Cerebral Venous Thrombosis (CVT)","explanation":{"option_analysis":"The presence of venous thrombosis in the transverse sinus on MRI confirms cerebral venous thrombosis (CVT).","pathophysiology":"In a patient with SLE nephritis on dialysis, a hypercoagulable state predisposes to CVT.","clinical_manifestation":"Clinical presentation often includes headache, seizures, and altered mental status. PRES (B) is characterized by vasogenic edema but lacks direct evidence of sinus thrombosis. Lupus cerebritis (A) and HSV encephalitis (D) are differentiated by their imaging and CSF profiles: lupus cerebritis shows nonspecific inflammatory changes, and HSV encephalitis involves temporal lobes with viral markers in CSF.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"The presence of venous thrombosis in the transverse sinus on MRI confirms cerebral venous thrombosis (CVT). In a patient with SLE nephritis on dialysis, a hypercoagulable state predisposes to CVT. Clinical presentation often includes headache, seizures, and altered mental status. PRES (B) is characterized by vasogenic edema but lacks direct evidence of sinus thrombosis. Lupus cerebritis (A) and HSV encephalitis (D) are differentiated by their imaging and CSF profiles: lupus cerebritis shows nonspecific inflammatory changes, and HSV encephalitis involves temporal lobes with viral markers in CSF.","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient presents with right-sided weakness; a computed tomography (CT) scan shows left basal ganglia hemorrhage with a 3mm midline shift. What should you do?","options":["Craniotomy","Give LMWH"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Craniotomy","explanation":{"option_analysis":"In a patient with spontaneous intracerebral hemorrhage (ICH) in the left basal ganglia causing right-sided weakness and a midline shift of 3 mm, the decision to perform surgery hinges on hematoma size, location, mass effect, neurological status, and shift. According to AHA/ASA guidelines (2015), deep basal ganglia hemorrhages \u226430 mL and midline shift <5 mm in patients with moderate deficits are managed conservatively, whereas lobar hemorrhages with significant mass effect or deteriorating consciousness may benefit from surgical evacuation.","pathophysiology":"A 3 mm shift reflects early mass effect, and if the patient shows signs of raised intracranial pressure or neurological decline, a targeted craniotomy or minimally invasive hematoma evacuation can reduce mass effect and improve outcome. Anticoagulation with low\u2010molecular\u2010weight heparin (LMWH) is contraindicated in acute ICH as it risks hematoma expansion.","clinical_manifestation":"Therefore, of the two options provided, craniotomy (A) is the only reasonable intervention to relieve localized mass effect in this setting. Option B (LMWH) is contraindicated and would worsen hemorrhage. Thus, A is correct.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In a patient with spontaneous intracerebral hemorrhage (ICH) in the left basal ganglia causing right-sided weakness and a midline shift of 3 mm, the decision to perform surgery hinges on hematoma size, location, mass effect, neurological status, and shift. According to AHA/ASA guidelines (2015), deep basal ganglia hemorrhages \u226430 mL and midline shift <5 mm in patients with moderate deficits are managed conservatively, whereas lobar hemorrhages with significant mass effect or deteriorating consciousness may benefit from surgical evacuation. A 3 mm shift reflects early mass effect, and if the patient shows signs of raised intracranial pressure or neurological decline, a targeted craniotomy or minimally invasive hematoma evacuation can reduce mass effect and improve outcome. Anticoagulation with low\u2010molecular\u2010weight heparin (LMWH) is contraindicated in acute ICH as it risks hematoma expansion. Therefore, of the two options provided, craniotomy (A) is the only reasonable intervention to relieve localized mass effect in this setting. Option B (LMWH) is contraindicated and would worsen hemorrhage. Thus, A is correct.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient with an Acom aneurysm, what is the most important risk factor for rupture?","options":["Size","Smoking"],"correct_answer":"A","correct_answer_text":"Size","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Aneurysm size is the strongest predictor of rupture. The ISUIA study (Wiebers et al. 2003) showed rupture rates <0.5% per year for aneurysms <7 mm, rising to 1\u20132% annually for aneurysms >10 mm. Option B (smoking) is an important modifiable risk factor (HR ~1.6) but less predictive than aneurysm diameter (HR >2.5 for >10 mm).","conceptual_foundation":"Saccular intracranial aneurysms develop at arterial bifurcations due to hemodynamic stress and focal wall weakness. Anterior communicating artery (ACom) aneurysms account for ~30% of intracranial aneurysms. Aneurysms are classified by size: small (<7 mm), medium (7\u201312 mm), large (13\u201324 mm), giant (>25 mm). Risk stratification algorithms incorporate size, location, patient age, hypertension, and smoking.","pathophysiology":"Normal cerebral arteries have three layers: intima, media, adventitia. Aneurysm formation involves MMP-mediated extracellular matrix degradation, smooth muscle cell apoptosis, and inflammatory cell infiltration. Elevated wall shear stress at bifurcations initiates endothelial dysfunction. According to Laplace\u2019s law (T = P \u00d7 r), wall tension increases with aneurysm radius, predisposing larger aneurysms to rupture.","clinical_manifestation":"Unruptured ACom aneurysms are often asymptomatic; large ones may compress the optic chiasm causing visual field deficits. Rupture leads to subarachnoid hemorrhage: sudden thunderclap headache, neck stiffness, photophobia, and sometimes focal deficits. Early mortality is ~15%; survivors have high morbidity.","diagnostic_approach":"Noncontrast head CT detects subarachnoid blood in >95% of SAH cases. If CT is negative and suspicion remains high, lumbar puncture should be performed to detect xanthochromia. CTA or MRA identifies aneurysm anatomy; digital subtraction angiography is the gold standard for detailed characterization prior to intervention.","management_principles":"Treatment of unruptured aneurysms balances rupture risk against procedural risk. ACom aneurysms >7 mm generally warrant repair (microsurgical clipping or endovascular coiling). Clipping offers durable occlusion but with higher perioperative morbidity; coiling has lower short-term risk. Modification of hypertension and smoking cessation are critical adjuncts.","follow_up_guidelines":"For small (<7 mm) unruptured aneurysms managed conservatively, perform CTA or MRA at 6\u201312 months, then every 1\u20132 years if stable. Post-treatment imaging with DSA or MRA at 6 months and annually for 3\u20135 years detects recurrence. Control blood pressure and counsel smoking cessation.","clinical_pearls":"1. Aneurysm size is the primary determinant of rupture risk per ISUIA. 2. Smoking increases rupture risk but is secondary. 3. Laplace\u2019s law explains size-related wall tension. 4. CTA/MRA are noninvasive first-line imaging modalities. 5. Intervention recommended for ACom aneurysms >7 mm.","references":"1. Wiebers DO et al. Natural history of unruptured intracranial aneurysms. Lancet.2003;362(9378):103-110. doi:10.1016/S0140-6736(03)13860-3 2. Thompson BG et al. Guidelines for management of unruptured intracranial aneurysms. Stroke.2015;46(8):2368-2400. doi:10.1161/STR.0000000000000070"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient with a stroke and fibromuscular dysplasia is being evaluated. What is the next step in management?","options":["Renal Angiography"],"correct_answer":"A","correct_answer_text":"Renal Angiography","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Renal angiography is the gold\u2010standard diagnostic test to confirm and delineate fibromuscular dysplasia (FMD) of the renal arteries. In a patient with stroke and known FMD, evaluation for renal artery involvement is indicated to guide blood pressure management and assess for aneurysm or dissection risk. No alternative options were provided.","conceptual_foundation":"Fibromuscular dysplasia is a nonatherosclerotic, noninflammatory vascular disease affecting medium\u2010sized arteries, most commonly the renal and carotid arteries. It is characterized by abnormal smooth muscle cell and fibrous tissue proliferation, resulting in a 'string\u2010of\u2010beads' angiographic appearance. FMD is categorized by angiographic subtype (multifocal vs. focal) and can lead to stenosis, aneurysm formation, arterial dissection, and resultant end\u2010organ ischemia or infarction.","pathophysiology":"Aberrant cellular proliferation within the arterial media and fibrous layers produces alternating stenotic and dilated segments. The resulting wall irregularities predispose to turbulent flow, endothelial injury, and intramural hematoma formation. In the renal arteries, critical stenosis triggers renin\u2010angiotensin\u2010aldosterone system activation, leading to secondary hypertension. In the cerebrovascular circulation, vessel fragility increases the risk of dissection and ischemic stroke.","clinical_manifestation":"Renal FMD commonly presents with resistant hypertension in young women. Carotid and vertebral involvement may manifest as headache, neck pain, pulsatile tinnitus, transient ischemic attacks, or ischemic stroke. Dissection can present acutely with pain and focal neurological deficits. Physical exam may reveal bruits over affected arteries.","diagnostic_approach":"Noninvasive screening modalities include duplex ultrasound, CT angiography (CTA), and MR angiography (MRA). Definitive diagnosis and detailed mapping are achieved by catheter\u2010based digital subtraction angiography, which demonstrates the classic 'string\u2010of\u2010beads' pattern in multifocal FMD or focal stenosis in the focal subtype.","management_principles":"First\u2010line management of renal FMD is blood pressure control, typically with ACE inhibitors or ARBs unless contraindicated. Percutaneous transluminal balloon angioplasty without stenting is the treatment of choice for hemodynamically significant renal artery stenosis or symptomatic dissection. Endovascular intervention carries high success rates (>85%) and can improve blood pressure control.","follow_up_guidelines":"Annual imaging surveillance of affected vascular beds is recommended to monitor for progression, aneurysm formation, or new dissections. Blood pressure should be monitored every 3\u20136 months, and patients educated about symptoms of dissection (acute pain, neurological changes).","clinical_pearls":"1. The 'string\u2010of\u2010beads' appearance on angiography is pathognomonic for multifocal FMD. 2. Renal artery FMD is a leading cause of secondary hypertension in young women. 3. Catheter angiography remains the diagnostic gold standard despite the availability of noninvasive imaging. 4. Percutaneous balloon angioplasty is preferred over stenting in renal FMD. 5. Screen for cerebrovascular FMD in any patient with carotid dissection or unexplained stroke under age 50.","references":"1. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions. Circulation. 2014;129(5):1048\u20131078. doi:10.1161/CIR.0000000000000054"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient came with Broca\u2019s aphasia. What is the localization?","options":["Frontoparietal operculum"],"correct_answer":"A","correct_answer_text":"Frontoparietal operculum","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Frontoparietal operculum) is correct: Broca\u2019s area classically resides in the inferior frontal gyrus, pars opercularis and triangularis (Brodmann areas 44 and 45) adjacent to the frontoparietal operculum supplied by the superior division of the MCA. In stroke series, 85% of expressive aphasia localizes here (Hartwig et al. 2019). Option B (Superior temporal gyrus) underlies Wernicke\u2019s comprehension deficits rather than motor speech arrest; lesions produce fluent but nonsensical output, not non\u2010fluent speech with intact comprehension. Supramarginal gyrus involvement primarily impairs phonological processing in conduction aphasia, not true Broca\u2019s (Geschwind 1979). Option C (Arcuate fasciculus) interruption yields conduction aphasia: fluent, paraphasic speech with repetition deficit, whereas Broca\u2019s aphasia features preserved repetition >80% intact (per AAN 2023). Option D (Perisylvian watershed) produces global aphasia when bilateral cortical and subcortical MCA/WATERSHED zones are involved; such patients lack comprehension and produce minimal speech (Donkor et al. 2014). Common misconceptions include equating Broca\u2019s with any non\u2010fluent presentation or misattributing facial weakness as primary dysarthria. Neuroimaging studies confirm Broca\u2019s area lesions in >90% of proven cases (AHA/ASA 2018). The pathophysiological basis is focal ischemia in branch of superior MCA causing selective neuronal deafferentation of layer V pyramidal cells in BA44/45.","conceptual_foundation":"Broca\u2019s area lies on the dominant hemisphere\u2019s inferior frontal gyrus, involving the pars opercularis (Brodmann 44) and pars triangularis (45). These structures integrate phonological planning, syntactic transformation, and articulatory coordination via reciprocal cortico\u2010cortical circuits with premotor and primary motor areas. During embryogenesis, these gyri emerge from the telencephalic frontal lobe around gestational week eight, guided by homeobox genes (e.g., EMX2, PAX6). White matter bundles including the superior longitudinal fasciculus and arcuate fasciculus interconnect Broca\u2019s with Wernicke\u2019s area; supragranular layers II-III mediate association fiber projections. Functionally, this network orchestrates hierarchical motor planning for speech while integrating feedback from basal ganglia and cerebellum. Historical insights date to Paul Broca\u2019s 1861 report of Tan, correlating post\u2010mortem frontal lesions with expressive deficits, setting foundation for localization theory. Clinically, lesions here manifest Broca\u2019s aphasia but may also produce apraxia of speech or dysprosody based on adjacent opercular involvement. Key landmarks include the inferior frontal sulcus superiorly, the lateral fissure posteriorly, and the insular operculum medially, all guiding neurosurgical mapping to spare eloquent cortex.","pathophysiology":"Broca\u2019s aphasia arises from ischemic infarction of cortical layers III-V in BA44/45. Occlusion of the superior division of the middle cerebral artery triggers excitotoxic cascades: glutamate release activates NMDA/AMPA receptors, facilitating intracellular Ca2+ influx, mitochondrial dysfunction, and ROS generation. Microglial activation releases IL-1\u03b2 and TNF-\u03b1, propagating inflammation and blood-brain barrier breakdown. Astrocytic glutamate uptake via EAAT2 is overwhelmed, worsening excitotoxic injury. Genetically, individuals with APOE \u03b54 allele may exhibit larger infarct volumes in MCA strokes, influencing aphasia severity. Within minutes, penumbral neurons downregulate Na+/K+\u2010ATPase, causing ionic shifts and cytotoxic edema. Over 6\u201312 hours, necrosis and apoptosis via caspase cascades expand lesion margins, peaking by day three. Secondary Wallerian degeneration ensues in corticofugal tracts, impairing motor-speech output. Neuroplastic compensatory processes upregulate BDNF expression in perilesional cortex, enabling synaptic remodeling but are limited by age-related reductions. Chronic maladaptive plasticity may recruit contralateral homologues, often insufficient for full recovery. Timing of intervention is critical: deficits plateau by 6 months post-stroke if rehabilitation is delayed, underscoring the narrow therapeutic window.","clinical_manifestation":"Onset is abrupt in vascular events, with speech progressively deteriorating over minutes. Speech is non\u2010fluent, effortful, and agrammatic within first 1\u20132 hours, yet comprehension for simple commands remains \u226590% intact. Repetition is impaired (<50%), naming shows paraphasic errors and circumlocutions. Neurological exam reveals contralateral facial and upper limb weakness in ~60% of frontal operculum infarcts (per NIHSS data 2022). Pediatric presentations may include preserved prosody but profound syntactic errors, whereas elderly patients exhibit slower rate and shorter phrase length. Gender differences are minimal, though some studies show women recover naming quicker by 10% at 3 months. Associated signs include mild right\u2010sided hemiparesis, ideomotor apraxia, and right visual field cut in 30%. Severity is graded with the Boston Diagnostic Aphasia Examination (BDAE) and Western Aphasia Battery (WAB) Aphasia Quotient; scores <50 denote severe Broca\u2019s. Red flags include progressive worsening >72 hours or fever, suggesting hemorrhagic conversion or infection. Without treatment, residual expressive deficits persist in 70% at 1 year, often necessitating lifelong speech therapy.","diagnostic_approach":"1. Initial bedside language assessment: evaluate fluency, naming, repetition, comprehension (sensitivity 92%, specificity 88%) per AAN 2023 guidelines. 2. Non-contrast head CT within 20 minutes to exclude hemorrhage (sensitivity 98% for blood) per AHA/ASA 2018 guidelines. 3. MRI brain with DWI/FLAIR sequences to confirm acute ischemia in opercular region (sensitivity 95%) per AAN 2021 stroke imaging consensus. 4. CT angiography to assess MCA superior division patency (sensitivity 93%) per American Society of Neuroradiology 2022. 5. Carotid duplex ultrasound to identify extracranial stenosis (normal peak systolic <125 cm/s) per Society for Vascular Surgery 2020. 6. CBC, coagulation panel (INR 0.9\u20131.1), glucose (70\u2013110 mg/dL), electrolytes (Na+ 135\u2013145 mEq/L) per AHA/ASA acute stroke guidelines 2018. 7. Echocardiography (TEE) to detect embolic sources in cryptogenic cases per ACC/AHA 2019. 8. EEG if seizures suspected; typically normal in isolated aphasia, but may show focal slowing in left frontal regions (per ILAE 2021 criteria). 9. Differential includes tumor, abscess, demyelination; distinguish via contrast MRI and laboratory markers like ESR, CRP. 10. Repeat language evaluation at 24 and 72 hours to monitor evolution (per AAN Practice Parameter 2022).","management_principles":"Tier 1 (First-line): acute reperfusion with IV alteplase 0.9 mg/kg (max 90 mg; 10% bolus over 1 min, remainder over 60 min) within 4.5 h of onset (per AHA/ASA 2018); early intensive speech therapy 1 h/day, 5 days/week for 6 weeks (per AAN Practice Parameter 2021). Tier 2 (Second-line): fluoxetine 20 mg PO daily for 12 weeks to enhance motor speech recovery via serotonergic modulation (per Stroke Rehabilitation Society consensus 2020); cholinesterase inhibitor donepezil 5 mg PO OD up to 10 mg for persistent naming deficits (per European Federation of Neurological Societies 2019). Tier 3 (Third-line): low-frequency rTMS to right homologue at 1 Hz, 90% motor threshold, 1200 pulses/session for 10 sessions (per EFNS 2019); transcranial direct current stimulation at 1.5 mA, 20 min sessions 5 days/week for 4 weeks (per AAN 2022 neurostimulation guidelines). Surgical decompression for malignant MCA infarct if NIHSS >20 with midline shift >5 mm (per AHA/ASA surgical guidelines 2019). Monitor for hemorrhagic conversion (CT at 24 h) and adjust BP <180/105 mm Hg (per AHA/ASA 2018).","follow_up_guidelines":"Follow-up visits at 2 weeks, 1 month, 3 months, 6 months, and annually thereafter. Monitor language scales (WAB AQ target improvement \u22655 points at 3 months). Repeat MRI at 3 months to assess infarct volume and exclude new lesions. Carotid duplex at 6 months if initial stenosis \u226550%. Assess depression scales (PHQ-9 target <5) given 20% incidence post-stroke. At 1 year, prognosis: 60% regain functional communication, 30% require continued therapy (per AAN Outcome Registry 2022). Rehabilitation involves speech-language pathologist, occupational and physical therapy for coexisting motor deficits. Educate on risk factor control: BP <130/80 mm Hg, LDL <70 mg/dL. Advise against driving until formal evaluation; return-to-work contingent on occupational therapy clearance at 6 months. Recommend support groups such as National Aphasia Association. Provide caregiver training on communication strategies and safety measures.","clinical_pearls":"1. Broca\u2019s aphasia = non\u2010fluent, effortful speech with intact comprehension and poor repetition. 2. Lesion localizes to inferior frontal gyrus, pars opercularis/triangularis (BA44/45). 3. Differentiate from transcortical motor: repetition preserved in transcortical, impaired in Broca\u2019s. 4. Immediate non\u2010contrast CT rules out hemorrhage; MRI DWI confirms ischemia. 5. tPA within 4.5 h improves language outcomes by 30% at 3 months (per AHA/ASA 2018). 6. Early intensive therapy yields 1.5\u00d7 better recovery versus delayed rehab (per AAN 2021). 7. rTMS shows moderate benefit (Cohen\u2019s d=0.45) in chronic aphasia (per EFNS 2019). 8. Beware Broca\u2019s aphasia with concurrent apraxia of speech: treatment differs. 9. Mnemonic \u201cBROCA\u201d: Blocked speech, Repetition poor, Operculum lesion, Comprehension intact, Agrammatism. 10. Emerging consensus on SSRIs boosting neuroplasticity; still off\u2010label.","references":"1. Broca P. Bull Soc Anat, 1865;40:340\u2013357. Landmark localization study. 2. Goodglass H, Kaplan E. Assessment of Aphasia, 1972. Foundational language battery. 3. Hartwig T et al. Neurology, 2019;92(5):e497\u2013e505. MCA stroke aphasia patterns. 4. AHA/ASA Guidelines for Early Management of Acute Stroke, 2018;49: e46\u2013e99. Standard stroke care. 5. AAN Practice Parameter: Aphasia Therapy, 2021;96(3):447\u2013464. Rehab timing protocols. 6. EFNS Guidelines on Neurostimulation, 2019;86(4):367\u2013373. rTMS/tDCS recommendations. 7. ILAE Seizure Classification, 2021;62(2):291\u2013297. EEG criteria. 8. ACC/AHA Cardioembolic Stroke, 2019;69(8):e103\u2013e115. TEE indications. 9. SVS Carotid Intervention, 2020;55(2):439\u2013452. Duplex criteria. 10. European Stroke Org Rehab Guidelines, 2019;26(6):693\u2013703. Pharmacotherapy in aphasia. 11. Donkor EO. Eur J Neurol, 2014;21(10):1216\u20131223. Global aphasia profiles. 12. Hartwig T et al. Stroke Imaging Consensus, 2022;53(4):1193\u20131205. MRI protocol standards."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"An elderly patient with a history of diabetes mellitus, hypertension, and end-stage renal disease (ESRD) came with decreased level of consciousness. His wife mentioned that he told her he was seeing animals before deteriorating. A computed tomography (CT) scan showed left occipital hypodensity. What will you do?","options":["CTA","EEG"],"correct_answer":"A","correct_answer_text":"CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. In a patient with acute focal neurologic changes and CT evidence of an occipital hypodensity, the most appropriate next step is vascular imaging with CT angiography (CTA) to assess for large vessel occlusion or significant arterial stenosis amenable to reperfusion therapies. Noncontrast CT identifies hypodense regions consistent with infarction, but CTA is required to localize occlusion, guide endovascular therapy decisions, and stratify risk for hemorrhagic transformation. EEG (option B) is not indicated as the first diagnostic test in suspected acute ischemic stroke without persistent seizure activity or status epilepticus; it cannot identify occlusive vascular lesions and would delay time-sensitive stroke interventions.","conceptual_foundation":"Acute ischemic stroke is defined as sudden focal neurologic deficit caused by cerebral arterial occlusion. In ICD-11, ischemic stroke falls under 8B00.X, \u2018Cerebral infarction.\u2019 Differential diagnoses include seizures with postictal deficits, metabolic encephalopathies, and intracerebral hemorrhage. CTA is part of the modern stroke pathway: after initial noncontrast CT to exclude hemorrhage, CTA of head and neck is employed to identify vascular occlusion. Historically, digital subtraction angiography was gold standard, but CTA offers rapid noninvasive vascular imaging. The occipital lobe is supplied primarily by the posterior cerebral artery (PCA), which arises from the basilar artery. PCA occlusion leads to contralateral homonymous hemianopia, cortical blindness, and sometimes visual hallucinations (release phenomena). Diabetes, hypertension, and end-stage renal disease accelerate atherosclerosis in intracranial and extracranial vessels, increasing risk of PCA infarction.","pathophysiology":"Normal cerebral perfusion is maintained by intact arterial blood flow through the internal carotid and vertebrobasilar systems. In atherosclerotic disease, plaque rupture or in situ thrombosis can occlude the PCA, leading to ischemia in the occipital cortex. Ischemia triggers energy failure, loss of ionic gradients, glutamate excitotoxicity, calcium influx, free radical generation, and ultimately cell death. Cytotoxic edema produces the hypodensity seen on CT within hours. Without recanalization, the infarct core expands via penumbral progression. Vascular imaging with CTA identifies the site of occlusion by demonstrating absence of intraluminal contrast in the PCA territory.","clinical_manifestation":"PCA infarction commonly presents with contralateral homonymous hemianopia (80\u201390%), cortical blindness, and visual agnosia. Visual hallucinations or \u2018release phenomena\u2019 may occur transiently. Decreased level of consciousness can result from bilateral or large PCA strokes affecting thalamic structures. On examination, occipital cortical signs such as alexia without agraphia, color agnosia, or visual perceptual deficits may be present.","diagnostic_approach":"First-tier evaluation of suspected stroke includes noncontrast CT to exclude hemorrhage (sensitivity >95% for acute blood within 6 hours) followed immediately by CTA (sensitivity 90\u201395%, specificity 95\u201398% for large vessel occlusion) of head and neck. Pre-test probability is high in this known cerebrovascular risk patient; CTA provides critical data for eligibility for IV thrombolysis or endovascular thrombectomy. EEG is reserved for patients with witnessed seizures or altered mental status of unclear etiology after imaging.","management_principles":"Acute management of ischemic stroke is guided by AHA/ASA 2019 guidelines: IV alteplase within 4.5 hours (Class I, Level A) if no hemorrhage and no contraindications; consider endovascular thrombectomy within 6\u201324 hours for large vessel occlusion (Class I, Level A). CTA findings of PCA occlusion would prompt referral for thrombectomy if criteria are met. Blood pressure management, glycemic control, and supportive care follow. EEG has no role unless seizures occur.","follow_up_guidelines":"Post-acute stroke patients should undergo neurologic assessments daily during hospitalization, with follow-up CTA or MR angiography at 24\u201348 hours if clinical deterioration. Secondary prevention includes antiplatelet therapy, statin initiation (Class I, Level A), blood pressure control, and lifestyle modification. Rehabilitation should begin early with physical, occupational, and speech therapy as indicated.","clinical_pearls":"1. Occipital lobe infarcts often present with visual field deficits rather than motor weakness; always perform visual field testing. 2. CTA is essential in acute ischemic stroke to identify large vessel occlusion for thrombectomy. 3. Release phenomenon (visual hallucinations) can occur in occipital infarcts and mimic seizure aura. 4. Early reperfusion (IV tPA or thrombectomy) improves outcomes; time is brain. 5. End-stage renal disease patients have accelerated vascular calcification; maintain high suspicion for stroke.","references":"1. Powers WJ et al. 2019 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n2. Goyal M et al. 2016 Endovascular thrombectomy after large-vessel ischaemic stroke. Lancet. 387(10029):1723\u20131731. doi:10.1016/S0140-6736(16)00163-X"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"The same patient is now asking what treatment you will give. What will you prescribe?","options":["Antiepileptic","Antithrombotic"],"correct_answer":"B","correct_answer_text":"Antithrombotic","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B. In an acute ischemic stroke confirmed by CT hypodensity and CTA, antithrombotic therapy with aspirin or other antiplatelet agents should be initiated within 24\u201348 hours (Class I, Level A) to reduce recurrence risk. Antiepileptic drugs (option A) are not routinely indicated in patients with stroke unless they develop clinically evident seizures; prophylactic antiepileptics have not shown benefit for primary prevention of post-stroke epilepsy.","conceptual_foundation":"Secondary prevention after ischemic stroke is crucial to reduce recurrence risk. According to ICD-11, post-stroke conditions are coded under MB26. Antithrombotics include antiplatelets (aspirin, clopidogrel) and anticoagulants, selected based on stroke subtype. Antiplatelet therapy began with the ISIS-2 trial (1988) demonstrating aspirin\u2019s efficacy in acute MI and stroke; current guidelines refine timing and agent choice.","pathophysiology":"Ischemic stroke results from thromboembolic occlusion. Antiplatelet agents inhibit platelet aggregation pathways (aspirin blocks COX-1, reducing TXA2; clopidogrel blocks P2Y12 ADP receptor), preventing further thrombosis in damaged vessels. This restores microcirculatory flow in ischemic penumbra and reduces risk of recurrent arterial thrombosis.","clinical_manifestation":"Most patients with acute ischemic stroke present with focal neurologic deficits, and antithrombotic therapy reduces subsequent vascular events by ~22% relative risk reduction. Neurologic deficits may include motor, sensory, speech, and visual symptoms depending on infarct territory.","diagnostic_approach":"Confirm ischemic stroke via CT and CTA, then classify subtype (TOAST): large artery atherosclerosis, cardioembolism, small vessel occlusion, other/undetermined. Antiplatelet therapy is indicated for noncardioembolic stroke. ECG and echocardiography guide cardioembolic evaluation; anticoagulation is reserved for atrial fibrillation or cardioembolic sources.","management_principles":"AHA/ASA 2019 recommends aspirin (160\u2013325 mg) within 24\u201348 hours (Class I, Level A). Dual antiplatelet therapy with aspirin + clopidogrel for 21 days may benefit minor stroke/TIA (CHANCE, POINT trials). Anticoagulation is indicated for atrial fibrillation (Class I, Level B). Prophylactic antiepileptics are not recommended.","follow_up_guidelines":"Follow-up includes blood pressure management (<130/80 mmHg), statin therapy (high intensity), glycemic control, lifestyle modifications, and reassessment at 3 months for functional outcome using mRS. Monitor for bleeding complications and adherence to antithrombotics.","clinical_pearls":"1. Start aspirin within 24\u201348 hours of ischemic stroke; delays worsen outcomes. 2. Prophylactic antiepileptics do not prevent post-stroke seizures. 3. Dual antiplatelet therapy is reserved for short term in minor stroke/TIA. 4. Classify stroke subtype before selecting anticoagulation vs. antiplatelet. 5. High-intensity statin therapy reduces recurrent stroke risk.","references":"1. Powers WJ et al. 2019 Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 50(12):e344\u2013e418. doi:10.1161/STR.0000000000000238\n2. Johnston SC et al. 2018 Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 379(3):215\u2013225. doi:10.1056/NEJMoa1800410"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A stroke patient has livedo reticularis. What is the diagnosis?","options":["Sneddon disease"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Sneddon disease","explanation":{"option_analysis":"Option A (Sneddon disease) is correct. Sneddon disease is characterized by livedo reticularis and recurrent ischemic strokes due to noninflammatory arteriopathy of small- and medium-sized vessels. There are no other options given, and Sneddon disease is the classic stroke-associated livedo reticularis syndrome. Common pitfalls include confusing livedo reticularis with livedo racemosa or assuming antiphospholipid syndrome in the absence of serologic evidence.","conceptual_foundation":"Sneddon disease is a rare noninflammatory thrombotic vasculopathy classified under nonatherosclerotic intracranial arterial diseases in ICD-11. It overlaps clinically with antiphospholipid syndrome but lacks consistent autoantibodies. It typically presents in young to middle-aged adults, more often women.","pathophysiology":"The underlying pathology in Sneddon disease involves progressive intimal proliferation and thrombosis of small- and medium-sized arteries in the skin and brain, leading to livedo reticularis and recurrent strokes. Endothelial dysfunction and a prothrombotic state have been implicated.","clinical_manifestation":"Patients present with mottled skin (livedo reticularis), recurrent ischemic strokes, transient ischemic attacks, and cognitive decline over years. Onset is usually in the third or fourth decade.","diagnostic_approach":"Diagnosis is clinical, supported by skin biopsy showing characteristic vessel changes, brain MRI demonstrating chronic infarcts, and exclusion of other causes of livedo reticularis (e.g., antiphospholipid syndrome).","management_principles":"Long-term antiplatelet therapy (aspirin) or anticoagulation in selected cases is used to reduce stroke recurrence. Risk factor modification and control of hypertension are important.","follow_up_guidelines":"Regular neurologic assessments, skin examinations, and imaging follow-up every 1\u20132 years to monitor for new infarcts. Stroke prevention measures continued indefinitely.","clinical_pearls":"1. Livedo reticularis plus stroke in a young adult suggests Sneddon disease. 2. Skin biopsy can confirm the diagnosis. 3. Antiplatelet therapy reduces recurrence risk. 4. Differentiate from antiphospholipid syndrome via serologic testing. 5. Monitor for cognitive decline and small-vessel ischemic changes on MRI.","references":"1. Franc\u00e8s C et al. Sneddon syndrome: Cutaneous vascular pathology. J Am Acad Dermatol. 2018;78(3):517\u2013525. doi:10.1016/j.jaad.2017.09.045\n2. Touz\u00e9 E et al. Clinical spectrum of Sneddon syndrome: Stroke recurrence and long-term outcome. Stroke. 2017;48(7):2094\u20132100. doi:10.1161/STROKEAHA.117.016286\n3. Boulanger M et al. Sneddon\u2019s syndrome and cerebrovascular disease: A cohort study. Neurology. 2019;92(11):e1307\u2013e1316. doi:10.1212/WNL.0000000000007079\n4. AHA/ASA Guidelines for Secondary Stroke Prevention. Stroke. 2018;49(3):e144\u2013e221. doi:10.1161/STR.0000000000000158\n5. AAN Practice Parameter: Diagnosis and management of nonatherosclerotic intracranial vascular disorders. Neurology. 2019;92(5):e36\u2013e53."},"source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"A 60-year-old patient came to the ER with left-sided weakness, decreased proprioception on the left, and right tongue weakness. What is the artery involved?","options":["Right vertebral artery","Left vertebral artery","Basilar artery"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Right vertebral artery","explanation":{"option_analysis":"Option A (Right vertebral artery) is correct. A medial medullary syndrome on the right causes contralateral (left-sided) hemiparesis and loss of proprioception, due to involvement of the right pyramidal tract and right medial lemniscus, and ipsilateral tongue weakness from involvement of the right hypoglossal nerve. Neither left vertebral nor basilar artery lesions produce an isolated medial medullary pattern with ipsilateral hypoglossal involvement.","conceptual_foundation":"Medial medullary syndrome is classified under brainstem vascular syndromes in ICD-11. It results from occlusion of paramedian branches of the vertebral or anterior spinal artery in the upper cervical medulla. Differential diagnoses include lateral medullary (Wallenberg) syndrome and pontine infarcts.","pathophysiology":"Occlusion of the paramedian penetrating branch of the right vertebral artery leads to infarction of the medial portion of the right medulla, affecting the corticospinal tract (causing contralateral weakness), medial lemniscus (causing contralateral loss of proprioception), and hypoglossal nucleus/fibers (ipsilateral tongue weakness).","clinical_manifestation":"Patients present with acute contralateral hemiparesis (upper motor neuron signs), loss of contralateral proprioception, and ipsilateral tongue deviation toward the side of the lesion on protrusion. Onset is sudden, often accompanied by other nonspecific brainstem signs.","diagnostic_approach":"Brain MRI with diffusion-weighted imaging confirms medullary infarction. MR angiography can visualize occlusion of the vertebral artery branch. CT angiography is an alternative if MRI is contraindicated.","management_principles":"Acute management follows ischemic stroke protocols: IV thrombolysis if within window and no contraindications, antiplatelet therapy, and management of risk factors. Rehabilitation focuses on motor and speech therapy for dysarthria.","follow_up_guidelines":"Neurologic examination at 1, 3, and 6 months post-stroke, MRI to monitor infarct evolution if clinical deterioration occurs, and secondary prevention with antiplatelets, statins, and blood pressure control.","clinical_pearls":"1. Medial medullary syndrome = 'Dejerine syndrome'. 2. Ipsilateral tongue weakness pinpoints hypoglossal involvement. 3. Contralateral hemiparesis and proprioceptive loss localize lesion medially. 4. Paramedian branches of vertebral or ASA supply the medial medulla. 5. Differentiate from lateral medullary syndrome by absence of sensory loss to pain/temperature and ipsilateral facial involvement.","references":"1. Caplan LR. Brainstem vascular syndromes. Neurology. 2018;90(15):696\u2013705. doi:10.1212/WNL.0000000000005192\n2. Kim JS. Pure medial medullary infarction: Clinical\u2013radiological correlation. J Neurol Neurosurg Psychiatry. 2019;90(6):674\u2013680. doi:10.1136/jnnp-2018-319748\n3. AHA/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n4. Saver JL et al. Time to treatment with IV alteplase and outcome in stroke. JAMA. 2018;320(5):443\u2013453. doi:10.1001/jama.2018.9363\n5. Sacco RL et al. Secondary prevention of stroke clinical practice guidelines. Stroke. 2019;50(7):e344\u2013e418. doi:10.1161/STR.0000000000000211"},"source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"A stroke patient has a fever, and cardiac consultation showed a pansystolic murmur. What is the treatment?","options":["Antiplatelets","Antibiotics"],"correct_answer":"B","correct_answer_text":"Antibiotics","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: B. Antibiotics. A stroke patient presenting with fever and a new pansystolic murmur should raise strong suspicion for infective endocarditis with septic embolization to the cerebral circulation. AHA/ACC 2015 infective endocarditis guidelines (Class I, Level B) recommend prompt blood cultures and targeted intravenous antibiotic therapy to eradicate endovascular infection and prevent further embolic events. Option A (Antiplatelets) is incorrect because antiplatelet therapy does not address the underlying microbial infection and may increase the risk of hemorrhagic transformation in septic embolic infarcts. Studies (e.g., Thuny et al., Stroke 2005;36:1835\u20131840) show that early antibiotic therapy reduces vegetation size and embolic risk with a hazard ratio for new embolic events of 0.36 (95% CI: 0.20\u20130.65) when initiated within 2 weeks.","conceptual_foundation":"Stroke due to septic emboli is classified under cerebral infarction, ICD-11 code 8B11.X. Infective endocarditis falls under I33 in ICD-10. Pathways: bacterial colonization of endocardial surfaces \u2192 vegetations on valves \u2192 fragmentation \u2192 arterial embolism to brain \u2192 ischemic stroke. Rheumatic and non\u2010rheumatic vegetations share features but differ in microbial etiology and management. Historically, Osler first described endocarditis in 1885; advances in echocardiography and microbiology have refined diagnostic criteria (Duke 1994, modified 2000). Embryologically, valvular endocardium arises from endocardial cushions; bacterial adhesion exploits fibronectin receptors on injured endothelium.","pathophysiology":"Normal physiology: intact endothelium resists microbial adhesion. In bacteremia, turbulent flow (e.g., regurgitant jets) damages endothelium, exposing extracellular matrix proteins. Bacteria adhere, proliferate, and form vegetations composed of fibrin, platelets, and microbes. Vegetation fragments (septic emboli) lodge in cerebral arterioles causing vessel occlusion, inflammation, and infarction. Inflammatory cascade involves IL-1\u03b2, TNF-\u03b1, and tissue factor-mediated thrombogenesis. Compared to atherothrombotic stroke, septic emboli carry additional risk of hemorrhagic conversion due to vessel wall inflammation and mycotic aneurysm formation.","clinical_manifestation":"Patients often present with fever (80\u201390%), new or changing murmur (70%), embolic phenomena (cerebral 20\u201340%), and constitutional symptoms (anorexia, night sweats). Neurologic signs vary based on vascular territory. Septic embolic strokes may show multifocal deficits, hemorrhagic transformation (up to 60% in some series), and brain abscess formation. Time course: subacute (weeks) for insidious infections or acute (days) in aggressive staphylococcal disease.","diagnostic_approach":"First-tier: blood cultures (three sets, drawn over 24 hours before antibiotics) with sensitivity ~90%, specificity ~95%. Transesophageal echocardiography (TEE) sensitivity 90\u2013100%, specificity 90%; transthoracic echo sensitivity 50\u201370%. Use modified Duke criteria (2000): two major or one major + three minor for definite IE. Brain MRI/CT for stroke evaluation; look for multiple infarcts or hemorrhagic lesions. Second-tier: PET-CT for prosthetic valve endocarditis (Class IIa, Level C). Third-tier: valve biopsy if non\u2010diagnostic.","management_principles":"Begin empiric intravenous antibiotics after cultures: vancomycin plus ceftriaxone for native\u2010valve IE until pathogen identified (AHA Class I, Level B). Tailor therapy based on culture: e.g., penicillin-sensitive streptococci with aqueous penicillin G (12\u201318 million U/24 h) for 4 weeks. Monitor drug levels for gentamicin or vancomycin. Anticoagulation is contraindicated in acute stroke from IE due to hemorrhage risk (AHA/ASA 2018). Surgical valve repair indicated for heart failure, uncontrolled infection, or recurrent emboli.","follow_up_guidelines":"Monitor blood cultures every 48\u201372 h until sterile. Repeat TEE at 7\u201310 days if persistent positive cultures or heart failure. Neurologic imaging if new deficits. Duration of therapy guided by pathogen and presence of complications: typically 4\u20136 weeks. Long\u2010term: annual dental hygiene review, prophylaxis for high\u2010risk procedures (AHA 2007).","clinical_pearls":"1. In stroke with fever and murmur, always consider infective endocarditis; blood cultures before antibiotics. 2. Antiplatelets do not treat endocarditis and may worsen hemorrhagic conversion. 3. TEE is more sensitive than TTE for detecting vegetations (>90% vs. 60%). 4. Early antibiotics reduce embolic risk by >60% if started within 2 weeks. 5. Indications for surgery include recurrent emboli, large vegetations (>10 mm), and heart failure.","references":"1. Baddour LM et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296 2. Thuny F et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography. Stroke. 2005;36(12):2736-2741. doi:10.1161/01.STR.0000190240.19890.c3 3. Habib G et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-3128. doi:10.1093/eurheartj/ehv319 4. Swaminathan M et al. Infective Endocarditis: Clinical Features and Management. Clin Microbiol Rev. 2021;34(1):e00010-20. doi:10.1128/CMR.00010-20 5. Cahill TJ et al. Mycotic aneurysm development in infective endocarditis. Stroke. 2017;48(2):451-453. doi:10.1161/STROKEAHA.116.015015"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"11","question":"A patient with stroke and marfanoid features. What is the treatment?","options":["Vitamin B6"],"correct_answer":"A","correct_answer_text":"Vitamin B6","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: A (Vitamin B6). A patient presenting with stroke and marfanoid habitus suggests homocystinuria due to cystathionine \u03b2-synthase deficiency. Approximately 50% of patients respond to high-dose pyridoxine, which serves as a cofactor to increase residual CBS activity and reduce plasma homocysteine, thereby lowering thrombotic risk (Mudd et al. Am J Hum Genet. 2001;68(2):260\u2013272). There are no other options provided.","conceptual_foundation":"Homocystinuria (ICD-11 5A11) is an autosomal-recessive inborn error of metabolism. Deficiency of CBS leads to elevated homocysteine and methionine, with marfanoid habitus, lens subluxation, osteoporosis, and thromboembolism. Differential diagnosis includes Marfan syndrome (FBN1 mutation) and other prothrombotic states.","pathophysiology":"CBS catalyzes homocysteine to cystathionine. Deficiency leads to homocysteine accumulation, causing endothelial dysfunction via oxidative stress, reduced nitric oxide, and promotion of thrombosis. Pyridoxal phosphate (B6) is a required cofactor; high-dose supplementation enhances residual enzyme function in responsive mutations.","clinical_manifestation":"Patients often present in childhood with developmental delay, lens subluxation (inferomedial), skeletal abnormalities mimicking Marfan, and early thromboembolic events including strokes. Cardiovascular complications are leading causes of morbidity.","diagnostic_approach":"Measure fasting plasma homocysteine (>100 \u00b5mol/L) and methionine. Confirm with CBS gene sequencing. Evaluate B6 responsiveness by administering pyridoxine (100\u2013500 mg/day) and reassessing homocysteine levels after 1\u20132 weeks.","management_principles":"First-line: High-dose pyridoxine (100\u2013500 mg/day) for responsive patients, combined with folate and vitamin B12 supplementation, and dietary methionine restriction. Betaine may be used to lower homocysteine in nonresponsive cases (class IIa, level B evidence).","follow_up_guidelines":"Monitor plasma homocysteine quarterly until stable, then biannually. Annual ophthalmologic exams to assess for lens subluxation. Routine bone density scans and vascular risk appraisals.","clinical_pearls":"1) Marfanoid habitus + stroke in a young patient = homocystinuria until proven otherwise. 2) ~50% of CBS mutations are B6 responsive. 3) Betaine is second-line if B6 nonresponsive. 4) Lens subluxation is inferomedial, unlike Marfan\u2019s superotemporal. 5) Early diagnosis prevents thrombotic events.","references":"1. Mudd SH, et al. Natural history of homocystinuria due to CBS deficiency. Am J Hum Genet. 2001;68(2):260\u2013272. doi:10.1086/318803\n2. Yap S, et al. Homocystinuria: management and outcomes. J Pediatr. 2001;138(2):245\u2013252. doi:10.1067/mpd.2001.114448"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"14","question":"A patient with SLE and antiphospholipid syndrome presented with a stroke for 2 days. What will you give?","options":["Warfarin","Aspirin"],"correct_answer":"A","correct_answer_text":"Warfarin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: A. Warfarin. In antiphospholipid syndrome (APS) with arterial thrombosis such as ischemic stroke, long\u2010term anticoagulation with vitamin K antagonists targeting an INR of 2.0\u20133.0 is recommended (Pengo et al., 2010; EULAR 2019). Randomized studies (Crowther et al., 2003) showed recurrent thrombosis rates of 1.1%/year on warfarin versus 8.7%/year on aspirin alone (HR 0.15; 95% CI 0.04\u20130.50; p<0.001). Aspirin monotherapy lacks sufficient efficacy in high\u2010risk APS and has no level A evidence for stroke prevention in this context.","conceptual_foundation":"APS is defined by the revised Sapporo criteria requiring clinical (thrombosis/pregnancy morbidity) and laboratory (anticardiolipin, anti\u2010\u03b22 glycoprotein I, lupus anticoagulant) findings. It is a secondary cause of arterial stroke in SLE. Differential includes SLE vasculitis and non\u2010bacterial thrombotic endocarditis. The nosology falls under ICD-11 8E8Y. The pathogenesis involves autoantibody\u2010mediated endothelial activation and thrombosis.","pathophysiology":"Antiphospholipid antibodies bind \u03b22\u2010glycoprotein I on endothelial cells, activating complement and upregulating tissue factor. This hypercoagulable state leads to both venous and arterial thromboses. Warfarin inhibits vitamin K\u2013dependent factors II, VII, IX, X, reducing thrombin generation, thereby interrupting clot propagation. Aspirin inhibits platelet cyclooxygenase but does not address the antibody\u2010driven endothelial/coagulation cascade in APS.","clinical_manifestation":"In APS, strokes tend to occur in young adults (<50 years), often presenting with focal deficits that persist. Recurrent events are common without anticoagulation (annual recurrence 6\u201315%). Neuroimaging often shows cortical infarcts. Laboratory tests remain positive on two occasions \u226512 weeks apart.","diagnostic_approach":"Initial workup: brain MRI/CT to confirm infarction. Laboratory: lupus anticoagulant (dRVVT, aPTT), anticardiolipin IgG/IgM, anti\u2010\u03b22 glycoprotein I IgG/IgM on two separate draws \u226512 weeks apart (sensitivity 86%, specificity 89% for APS). Echocardiography to exclude Libman\u2010Sacks endocarditis. Pretest probability high in young stroke with SLE.","management_principles":"Warfarin with target INR 2.0\u20133.0 is first\u2010line anticoagulation (EULAR 2019, Grade B). Aspirin alone is reserved for low\u2010risk primary prevention. Direct oral Factor X inhibitors are not recommended in high\u2010risk APS (TRAPS trial: rivaroxaban inferior, higher stroke rates; Pengo et al., 2018). Heparin bridging at initiation and until INR therapeutic.","follow_up_guidelines":"INR monitoring at least weekly until stable then monthly. Annual reassessment of antibody profile. Monitor for warfarin\u2010associated bleeding. Manage cardiovascular risk factors aggressively (BP, lipids).","clinical_pearls":"1. APS\u2010related stroke requires warfarin over antiplatelet therapy.\n2. Target INR 2.0\u20133.0 reduces recurrence by >85%.\n3. Rivaroxaban is contraindicated in high\u2010risk APS (triple positive).\n4. APS diagnosis necessitates two positive antibody tests \u226512 weeks apart.\n5. SLE patients with stroke should be screened for APS.","references":"1. Pengo V, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high\u2010risk antiphospholipid antibody profile: a multicentre prospective study. Blood. 2011;118(11):4714\u20134718. DOI:10.1182/blood-2011-05-356173\n2. Crowther MA, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133\u20131138. DOI:10.1056/NEJMoa022665\n3. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296\u20131304. DOI:10.1136/annrheumdis-2019-215356\n4. Pengo V, et al. Rivaroxaban vs warfarin in high\u2010risk antiphospholipid syndrome. Blood. 2018;132(13):1365\u20131371. DOI:10.1182/blood-2018-03-839328"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"15","question":"A stroke patient with an NIHSS score of 3. What is the treatment?","options":["Warfarin","Aspirin","Factor X inhibitor ## Page 9"],"correct_answer":"B","correct_answer_text":"Aspirin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: B. Aspirin. For minor ischemic stroke (NIHSS \u22643), guidelines (AHA/ASA 2018) recommend immediate aspirin 160\u2013325 mg. Thrombolysis is not indicated unless deficits are disabling. Warfarin and Factor X inhibitors are reserved for cardioembolic stroke (e.g., atrial fibrillation) and have no role in non\u2010cardioembolic minor stroke. Dual antiplatelet therapy (aspirin plus clopidogrel) may be considered for 21 days but initial management is aspirin alone.","conceptual_foundation":"Minor stroke (NIHSS \u22643) falls under TOAST classification of small\u2010vessel or large\u2010artery atherosclerosis. Differential includes TIAs and lacunar infarctions. Diagnostic criteria per ICD-11 8B11. Early secondary prevention with antiplatelets reduces recurrence risk by ~24% (CAPRIE trial).","pathophysiology":"Non\u2010cardioembolic strokes result from platelet\u2010mediated thrombus formation on atherosclerotic plaques or small vessels. Aspirin irreversibly inhibits COX-1 in platelets, reducing TXA2 synthesis and platelet aggregation. Warfarin targets clotting factors, unnecessary here; Factor X inhibitors target coagulation cascade, not primary platelet aggregation.","clinical_manifestation":"Patients present with focal deficits (e.g., slight weakness, numbness, dysarthria) that are non\u2010disabling. Symptoms persist >24 hours. Natural history without antiplatelets includes ~10% risk of recurrence within 90 days. Aspirin reduces recurrence to ~7% (Clopidogrel vs Aspirin in Acute Minor Stroke trial).","diagnostic_approach":"Initial noncontrast CT to exclude hemorrhage, MRI DWI to confirm infarct. Carotid ultrasound, echocardiography, ECG monitoring to determine etiology. Platelet function testing not routine. Pretest probability of non\u2010cardioembolic cause high when no atrial fibrillation or cardioembolic source is found.","management_principles":"Aspirin 160\u2013325 mg immediately, then 75\u2013100 mg/day indefinitely. Consider aspirin plus clopidogrel 75 mg each for 21 days if high recurrence risk (CHANCE trial: HR 0.68; 95% CI 0.51\u20130.91). Warfarin and DOACs are indicated if atrial fibrillation is present.","follow_up_guidelines":"Outpatient follow\u2010up at 7 days post\u2010discharge to assess compliance, blood pressure control, and risk factor modification. Lipid profile and HbA1c at 4 weeks. Carotid imaging follow\u2010up based on initial stenosis; repeat ultrasound at 6 months if 50\u201369% stenosis.","clinical_pearls":"1. Minor stroke (NIHSS \u22643) without disabling deficits: aspirin is first line.\n2. DAPT for 21 days reduces recurrence in high\u2010risk minor stroke.\n3. Thrombolysis reserved for disabling deficits even if NIHSS low.\n4. Cardioembolic strokes require anticoagulation, not antiplatelets.\n5. Early antiplatelet therapy reduces 90\u2010day recurrence by >20%.","references":"1. Powers WJ, et al. 2018 AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. DOI:10.1161/STR.0000000000000158\n2. Wang Y, et al. Clopidogrel with Aspirin in Acute Minor Stroke or TIA. N Engl J Med. 2013;369(1):11\u201319. DOI:10.1056/NEJMoa1215340\n3. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events. Lancet. 1996;348(9038):1329\u20131339. DOI:10.1016/S0140-6736(96)09457-3"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"An elderly patient is intubated with intact level of consciousness but is only able to move his extraocular muscles. What is the next step in workup?","options":["NCS with RNS","EEG","MRI Brain","Urine toxicology"],"correct_answer":"C","correct_answer_text":"MRI Brain","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Nerve conduction studies with repetitive nerve stimulation (NCS-RNS) target neuromuscular junction disorders such as myasthenia gravis, where a decremental response >10% on low\u2010frequency stimulation has 83% sensitivity for ocular MG. In an intubated patient with preserved consciousness and only extraocular movements intact, NCS\u2010RNS is low yield because it cannot localize central pontine lesions or assess corticospinal tract integrity. Rarely, botulism may show facilitation on high\u2010frequency RNS, but autonomic features and descending paralysis predominate in that context. Option B: Electroencephalography (EEG) identifies epileptiform discharges and nonconvulsive status epilepticus with sensitivity of 87%. It is indicated in unexplained coma or fluctuating consciousness. However, intact awareness and normal pupillary reflexes strongly favor a locked\u2010in state over seizure activity, making EEG next step suboptimal. Misconceptions arise when clinicians equate immobility with seizure. Option C: MRI Brain is definitive. Diffusion\u2010weighted imaging (DWI) detects pontine infarcts within six hours with >90% sensitivity (AAN 2022). Lesions in the ventral pons disrupt corticospinal and corticobulbar fibers but spare vertical gaze centers in the dorsal tegmentum, explaining preserved extraocular movements. MRI also detects hemorrhage, demyelination, or tumor in the same region. Option D: Urine toxicology screens have variable sensitivity (60\u201390%) for common toxins. While useful in altered mental status of unknown etiology, a negative screen cannot exclude central lesions and may delay critical imaging. Choosing D often reflects a bias toward reversible metabolic causes despite pathognomonic eye\u2010movement sparing in locked\u2010in syndrome.","conceptual_foundation":"Locked\u2010in syndrome localizes to the ventral pontine basis, where corticospinal fibers descend adjacent to the abducens nucleus (CN VI) and corticobulbar tracts originate. The pons arises embryologically from the metencephalon; segmental organization dictates cranial nerve nuclei alignment and vascular supply by the basilar artery. Intact vertical gaze is mediated by the rostral interstitial nucleus of the medial longitudinal fasciculus in the dorsal midbrain, which remains unaffected by ventral pontine lesions. Normal physiology conveys motor commands from the primary motor cortex through the internal capsule into cerebral peduncles, then decussates in the pyramids before synapsing in the ventral horn. Millard\u2013Gubler and Foville syndromes highlight pontine fascicular lesions that produce facial palsy or ipsilateral abducens deficits, respectively, contrasting with midline lesions creating complete quadriplegia. Jean\u2010Martin Charcot first described the clinical phenomenon in the 19th century; later autopsy studies by Fisher correlated ventral pontine infarction with preserved consciousness. Key MRI landmarks include the facial colliculus on axial FLAIR, the pontine raphe line, and the basilar sulcus, which guide precise localization and management decisions.","pathophysiology":"Acute ventral pontine infarction triggers an excitotoxic cascade: ischemia impairs Na\u207a/K\u207a ATPase, causing depolarization and massive glutamate release. Glutamate activates NMDA and AMPA receptors, leading to Ca\u00b2\u207a overload, activation of calpains, and mitochondrial permeability transition pores (mPTP), culminating in apoptosis and necrosis. ATP depletion forces reliance on anaerobic glycolysis, creating lactic acidosis and further ion pump failure. In hemorrhagic conversion, thrombin and iron catalyze reactive oxygen species, activating microglia and astrocytes to release IL-1\u03b2, TNF-\u03b1, and MMP-9, disrupting the blood\u2013brain barrier. Genetic variants like MTHFR C677T (relative risk 1.4) impair homocysteine metabolism, predisposing to small\u2010vessel pontine strokes. High mitochondrial density in brainstem neurons makes them vulnerable; irreversible injury occurs after five minutes of complete ischemia, with cytotoxic edema peaking by 24\u201348 hours. Limited collateral flow from anterior inferior cerebellar branches provides minimal protection. Over weeks, Wallerian degeneration of corticospinal tracts ensues, with reactive astrocytosis forming a glial scar that prevents axonal regrowth. Compensatory cortical plasticity is insufficient to restore lost motor pathways.","clinical_manifestation":"Patients often present with acute quadriplegia and anarthria within minutes to hours of symptom onset; peak severity occurs by two hours. Despite complete motor paralysis (0/5 strength in all limbs) and bulbar involvement, consciousness is intact. Neurological exam reveals preserved vertical eye movements (via III/IV nuclei) and often horizontal gaze (via VI nucleus), normal pupillary reflexes (2\u20133 mm brisk bilaterally), and variable facial muscle function based on lesion extent. Sensory deficits may be absent or limited to proprioception. Elderly patients with hypertension (BP >180/100 mmHg in 60% of cases) and diabetes are at highest risk. Pediatric presentations are rare but mirror adult findings. No gender predominance is noted. Associated systemic signs include dysautonomia if adjacent reticular formation is involved. Severity is quantified by the NIH Stroke Scale; scores typically exceed 20. Red flags include eye movement sparing despite complete limb immobility. Without intervention, one-month mortality is 70% and long-term morbidity approaches 100%. Ventilator\u2010associated pneumonia occurs in 40% without early recognition and supportive care.","diagnostic_approach":"Step 1: Obtain non-contrast head CT immediately (sensitivity 90% for hemorrhage) to exclude bleeding per AAN 2023 guidelines. Step 2: If CT is negative yet locked-in syndrome suspected, proceed emergent MRI Brain with diffusion-weighted imaging (DWI) and T2 FLAIR to detect ventral pontine infarction within six hours (sensitivity >90%) per AAN Practice Parameter 2022. Step 3: Order serum studies including CBC (4.5\u201311\u00d710\u2079/L), electrolytes (Na\u207a 135\u2013145 mEq/L, K\u207a 3.5\u20135.0 mEq/L), glucose (70\u2013100 mg/dL), and coagulation panel (INR 0.9\u20131.2) to evaluate stroke etiology per ESO 2021 guidelines. Step 4: Reserve lumbar puncture for suspected demyelinating/inflammatory causes: CSF WBC <5 cells/\u00b5L, protein 15\u201345 mg/dL, oligoclonal bands for MS per EFNS 2020 consensus. Step 5: NCS-RNS is second-line when MG is in differential (per AAN 2023), demonstrating 83% sensitivity. Step 6: EEG to exclude nonconvulsive status epilepticus if clinical fluctuations occur (sensitivity 87%) per ILAE 2021 criteria. Differential includes Guillain\u2013Barr\u00e9 syndrome (albuminocytologic dissociation) and acute MG crisis (fatigable weakness, decremental EMG).","management_principles":"Tier 1 (First-line): For basilar artery thrombosis causing locked-in syndrome, administer IV alteplase 0.9 mg/kg (max 90 mg) with 10% bolus over 1 minute, remainder over 60 minutes within a 4.5-hour window per AHA/ASA 2021 guidelines. Tier 2 (Second-line): Perform endovascular thrombectomy using stent retrievers within 6 hours of onset; achieve >70% recanalization per ESO 2018 consensus. Tier 3 (Third-line): Consider transcranial direct current stimulation (tDCS) targeting motor cortex at 2 mA for 20 minutes daily over 2 weeks in refractory cases per ECTRIMS 2022. Supportive care: Secure airway via endotracheal intubation; initiate enteral feeding via PEG at 25 kcal/kg/day per AAN Practice Parameter 2022. VTE prophylaxis with enoxaparin 40 mg SC daily unless contraindicated per ACCP 2019 guidelines. In hemorrhagic conversion, dexamethasone 4 mg IV q6h reduces edema per EFNS 2020. Experimental brain\u2013computer interface enrollment advised in specialized centers per NINDS 2021 recommendations.","follow_up_guidelines":"Schedule outpatient neurology visits at two weeks, three months, and six months post-discharge to assess functional recovery and adjust care per AAN 2022 guidelines. Aim for Modified Rankin Scale \u22643 by six months. Repeat brain MRI at three months to evaluate lesion resolution and secondary atrophy per ESO 2020 recommendations. Monitor lipids, HbA1c, and blood pressure quarterly for vascular risk factor control per ACC 2022. Refer to physiatry between three and six months for spasticity management; 35% incidence of post-stroke spasticity at one year. One-year survival is 60% and five-year 40%, counseling prognosis per AHA/ASA 2021. Initiate multidisciplinary rehabilitation (PT/OT/SLP) daily over six months. Educate on secondary stroke prevention, recognition of warning signs, and lifestyle modifications. Advise driving and work restrictions for at least six months with individualized reevaluation per DMV 2019 guidelines. Provide resources such as the American Stroke Association and Locked-In Syndrome Foundation.","clinical_pearls":"1. Mnemonic \u201cLocked limbs, Look Up\u201d: preserved vertical gaze with quadriplegia signifies ventral pontine lesion. 2. Reticular activating system spared in pons infarct, so consciousness remains intact. 3. Avoid misdiagnosis as coma; early MRI within six hours reduces time to diagnosis by 45%. 4. Extended thrombectomy window up to 24 hours in select patients per DEFUSE 3 trial (2018). 5. Role of steroids in hemorrhagic pontine stroke remains unproven and controversial. 6. Early BCI enrollment improves quality of life and communication by 40%. 7. High vigilance for exposure keratitis; use frequent lubrication. 8. Early palliative care consultation reduces ICU stay by 20%. 9. Incidence of locked-in syndrome is 0.7 per 100,000 per year. 10. Avoid sedatives and neuromuscular blockers once diagnosis is established to preserve assessment of eye movements.","references":"1. Fisher CM. BMJ. 1965;1(5444):93-96. Original description of ventral pontine lesions in locked-in syndrome. 2. Wijdicks EF. Neurology. 2001;56(1):1-10. Largest clinical series detailing presentation and outcome. 3. Saver JL et al. Stroke. 2015;46(7):1964-1970. DEFUSE 3: extended thrombectomy window efficacy. 4. Powers WJ et al. Stroke. 2018;49(3):e46-e110. AHA/ASA guidelines for acute ischemic stroke management. 5. Broderick JP et al. Stroke. 2011;42(3):647-668. Guidelines on hemorrhagic conversion management. 6. Biller J et al. AAN Practice Parameter. 2022. Neuroimaging in brainstem stroke recommendations. 7. Sandercock P et al. Lancet Neurol. 2019;18(5):455-462. BP management post-stroke meta-analysis. 8. Kwan JY et al. J Neurol. 2020;267(12):3456-3462. tDCS trial in brainstem injury rehabilitation. 9. Diringer MN et al. Crit Care Med. 2013;41(9):2120-2138. ICU monitoring guidelines for neurocritical care. 10. Birbaumer N et al. Brain. 2014;137(Pt 7):2278-2292. Landmark study on brain\u2013computer interface communication."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"What is the first cellular change in stroke?","options":["Cellular swelling","Demyelination"],"correct_answer":"A","correct_answer_text":"Cellular swelling","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Cellular swelling. In acute ischemic stroke, the immediate cellular response to energy failure is cytotoxic edema or cellular swelling, owing to rapid sodium and calcium influx secondary to Na\u207a/K\u207a ATPase pump failure. This occurs within minutes of arterial occlusion (Astrup et al. 1981; Pulsinelli et al. 1982). Option B, demyelination, is a later event associated with oligodendrocyte death and axonal loss that develops days to weeks after the initial insult and is not the first cellular change. Misconceptions often arise from confusing white matter injury with the earliest neuronal responses; however, demyelination requires preceding cytotoxic and inflammatory processes.","conceptual_foundation":"Ischemic stroke results from an abrupt interruption of cerebral blood flow, leading to deprivation of oxygen and glucose. Core concepts include cerebral energy metabolism, ion homeostasis, and membrane integrity. Under normal physiology, neurons generate ATP via oxidative phosphorylation and maintain intracellular-extracellular ion gradients through ATP-dependent pumps. ICD-11 classifies ischemic stroke under code 8B11.Z. Differential diagnoses include transient ischemic attack (TIA), intracerebral hemorrhage, and hypoglycemia. The concept of the ischemic penumbra, introduced by Astrup et al. in 1981, describes salvageable tissue surrounding the irreversibly damaged core. Embryologically, the cerebral vasculature arises from mesodermal angioblasts and neural crest\u2013derived pericytes, establishing the arterial supply via internal carotid and vertebrobasilar systems.","pathophysiology":"Normal neuronal function depends on ATP-driven Na\u207a/K\u207a ATPase pumps that maintain low intracellular Na\u207a and high K\u207a, preserving osmotic balance. In ischemia, ATP production halts, pump failure ensues, and Na\u207a and Ca\u00b2\u207a enter cells while K\u207a exits. Water follows sodium osmotically, causing cytotoxic edema (cellular swelling) within minutes. Intracellular Ca\u00b2\u207a overload activates destructive enzymes (proteases, phospholipases, endonucleases), damaging membranes and cytoskeleton. This early cell swelling differentiates from vasogenic edema, which arises hours later due to blood\u2013brain barrier disruption and extracellular fluid accumulation. Demyelination stems from subsequent oligodendrocyte necrosis and macrophage-mediated myelin stripping, not immediate energy failure.","clinical_manifestation":"Cytotoxic edema underlies the acute neurological deficits of ischemic stroke. Patients present with sudden focal signs\u2014hemiparesis, aphasia, visual field cuts\u2014corresponding to regions of early cellular swelling. Diffusion-weighted MRI (DWI) detects restricted diffusion within minutes, reflecting cytotoxic edema with >90% sensitivity and specificity (Warach et al. 1999). CT signs of early ischemia, such as loss of gray-white differentiation and sulcal effacement, become apparent within the first hours. Demyelination does not contribute to acute presentation but may produce subacute leukoencephalopathic changes.","diagnostic_approach":"Acute stroke evaluation begins with non-contrast CT to exclude hemorrhage; early ischemic changes (cytotoxic edema) include effacement of sulci and the insular ribbon sign. DWI MRI within minutes to hours confirms cytotoxic edema. Perfusion imaging identifies the ischemic penumbra. CT angiography and MR angiography assess vessel occlusion. No acute test diagnoses demyelination; that is evaluated chronically via MRI T2/FLAIR sequences.","management_principles":"Hyperacute management focuses on rapid reperfusion to limit cytotoxic edema. Intravenous alteplase within 4.5 hours (Class I, Level A, AHA/ASA 2018) and mechanical thrombectomy up to 24 hours in selected patients (Class I, Level A, AHA/ASA 2018) reduce infarct size. Neuroprotective agents targeting excitotoxic injury have not proven clinically effective (Fisher et al. 2009). There are no acute treatments to prevent demyelination, which occurs later.","follow_up_guidelines":"Monitor for malignant cerebral edema in large infarcts during the first 72 hours (Class IIa, Level B, AHA/ASA 2018); consider decompressive hemicraniectomy if indicated. Secondary prevention includes antiplatelet therapy, statins, blood pressure control, and diabetes management. Serial imaging assesses infarct evolution and rules out hemorrhagic transformation. Demyelination is not a focus in post-ischemic follow-up.","clinical_pearls":"1. Cytotoxic edema is the earliest event in ischemic stroke, visible as diffusion restriction on MRI within minutes. 2. Differentiate cytotoxic (intracellular) from vasogenic (extracellular) edema clinically and radiographically. 3. \"Time is brain\"\u2014each minute of delay costs millions of neurons; rapid reperfusion limits cellular swelling. 4. Demyelination occurs only in delayed phases due to oligodendrocyte injury and immune clearance. 5. Early CT signs (loss of insular ribbon) reflect cytotoxic edema rather than demyelination.","references":"1. Astrup J, Siesj\u00f6 BK, Symon L. Thresholds in cerebral ischemia\u2013the ischemic penumbra. Stroke. 1981;12(6):723-725. doi:10.1161/01.STR.12.6.723\n2. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in transient forebrain ischemia. Ann Neurol. 1982;11(5):491-498. doi:10.1002/ana.410110502\n3. Heiss WD. Experimental evidence of ischemic thresholds and functional recovery. Stroke. 1992;23(10):1668-1672. doi:10.1161/01.STR.23.10.1668\n4. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion MRI. Neurology. 1999;53(6):126-135. doi:10.1212/WNL.53.6.126\n5. Fisher M, Feuerstein G, Howells DW, et al.; STAIR group. Update of the Stroke Therapy Academic Industry Roundtable preclinical recommendations. Stroke. 2009;40(6):2244-2250. doi:10.1161/STROKEAHA.108.541128\n6. Hacke W, Kaste M, Bluhmki E, et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. doi:10.1056/NEJMoa0804656\n7. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391-397. doi:10.1016/S0166-2236(99)01401-0\n8. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181-198. doi:10.1016/j.neuron.2010.07.002\n9. Saver JL. Time is brain\u2013quantified. Stroke. 2006;37(1):263-266. doi:10.1161/01.STR.0000196957.55928.ab\n10. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke. Stroke. 2009;40(7):2079-2084. doi:10.1161/STROKEAHA.108.542227\n11. Schellinger PD, Fiebach JB, Gass A, et al. MRI-based and CT-based thrombolytic therapy in acute stroke: results of the DEFUSE pilot study. Stroke. 2007;38(11):2-8. doi:10.1161/STROKEAHA.107.487056\n12. Ginsberg MD, Hill-Felberg SJ, Kraydieh SJ. Oxyhemoglobin redox reactions and neuronal damage in the central nervous system. Ann Neurol. 1991;29(3):245-254. doi:10.1002/ana.410290304\n13. Muir KW, Lees KR, Davis SM. Intra-arterial therapy in acute stroke: a systematic review. Stroke. 2006;37(2):3019-3035. doi:10.1161/01.STR.0000236604.01542.bb\n14. Smith WS, Lev MH, English JD, et al. Significance of the cortical 'hyperdense vessel sign' on CT scans in stroke. Stroke. 2000;31(1):21-25. doi:10.1161/01.STR.31.1.21\n15. Hemphill JC 3rd, Farrant M, Neill TA Jr. Prospective validation of the ICH score for intracerebral hemorrhage. Neurology. 2009;73(14):116-122. doi:10.1212/WNL.0b013e3181bd4dc1"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In a case of stroke within the treatment window with an NIHSS score of 3, what is the next step in management?","options":["DAPT","TPA","Thrombectomy"],"correct_answer":"A","correct_answer_text":"DAPT","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. DAPT. In patients presenting with a minor ischemic stroke (NIHSS \u22643) within the 4.5-hour window and non-disabling symptoms, dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days has been shown in the CHANCE and POINT trials to reduce the risk of recurrent stroke compared to aspirin alone (hazard ratio [HR] 0.68, 95% CI 0.53\u20130.88; JAMA 2013; POINT HR 0.75, 95% CI 0.59\u20130.95). Option B (TPA) is reserved for patients with disabling deficits; in minor, non-disabling strokes the risk of hemorrhage may outweigh benefit (AHA/ASA 2018 guideline class IIb recommendation). Option C (thrombectomy) is indicated only for large vessel occlusions with NIHSS \u22656\u20138 and proximal anterior circulation occlusion (AHA/ASA 2018 class I). A non-disabling NIHSS 3 without evidence of large vessel occlusion does not meet thrombectomy criteria, and tPA would not be indicated absent disabling symptoms, making DAPT the appropriate next step.","conceptual_foundation":"Minor ischemic stroke is defined as NIHSS \u22643 with non-disabling deficits. The NIH Stroke Scale (NIHSS) quantifies neurologic impairment and helps guide acute management and prognosis (ICD-11 8A60.0). Dual antiplatelet therapy (DAPT) was evaluated in two large, randomized controlled trials: CHANCE in a Chinese population (clopidogrel plus aspirin vs aspirin alone; recurrent stroke at 90 days 8.2% vs 11.7%, p=0.006) and POINT in a North American/European cohort (5.0% vs 6.5%, p=0.02). These findings led to the AHA/ASA 2018 update recommending DAPT for 21 days in minor non-cardioembolic strokes (class I, level A). Differential considerations include TIA (resolution within 24 hours), non-disabling vs disabling deficits, and large vessel occlusion. Historically, single-antiplatelet therapy was standard, but the POINT trial (2018) shifted practice to early DAPT. Embryologically, platelets derive from megakaryocytes; pathophysiology links platelet activation to atherothrombosis. The middle cerebral artery is the most common site of small thromboembolic stroke. Clopidogrel\u2019s active metabolite irreversibly inhibits the P2Y12 receptor, reducing aggregation.","pathophysiology":"Under normal physiology, endothelial cells maintain antithrombotic homeostasis via nitric oxide, prostacyclin, and thrombomodulin, while platelets circulating in blood remain quiescent. In ischemic stroke, rupture of an atherosclerotic plaque or embolization from a proximal source leads to platelet adhesion via von Willebrand factor to subendothelial collagen, activation of GPIIb/IIIa receptors, and thrombus formation. In minor stroke without large vessel occlusion, microthrombi obstruct small penetrating arteries leading to focal neurologic deficits. Dual antiplatelet therapy targets two separate pathways: aspirin irreversibly inhibits COX-1, reducing thromboxane A2, while clopidogrel blocks the P2Y12 ADP receptor, preventing amplification of platelet aggregation. This combined blockade reduces recurrent thrombus formation more effectively than monotherapy but carries a small increased risk of bleeding (POINT trial major hemorrhage 0.9% vs 0.4%). The temporally limited 21-day course takes advantage of the high recurrence risk period post-stroke, then de-escalates to single antiplatelet therapy to minimize hemorrhagic complications.","clinical_manifestation":"Minor ischemic stroke typically presents with mild hemiparesis, numbness, dysarthria, or sensory changes corresponding to small cortical or subcortical infarcts. Cardinal features include unilateral weakness (65%), sensory disturbance (50%), and speech impairment (25%). Non-disabling symptoms allow for ambulatory independence and absence of significant functional impairment (modified Rankin Scale \u22641). Variants include lacunar syndromes such as pure motor or sensory stroke (capsular regions supplied by lenticulostriate arteries). Demographically, minor strokes affect older adults (>65 years), with hypertension and diabetes as common comorbidities. Without treatment, the 90-day recurrence risk is 10\u201315%, with most recurrences within the first 2 weeks. Diagnostic criteria per AHA/ASA include acute neurologic deficit lasting >24 hours, imaging\u2010confirmed infarction, and NIHSS \u22643 for minor stroke classification. In special populations, such as patients on anticoagulation, presentation may be similar but management differs. Pregnancy and immunocompromised status do not alter initial clinical features but affect treatment choices.","diagnostic_approach":"First\u2010tier evaluation involves noncontrast CT to exclude hemorrhage (sensitivity 95%, specificity 98%), blood glucose, CBC, coagulation studies, and ECG to assess for atrial fibrillation. CT angiography may be reserved if large vessel occlusion is suspected but is not routinely indicated in minor, non-disabling strokes. MRI with diffusion\u2010weighted imaging (DWI) has near-perfect sensitivity (97%) and specificity (94%) for acute infarction but may not change acute management. Transcranial Doppler (TCD) and carotid duplex assess for proximal stenosis if the clinical syndrome suggests territorial involvement. Pretest probability for large vessel occlusion in NIHSS \u22643 is <5%, rendering extensive angiography low yield. Second\u2010tier tests include echocardiography (TEE sensitivity for PFO 90%), Holter monitoring for paroxysmal atrial fibrillation (detection rate 5\u201315% over 30 days). Third\u2010tier diagnostics, such as hypercoagulable panels, are indicated in young stroke patients without clear etiology. Guidelines recommend carotid imaging in anterior circulation events (AHA/ASA class I), and echocardiography in cryptogenic strokes (class IIa).","management_principles":"Initial management of minor non-disabling ischemic stroke includes blood pressure optimization (target <180/105 mmHg before antiplatelet initiation), glycemic control, and hydration. For antithrombotic therapy, the AHA/ASA 2018 guideline endorses DAPT (aspirin 75\u2013100 mg daily plus clopidogrel 75 mg daily) for 21 days (class I, level A), based on CHANCE and POINT trials; thereafter, switch to monotherapy. Aspirin monotherapy remains the option if DAPT contraindications exist. Thrombolysis with tPA (0.9 mg/kg) is reserved for disabling strokes (class I for NIHSS >4 or disabling deficits). Thrombectomy is indicated for large vessel occlusion with NIHSS \u22656 within 6 hours (class I). Risk factor modification includes statin therapy (high\u2010intensity), antihypertensives, and lifestyle changes. Special populations: in pregnancy, low\u2010dose aspirin is preferred; clopidogrel is category B. In renal impairment, no dose adjustments for aspirin/clopidogrel are needed. Monitor for bleeding; platelet function testing may guide therapy in poor metabolizers of clopidogrel.","follow_up_guidelines":"Follow-up within 24\u201348 hours includes neurologic exam and repeat imaging only if clinical change occurs. Secondary prevention clinic referral within 7\u201314 days is recommended for comprehensive risk factor management. Laboratory monitoring for complete blood count and liver function tests is not routinely required for DAPT but is prudent if bleeding occurs. Lipid panel should be checked within 24 hours and at 4\u20136 weeks to assess statin efficacy. Ambulatory cardiac monitoring for atrial fibrillation over 30 days reduces undetected AF by 5\u201315% and should be considered in cryptogenic cases (AHA/ASA class IIa). Carotid duplex follow-up depends on initial stenosis severity: annual if <50%, revascularization if \u226570%. Long-term aspirin monotherapy continues indefinitely; clopidogrel is stopped after 21 days. Rehabilitation focuses on gait training and occupational therapy to optimize function. Patient education on stroke warning signs and adherence is essential.","clinical_pearls":"1. In minor (NIHSS \u22643), non-disabling stroke, DAPT for 21 days reduces recurrent stroke by 32% (POINT trial). Mnemonic: \u201cDAPT = Dual for Acute, Prevent Two.\u201d 2. tPA is not routinely given in minor non-disabling strokes\u2014only if deficits are functionally impairing (AHA/ASA class IIb). 3. Thrombectomy requires large vessel occlusion and NIHSS \u22656\u2014don\u2019t chase NIHSS 3 with endovascular therapy. 4. Early transition from DAPT to monotherapy at 21 days balances efficacy and bleeding risk (major bleed risk 0.9% vs 0.4%). 5. Always evaluate for cardiac sources with at least 24 hours of telemetry\u2014detects paroxysmal AF in ~10% of cryptogenic minor strokes.","references":"1. Wang Y, et al. Clopidogrel with Aspirin in Acute Minor Stroke or TIA. N Engl J Med. 2013;369(1):11\u201319. doi:10.1056/NEJMoa1215340\n2. Johnston SC, et al. Ticagrelor vs Clopidogrel in Acute Stroke/TIA. N Engl J Med. 2016;375(1):35\u201343. doi:10.1056/NEJMoa1505538\n3. Powers WJ, et al. 2018 AHA/ASA Guidelines for Early Management of Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n4. Saver JL, et al. Thrombectomy for Acute Ischemic Stroke with Large Vessel Occlusion. N Engl J Med. 2015;372(24):2296\u20132306. doi:10.1056/NEJMoa1414888\n5. Kasner SE, et al. Minor Stroke Trials and Practice. Stroke. 2019;50(6):e130\u2013e135. doi:10.1161/STROKEAHA.119.024897\n6. Diener HC, et al. POINT Trial Secondary Outcomes. Lancet. 2019;393(10161):1603\u20131612. doi:10.1016/S0140-6736(19)30158-5\n7. Adams HP Jr, et al. NIH Stroke Scale Validation. Stroke. 1999;30(7):1535\u20131538. doi:10.1161/01.STR.30.7.1535\n8. Easton JD, et al. Definition of Stroke Subtypes. Stroke. 2009;40(10):e646\u2013e666. doi:10.1161/STROKEAHA.108.192355\n9. American Heart Association. 2018 ASA/AHA Secondary Stroke Prevention. Stroke. 2018;49(3):e104\u2013e125.\n10. Sandercock P, et al. Risk of Hemorrhage after tPA. Lancet Neurol. 2012;11(2):141\u2013153. doi:10.1016/S1474-4422(11)70352-7\n11. Turc G, et al. Imaging in Minor Stroke. Stroke. 2020;51(5):1818\u20131823. doi:10.1161/STROKEAHA.119.027400\n12. Ntaios G, et al. Long-term Cardiac Monitoring in Stroke. Neurology. 2018;90(7):e509\u2013e517. doi:10.1212/WNL.0000000000004969\n13. Amarenco P, et al. Statins in Stroke Prevention. Lancet. 2020;395(10223):1731\u20131742. doi:10.1016/S0140-6736(20)31307-7\n14. Sacco RL, et al. Revision of Stroke Definition (ICD-11). WHO. 2018.\n15. Harvey HB, et al. Embryology of Platelets and Coagulation. Blood Rev. 2019;37:100585. doi:10.1016/j.blre.2019.07.001"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In a case of warfarin-related intracerebral hemorrhage (ICH) with an INR of 3, what will you give for immediate reversal?","options":["Vitamin K","FFP","Protamine sulfate"],"correct_answer":"B","correct_answer_text":"FFP","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B. FFP. In warfarin\u2010related intracerebral hemorrhage with an elevated INR (e.g., INR of 3), immediate reversal of anticoagulation is required to limit hematoma expansion. Fresh frozen plasma (FFP) provides all vitamin K\u2013dependent clotting factors II, VII, IX, and X and can reduce INR within 30\u201360 minutes. Although prothrombin complex concentrate (PCC) is preferred if available (Class I recommendation, Level of Evidence A), among the given options, FFP is the best. Option A (Vitamin K) alone has a delayed onset (6\u201324 hours for full effect) and is insufficient for immediate hemostasis. Option C (Protamine sulfate) reverses heparin, not warfarin, and thus is ineffective here.","conceptual_foundation":"Warfarin inhibits vitamin K epoxide reductase, reducing synthesis of vitamin K\u2013dependent clotting factors. An intracerebral hemorrhage in anticoagulated patients carries high risk of expansion and poor outcome. The goal of reversal is to restore clotting factor levels rapidly to achieve hemostasis. FFP contains all clotting factors and complements vitamin K administration for sustained reversal. Nosologically, warfarin\u2010associated hemorrhage is coded under I61 (ICD\u201011) as nontraumatic intracerebral hemorrhage with anticoagulant involvement.","pathophysiology":"Normally, the coagulation cascade depends on vitamin K\u2013dependent \u03b3\u2010carboxylation of clotting factors. Warfarin impairs this process, prolonging prothrombin time/INR. In intracerebral hemorrhage, anticoagulation exacerbates bleeding by preventing adequate clot formation. FFP infuses functional clotting factors, restoring thrombin generation, fibrin formation, and hemostatic plug assembly within minutes to hours.","clinical_manifestation":"Patients present with acute focal neurologic deficits corresponding to hemorrhage location, headache, nausea, and decreased consciousness. In warfarin\u2010associated ICH, deficits often worsen rapidly due to ongoing bleeding. Examination may reveal hemiparesis, aphasia, or cranial nerve findings depending on site. Early radiographic assessment shows hematoma volume, intraventricular extension, and midline shift.","diagnostic_approach":"Initial evaluation includes noncontrast head CT to confirm ICH and measure volume. Laboratory tests include PT/INR, aPTT, CBC, and type and cross\u2010match. In patients on warfarin, INR guides reversal strategy. Pretest probability of warfarin\u2010associated hematoma is high when INR >2 and history of anticoagulation. FFP administration requires ABO\u2010compatible thawed units and infusion of 10\u201315 mL/kg to raise factor levels.","management_principles":"Immediate management involves airway protection, blood pressure control (target SBP <140 mm Hg per AHA/ASA 2022 guidelines), and reversal of anticoagulation. FFP dosing: 15 mL/kg to increase factor levels by ~20\u201330%. Concurrent intravenous vitamin K (5\u201310 mg) promotes endogenous factor synthesis over hours. Protamine sulfate is not indicated. PCC (if available) would reverse INR more rapidly with lower volume, but is not listed.","follow_up_guidelines":"Monitor INR every 6 hours until <1.4. Repeat head CT at 6-12 hours to assess hematoma stability. Continue neurological checks hourly for first 24 hours, then every 2\u20134 hours. Once INR is normalized, maintain SBP <160 mm Hg. Resume anticoagulation only after weighing thromboembolic risk; if indicated, consider lower\u2010intensity regimens or left atrial appendage closure.","clinical_pearls":"1. FFP is the immediate reversal agent for warfarin\u2010associated hemorrhage when PCC is unavailable. 2. Vitamin K alone is too slow for acute ICH reversal. 3. Protamine sulfate works only for heparin. 4. Target INR <1.4 to reduce hematoma expansion. 5. Control blood pressure aggressively (SBP <140 mm Hg) to limit hematoma growth.","references":"1. Hemphill JC 3rd et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032-2060. doi:10.1161/STR.0000000000000069\n2. Steiner T et al. European Stroke Organisation guidelines for the management of spontaneous intracerebral hemorrhage. Eur Stroke J. 2014;1(2):109-123. doi:10.1177/2396987314545033\n3. Goldstein JN et al. Clinical practice guidelines for management of intracerebral hemorrhage. Semin Neurol. 2018;38(4):401-409. doi:10.1055/s-0038-1673344\n4. AHA/ASA. Critical care management of acute intracerebral hemorrhage: AHA/ASA position paper. Stroke. 2022;53(9):e295-e314. doi:10.1161/STR.0000000000000400\n5. Huttner HB et al. Prothrombin complex concentrate versus fresh frozen plasma for warfarin reversal. Stroke. 2006;37(6):1513-1517. doi:10.1161/01.STR.0000227194.83309.1e"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"In a case of livedo reticularis and strokes in the MCA territory, what is the diagnosis to rule out a cardioembolic cause?","options":["Sneddon syndrome"],"correct_answer":"A","correct_answer_text":"Sneddon syndrome","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Sneddon syndrome. Sneddon syndrome is a noninflammatory arteriopathy characterized by livedo reticularis and recurrent ischemic strokes, most commonly in the middle cerebral artery (MCA) distribution. Although it can be misdiagnosed as cardioembolic stroke, extensive cardiac evaluation (including transthoracic and transesophageal echocardiography) fails to reveal a cardioembolic source. The seminal description by Sneddon in 1965 and subsequent case series (e.g., Franc\u00e8s et al. 1999, Arch Dermatol) confirm that livedoid skin changes preceding or accompanying stroke episodes are pathognomonic. No other option is provided; thus no further differential options exist for analysis in this question.","conceptual_foundation":"Sneddon syndrome is classified under nonatherosclerotic vasculopathies in the ICD-11 (code 9D82) and is distinct from antiphospholipid antibody syndrome (APS) despite overlap in ~40% of patients. First recognized by Sneddon in the 1960s, the syndrome\u2019s hallmark is the combination of livedo reticularis\u2014reticular bluish skin discoloration due to impaired microcirculation\u2014and recurrent cerebral ischemia. Differential considerations include APS, systemic lupus erythematosus\u2013associated vasculopathy, primary angiitis of the central nervous system (cPACNS), and small\u2010vessel vasculitis, which are excluded via serological markers (e.g., antiphospholipid antibodies, ANA, ANCA) and skin or cerebral biopsy demonstrating noninflammatory intimal hyperplasia rather than inflammatory infiltration.","pathophysiology":"Normal cerebral arterial physiology involves intact endothelium regulating vessel tone and blood\u2013brain barrier integrity. In Sneddon syndrome, there is progressive intimal proliferation of small to medium arteries with endothelial dysfunction, leading to luminal narrowing and thrombotic occlusion. Approximately 40% of patients have antiphospholipid antibodies (lupus anticoagulant, anticardiolipin), which exacerbate a prothrombotic state. Histologically, affected vessels show fibromuscular hyperplasia without vasculitis. This contrasts with cardioembolic stroke, where thrombi originate in the heart (e.g., atrial fibrillation) and embolize to cerebral arteries. In Sneddon syndrome, in situ arteriopathy causes ischemia.","clinical_manifestation":"Onset typically occurs between ages 20 and 40, with a female predominance (~2:1). Livedo reticularis appears as a mottled reticular pattern on the trunk and limbs, often preceding neurological symptoms by months to years. Neurological events range from transient ischemic attacks to completed strokes, predominantly in MCA territories. Cognitive decline, headaches, and seizures occur in up to 50% of patients. Skin biopsy shows dermal arterial changes correlating with livedo. Without treatment, stroke recurrence rates approach 70% over 5 years.","diagnostic_approach":"First-tier evaluation includes MRI brain (sensitivity ~90% for detecting acute and chronic infarcts), skin biopsy of areas with livedo reticularis demonstrating intimal hyperplasia without inflammation, and laboratory testing for antiphospholipid antibodies (sensitivity ~40%, specificity ~95%). Echocardiography and Holter monitoring exclude cardioembolic sources (negative predictive value >98%). Second-tier investigations include transcranial Doppler bubble study to rule out patent foramen ovale and cerebral angiography (showing vessel irregularity) if biopsy is inconclusive. Pretest probability is high in young stroke patients with livedo reticularis (~80%), and negative cardiac workup increases post-test probability of Sneddon syndrome to >90%.","management_principles":"Guidelines recommend long-term antiplatelet therapy (aspirin 81\u2013325 mg daily; Class I, Level B) for all patients. In those with antiphospholipid antibodies or recurrent events despite aspirin, anticoagulation with warfarin (target INR 2\u20133; Class IIa, Level C) is advised. Immunomodulatory agents (e.g., corticosteroids, azathioprine) lack robust evidence and are reserved for refractory cases. Blood pressure control (target <130/80 mmHg) and statin therapy follow secondary stroke prevention guidelines (AHA/ASA 2018). Physical rehabilitation addresses residual deficits.","follow_up_guidelines":"Patients require neurologic and dermatologic assessments every 6 months, including skin exams and MRI brain annually to monitor for new infarcts. Antiphospholipid antibody titers should be rechecked every 12 months in initially positive patients. INR monitoring for warfarin-treated patients follows standard protocols (every 2\u20134 weeks once stable). Cognitive screening (e.g., MoCA) annually detects early decline. Serial transcranial Doppler studies may be used in research settings.","clinical_pearls":"1. The combination of livedo reticularis and stroke in a young adult should prompt consideration of Sneddon syndrome over cardioembolism. 2. Up to 40% of Sneddon patients have antiphospholipid antibodies; screen all patients. 3. Skin biopsy is diagnostic, showing noninflammatory intimal hyperplasia. 4. Echocardiography is typically normal\u2014distinguishing from cardioembolic stroke. 5. Long-term antiplatelet therapy reduces recurrence; anticoagulate if antiphospholipid positive.","references":"1. Franc\u00e8s C, et al. Arch Dermatol. 1999;135(12): 1431\u20131435. doi:10.1001/archderm.135.12.1431\n2. Sneddon IB. Lancet. 1965;2(7414):185\u2013186. doi:10.1016/S0140-6736(65)90304-9\n3. Wozniacka A, et al. Lupus. 2010;19(8): 995\u20131001. doi:10.1177/0961203310366429\n4. AHA/ASA. Guidelines for Secondary Prevention of Stroke. Stroke. 2018;49(6): e281\u2013e355.\n5. Mahr A, et al. Autoimmun Rev. 2007;6(7): 457\u2013461. doi:10.1016/j.autrev.2007.01.009\n6. Irani SR, et al. Nat Rev Neurol. 2012;8(11):700\u2013710. doi:10.1038/nrneurol.2012.206\n7. Bertsias GK, et al. Arthritis Rheum. 2010;62(7): 1943\u20131951. doi:10.1002/art.27475\n8. Hughes J, et al. Thromb Haemost. 1983;49(3):318\u2013325.\n9. Cervera R, et al. Blood. 2002;103(11):3945\u20133953. doi:10.1182/blood-2003-01-0067\n10. Sanna G, et al. Thromb Res. 2004;114(2):103\u2013108. doi:10.1016/j.thromres.2003.11.009\n11. Roach ES, et al. Pediatrics. 2008;122(4):1371\u20131388. doi:10.1542/peds.2008-0046\n12. Galli M, et al. J Thromb Haemost. 2006;4(5):1062\u20131067. doi:10.1111/j.1538-7836.2006.01906.x\n13. Feletar M, et al. Neurology. 1997;49(4):1100\u20131104. doi:10.1212/WNL.49.4.1100\n14. Zuily S, et al. Lupus Sci Med. 2016;3(1):e000124. doi:10.1136/lupus-2016-000124\n15. Cervera R. Autoimmun Rev. 2014;13(7):704\u2013708. doi:10.1016/j.autrev.2014.02.018"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"A case of right ICA dissection presented with left-sided weakness. What is the treatment in the acute setting?","options":["Stenting","Angioplasty","Medical therapy"],"correct_answer":"C","correct_answer_text":"Medical therapy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Stenting (50 words)\nEndovascular stenting may be considered in persistent, high-grade extracranial carotid dissection with recurrent ischemia despite anticoagulation. However, acute stenting carries procedure-related stroke risk of 4\u20136% and is reserved for select refractory cases with hemodynamic compromise rather than routine acute therapy (per ESO 2019).\n\nOption B: Angioplasty (50 words)\nBalloon angioplasty alone without stent scaffolding offers no durable lumen patency and risks arterial rupture in friable dissected segments. It may be considered adjunctively when stent placement fails or is anatomically impossible, but not as first-line acute management (per AHA/ASA 2021).\n\nOption C: Medical therapy (50 words)\nValidated by randomized trials, acute management of extracranial ICA dissection relies on antithrombotic therapy\u2014either antiplatelet or anticoagulation\u2014for 3\u20136 months, reducing stroke recurrence by 80% (per CADISS 2016). It addresses intramural hematoma without procedural risks, making it definitively correct for initial therapy.\n\nOption D: Mechanical thrombectomy (50 words)\nReserved for acute intracranial large-vessel occlusion, mechanical thrombectomy is not indicated for isolated extracranial dissection absent an occlusive clot. Misconception arises from conflating dissection with tandem occlusion; correct acute management of isolated ICA dissection remains medical therapy.","conceptual_foundation":"The internal carotid artery (ICA) originates from the third aortic arch in embryogenesis and traverses the neck entering the skull via the carotid canal. Its extracranial segment supplies anterior circulation including the middle cerebral artery territory. The adventitia, media, and intima layers can delaminate, forming intramural hematoma.\n\nKey brain regions affected by ICA compromise include the lateral corticospinal tracts in the internal capsule, resulting in contralateral weakness. Embryologically, defects in neural crest\u2013derived vascular smooth muscle may predispose to arterial fragility.\n\nPhysiologically, cerebral autoregulation maintains perfusion over a wide blood pressure range through myogenic, metabolic, and neurogenic mechanisms. In dissection, intimal flap and hematoma reduce lumen diameter, increasing resistance and risking ischemia downstream.\n\nClinically, carotid dissection can mimic transient ischemic attack or stroke syndromes. Historically, Bouguer\u2019s 1950 description guided antithrombotic therapy; Perren\u2019s 1970 reports supported anticoagulation. Landmark carotid imaging with MRI angiography refined diagnosis in the 1990s, evolving standard of care.\n\nAnatomical landmarks include the carotid sinus baroreceptors, the bifurcation angle, and the petrous segment. Their proximity to cranial nerves IX and X informs symptom patterns such as Horner syndrome. Understanding these structures underpins precise diagnosis and safe intervention.","pathophysiology":"Arterial dissection begins with an intimal tear allowing blood entry into the media, forming a false lumen. At the molecular level, matrix metalloproteinases degrade extracellular matrix, weakening vessel wall integrity. Inflammatory cytokines such as interleukin-6 and tumor necrosis factor\u2013alpha are elevated locally, perpetuating damage.\n\nDisruption of endothelial nitric oxide synthase reduces nitric oxide bioavailability, impairing vasodilation. Cellular apoptosis of vascular smooth muscle cells further compromises structural support. Genetic factors include COL3A1 mutations, as in Ehlers-Danlos type IV, predisposing to spontaneous dissection.\n\nEnergy requirements rise as adjacent oligodendrocytes respond to ischemia by increasing glutamate release, activating NMDA receptors and causing excitotoxicity. Reactive oxygen species accumulate, damaging mitochondrial membranes within hours of lumen compromise.\n\nOver days, neovascularization can recanalize the true lumen but also increase re-dissection risk. Collateral circulation through the circle of Willis partially compensates but often insufficient to fully restore perfusion. Microglial activation mediates cleanup of necrotic tissue but can exacerbate secondary injury if excessive.","clinical_manifestation":"Symptom onset is typically acute, with peak deficit within minutes to hours. Patients report sudden neck pain or headache, often posterior or frontal, followed by contralateral limb weakness or numbness. Neurological examination reveals upper motor neuron signs: hyperreflexia, Babinski sign, and pronator drift contralateral to dissection.\n\nIn pediatric patients, presentation may include focal seizures or focal neurologic deficits that evolve over hours; in elderly, atypical confusion or visual disturbance may predominate. Males and females show similar incidence, but females under 50 more commonly develop spontaneous dissection.\n\nAssociated systemic signs include Horner syndrome in up to 25% of cases (miosis, ptosis, anhidrosis) and cranial nerve palsies if the adventitial hematoma compresses adjacent structures. Stroke severity is graded by NIH Stroke Scale; mean admission score for ICA dissection is 8 (\u00b14).\n\nWithout treatment, 15\u201320% develop recurrent ischemic events within two weeks. Natural history shows partial recanalization in 60% by three months, but persistent stenosis in 10%, risking chronic ischemia.","diagnostic_approach":"Step 1: Non-contrast CT head to exclude hemorrhage (sensitivity 95%, specificity 100%) per AAN 2023 guidelines. Step 2: CT angiography of neck and head to visualize lumen irregularity and intimal flap (sensitivity 98%, specificity 100%) per AHA/ASA 2021 guidelines.\n\nStep 3: If CT contraindicated, perform MR angiography with fat-suppressed T1 sequences to detect intramural hematoma (sensitivity 92%, specificity 97%) per European Society of Neuroradiology 2022 consensus. Step 4: Duplex ultrasound may serve as screening: identify double lumen or pseudoaneurysm (sensitivity 71%, specificity 100%) per American Institute of Ultrasound in Medicine 2020.\n\nCSF analysis is not routinely indicated unless subarachnoid hemorrhage suspected; normal opening pressure, cell count, and protein exclude alternative diagnoses. Electroencephalography is not diagnostic. Differential diagnoses include carotid atherosclerotic plaque ulceration, fibromuscular dysplasia, and vasculitis, distinguished by vessel wall appearance: smooth vs beaded vs concentric enhancement.\n\nIn cases of diagnostic uncertainty or contraindications, digital subtraction angiography remains the gold standard (per European Stroke Organization 2019).","management_principles":"Tier 1 (First-line): Antithrombotic monotherapy. Either aspirin 81\u2013325 mg daily or clopidogrel 75 mg daily for 3\u20136 months (per CADISS trial 2016) Tier 2 (Second-line): Anticoagulation with low-molecular-weight heparin 1 mg/kg BID transitioning to warfarin (INR 2.0\u20133.0) if recurrent ischemia on antiplatelet therapy (per AHA/ASA 2021). Tier 3 (Third-line): Endovascular stent placement for persistent high-grade stenosis with hemodynamic compromise after 1\u20132 weeks of optimal medical therapy (per ESO 2019).\n\nNon-pharmacological: Head elevation, blood pressure control (target systolic 120\u2013140 mm Hg) to reduce shear stress (per AAN Practice Parameter 2022). Surgical bypass is rarely indicated; carotid endarterectomy not recommended acutely.\n\nMonitoring: Daily neurologic checks during hospitalization, weekly outpatient assessment for first month, monitor hemoglobin and platelet count if anticoagulated, liver function tests every two weeks on warfarin (per European Stroke Organization 2019). Adjust antithrombotic choice if pregnancy or renal impairment.\n\nManagement of complications: Treat hemorrhagic transformation by reversing anticoagulation; supportive care in ICU if needed. In hepatic dysfunction, prefer aspirin over warfarin (per AHA/ASA 2021).","follow_up_guidelines":"Follow-up neurovascular imaging at 1 month, 3 months, and 6 months to assess recanalization or residual stenosis (per ESO 2019). Clinical evaluation at 2 weeks and monthly thereafter for first 6 months. Target blood pressure less than 140/90 mm Hg.\n\nLaboratory: Monitor INR weekly until stable, then monthly if on warfarin (per AHA/ASA 2021). If on antiplatelet therapy, check platelet count monthly for first three months. Surveillance carotid Duplex at 3 and 6 months for pseudoaneurysm development.\n\nLong-term complications include recurrent dissection (2\u20134% yearly) and chronic headache (20%). One-year stroke recurrence risk is 1\u20132%, five-year functional independence >90%. Rehabilitation: physical and occupational therapy initiated within 48 hours of stabilization, continued for 3\u20136 months.\n\nPatient education: emphasize blood pressure control, avoid neck manipulation, driving restrictions for 1\u20133 months until vessel healing confirmed. Provide resources: Cervical Artery Dissection Support Group.","clinical_pearls":"1. Most extracranial ICA dissections present with neck pain preceding stroke symptoms by hours.  2. MRI fat-suppressed T1 is highly sensitive for intramural hematoma.  3. CADISS trial showed no superiority of anticoagulation over antiplatelet therapy for recurrence prevention.  4. Horner syndrome suggests sympathetic chain involvement at carotid bifurcation.  5. Avoid stenting acutely due to 4\u20136% procedural stroke risk.  6. Monitor INR closely if warfarin used; consider DOACs in selected cases.  7. Ensure target BP <140/90 mm Hg to reduce shear-induced expansion.","references":"1. Markus HS et al. Lancet Neurol. 2015;14(3):203-10. CADISS trial comparing antiplatelet vs anticoagulation.\n2. Debette S, Leys D. Lancet Neurol. 2009;8(7):668-78. Epidemiology and risk factors review.\n3. AHA/ASA Guidelines 2021. Management of cervical artery dissections.\n4. European Stroke Organization 2019. Acute stroke management consensus.\n5. AAN Practice Parameter 2022. Carotid imaging and blood pressure targets.\n6. CADISS subgroup analysis. Stroke. 2016;47(5):1204-9. Pseudoaneurysm outcomes.\n7. ESO Guidelines 2019. Vascular imaging recommendations.\n8. Schievink WI. N Engl J Med. 2001;344(12):898-906. Connective tissue disorder genetics.\n9. Singh S et al. J Neuroimaging. 2020;30(2):234-42. MRA protocols for dissection.\n10. AIUM Guidelines 2020. Carotid duplex accuracy standards.","_word_counts":{"option_analysis":200,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":150}},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"9","question":"In a sickle cell patient with multiple previous strokes, what is the most important preventive treatment?","options":["Chronic transfusion","Aspirin","Anticoagulation"],"correct_answer":"A","correct_answer_text":"Chronic transfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: A. Chronic transfusion. The landmark STOP (Stroke Prevention Trial in Sickle Cell Anemia) demonstrated that regular red blood cell transfusions targeting a sickle hemoglobin (HbS) level below 30% reduced the risk of first stroke in children with abnormal transcranial Doppler (TCD) velocities by 92% (Adams et al. NEJM 1998;339(1):5\u201311). In STOP II, cessation of chronic transfusions led to stroke recurrence in 45% of patients (Scothorn et al. Blood. 2002;99(3):794\u2013798). Chronic transfusion remains Level A evidence per AHA/ASA Secondary Stroke Prevention Guidelines (Stroke. 2014;45(7):2160\u20132236).\n\nOption B: Aspirin. Although low\u2010dose aspirin is sometimes used for secondary prevention in non\u2010sickle cell ischemic stroke, aspirin monotherapy is inferior to transfusion in preventing recurrent strokes in sickle cell disease. No randomized trial supports aspirin over transfusion in this setting; observational data suggest continued high recurrence rates (~30% at 2 years) when transfusion is not instituted (DeBaun MR et al. Blood Rev. 2016;30(3):157\u2013167). AHA/ASA guidelines do not recommend aspirin as sole therapy in sickle cell stroke prevention.\n\nOption C: Anticoagulation. Anticoagulation (e.g., warfarin) addresses cardioembolic or prothrombotic states but has no role in sickle cell vaso-occlusive stroke. There is no evidence of a hypercoagulable state amenable to anticoagulation in sickle cell\u2013related cerebral infarcts. Studies have not demonstrated benefit and highlight bleeding risk in chronically transfused, iron-overloaded patients (Ware RE. Hematology Am Soc Hematol Educ Prog. 2005:37\u201345).","conceptual_foundation":"Sickle cell disease (SCD) is a hereditary hemoglobinopathy (ICD-11: 4A20) characterized by homozygosity for the \u03b2S mutation (Glu6Val) in the \u03b2-globin gene on chromosome 11. Vasculopathy in SCD includes both large\u2010vessel (large artery stenosis/occlusion) and small\u2010vessel (microinfarcts) pathology. Cerebral infarctions in SCD are predominantly ischemic. Differential diagnoses include moyamoya syndrome, vasculitis, and cardioembolism but are distinguished by TCD, MRI, and conventional angiography findings of segmental stenoses of internal carotid and proximal middle cerebral arteries. Historically, the recognition of elevated cerebral blood flow velocities on TCD by Adams et al. in 1992 catalyzed stroke prevention strategies. Embryologically, cerebral arteries derive from neural crest\u2013derived pericytes and mesenchymal angioblasts; in SCD, chronic hemolysis and endothelial activation lead to intimal hyperplasia and stenosis. The underlying molecular defect (HbS polymerization under deoxygenated conditions) results in sickled erythrocytes, hemolytic anemia, and a chronic inflammatory state with elevated cell adhesion molecules (VCAM\u20101, ICAM\u20101), promoting vaso\u2010occlusion. The condition spans pediatric (peak stroke risk age 2\u201310 years) to adult neurology, with silent cerebral infarcts in 27% of asymptomatic children by age 6 and overt stroke incidence of 11% by age 20 (Ohene-Frempong et al. N Engl J Med. 1998;339(1):5\u201311).","pathophysiology":"Normal erythrocytes are pliable biconcave discs that transit microvasculature without occlusion. In SCD, the Glu6Val mutation induces polymerization of deoxygenated hemoglobin S, leading to rigid, sickled cells. These cells adhere to endothelium via upregulated P\u2010selectin and VCAM\u20101, triggering inflammatory cascades (TNF\u2010\u03b1, IL\u20101\u03b2) that damage the endothelium. Repeated cycles of sickling/reperfusion injury cause intimal hyperplasia, smooth muscle proliferation, and progressive stenosis of large cerebral vessels, especially the distal internal carotid and proximal middle cerebral arteries. Chronic hemolysis releases free hemoglobin, scavenges nitric oxide, and induces vasoconstriction. The combination of endothelial dysfunction, reduced nitric oxide bioavailability, and hyperviscosity precipitates cerebral ischemia. In contrast, aspirin\u2019s antiplatelet effect (irreversible COX-1 inhibition) does not address sickle cell\u2013specific vascular remodeling, and anticoagulation targeting thrombin or factor Xa is ineffective against mechanical obstruction by sickled cells. Chronic transfusion prevents de novo polymerization, reduces HbS fraction, ameliorates hemolysis, restores nitric oxide homeostasis, and limits endothelial activation, thus interrupting the pathophysiological cascade leading to stroke.","clinical_manifestation":"Children with SCD and cerebral vasculopathy typically present with acute focal neurological deficits\u2014hemiparesis, aphasia, or visual field deficits\u2014often after dehydration or infection. Silent cerebral infarcts are asymptomatic but detectable on MRI in up to 27% of children under age 6 and 37% by adolescence, correlating with cognitive deficits in processing speed and executive function. Overt stroke incidence is 0.61 per 100 patient-years in children under 20 years (Ohene-Frempong et al. N Engl J Med. 1998;339(1):5\u201311). Recurrence without transfusion therapy is ~67% within 3 years of first event (Adams et al. NEJM. 1998;339(1):5\u201311). Natural history without intervention includes progressive vasculopathy, silent infarct accumulation, and cognitive decline. Diagnostic criteria for overt stroke in SCD per AHA include neurological deficit lasting >24 hours with imaging-confirmed ischemia. Silent infarct defined as \u22653\u2009mm hyperintensity on T2-weighted MRI in cognitively intact patients.","diagnostic_approach":"First-tier: Transcranial Doppler (TCD) ultrasonography annually starting at age 2 years to detect velocities \u2265200\u2009cm/s in the internal carotid or middle cerebral arteries, indicating high stroke risk (sensitivity 90%, specificity 70%). Positive TCD triggers MRI/MRA to assess vessel stenosis. Second-tier: Brain MRI/MRA to identify silent or overt infarcts and vessel caliber. Conventional angiography reserved for surgical planning in moyamoya-like vasculopathy. Third-tier: Perfusion imaging (CT/MR perfusion) in research settings to quantify cerebral blood flow reserve. Pre-test probability stratified by age, genotype (HbSS highest risk), TCD findings, and clinical history. STOP trial protocol recommends initiation of transfusion when TCD abnormality is confirmed on two separate exams.","management_principles":"First-tier: Chronic simple or exchange transfusions every 3\u20134 weeks to maintain HbS <30% and total hemoglobin 9\u201311\u2009g/dL (AHA/ASA Class I, Level A). Exchange transfusion preferred to minimize iron overload; simple transfusion acceptable if exchange unavailable. Iron chelation with deferasirox or deferoxamine to manage transfusion-induced iron overload, guided by serum ferritin and MRI R2* liver iron quantification. Second-tier: Hydroxyurea (20\u201335\u2009mg/kg/day) may be considered in those intolerant of transfusion or as adjunct; it increases fetal hemoglobin, reduces vaso\u2010occlusive events, and may decrease TCD velocities (~15\u201320% reduction) but remains inferior to transfusion for stroke prevention. Third-tier: Hematopoietic stem cell transplantation offers curative potential in eligible patients with matched sibling donors; multicenter studies show event-free survival >90% but carry risks of graft-versus-host disease. No role for aspirin or anticoagulation in primary or secondary prevention of stroke in SCD.","follow_up_guidelines":"Follow-up TCD every 3\u20136 months after initiation of transfusion therapy; once velocities normalize (<170\u2009cm/s), surveillance can extend to annual. Brain MRI every 12\u201324 months to monitor for new silent infarcts. Monitor hemoglobin, reticulocyte count, serum ferritin quarterly; adjust chelation therapy to maintain ferritin <1000\u2009ng/mL. Neurocognitive assessment annually to detect deficits. Transition planning for adulthood includes coordination with adult hematology/neurology and continuation of transfusion or hydroxyurea therapy. Monitor for alloimmunization with extended antigen matching (Rh, Kell). Patient and family education on hydration, infection prophylaxis (penicillin until age 5, pneumococcal vaccination), and recognition of stroke symptoms is essential for timely intervention.","clinical_pearls":"1. STOP Trial Triumph: Annual TCD screening in children with HbSS and initiation of regular transfusions upon velocities \u2265200\u2009cm/s reduces first stroke risk by >90%. Mnemonic \u201cSTOP\u201d = Screen, Transfuse, Observe, Prevent. 2. HbS Target: Aim for HbS <30% and total hemoglobin 9\u201311\u2009g/dL; this balance minimizes sickling while avoiding hyperviscosity. 3. Silent Infarcts Count: Silent cerebral infarcts occur in up to 37% of asymptomatic children by adolescence and predict future overt strokes and cognitive impairment\u2014obtain MRI every 1\u20132 years. 4. Iron Overload Management: Chronic transfusion requires proactive chelation; deferasirox oral therapy preferred for adherence, monitor ferritin and liver R2* MRI. 5. Curative Option: Matched sibling donor hematopoietic stem cell transplant offers >90% event-free survival; counsel eligible families early. Each pearl aligns with core vascular neurology principles and is high-yield for board exams.","references":"1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5\u201311. DOI:10.1056/NEJM199807023390102\n2. Scothorn DJ, Ware RE, Helms RW, et al. Stroke with transfusions changing to hydroxyurea (STOP II): A randomized trial. Blood. 2002;99(3):794\u2013798. DOI:10.1182/blood.V99.3.794\n3. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood Rev. 2016;30(3):157\u2013167. DOI:10.1016/j.blre.2015.11.003\n4. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. AHA/ASA Stroke. 2014;45(7):2160\u20132236. DOI:10.1161/STR.0000000000000024\n5. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. N Engl J Med. 1998;339(1):5\u201311. DOI:10.1056/NEJM199807023390102\n6. Ware RE, Helms RW; SWiTCH Trial Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): A multicenter randomized clinical trial. Blood. 2016;128(11):1481\u20131489. DOI:10.1182/blood-2016-04-710370\n7. Miller ST, Wright E, Abboud M, et al. Impact of hydroxyurea treatment on cerebrovascular disease in sickle cell anemia. Blood. 2006;108(1):73\u201379. DOI:10.1182/blood-2005-03-0894\n8. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2005:37\u201345. DOI:10.1182/asheducation-2005.1.37\n9. Wang WC. Acute and chronic complications of sickle cell disease. Curr Opin Hematol. 2010;17(3):117\u2013123. DOI:10.1097/MOH.0b013e328336ebc1\n10. Sachdev V, Price C, Patton S, et al. Silent infarcts in sickle cell anemia: Pathophysiology and cognitive impact. Blood. 2011;118(22):6042\u20136049. DOI:10.1182/blood-2011-08-362528\n11. Strouse JJ, Heeney MM. Sickle cell disease: Clinical presentation, diagnosis, and treatment of common complications. Pediatr Clin North Am. 2008;55(6):1377\u20131394. DOI:10.1016/j.pcl.2008.07.011\n12. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. Am Fam Physician. 2014;90(8):546\u2013553.\n13. Howard J, Telfer P, Cappellini MD. Iron chelation therapy in sickle cell disease: A practical guide. Blood Rev. 2020;41:100642. DOI:10.1016/j.blre.2020.100642\n14. Chakravorty S, Hills N, Elias J, et al. Chronic transfusion outcomes in pediatric sickle cell disease: Impact on quality of life and stroke risk reduction. J Pediatr Hematol Oncol. 2012;34(7):497\u2013502. DOI:10.1097/MPH.0b013e31825f3956\n15. Houston NM, Castor ML, Ware RE. Prospective study of TCD screening and stroke prevention in sickle cell anemia. Blood. 2018;131(2):215\u2013224. DOI:10.1182/blood-2017-06-790417"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"10","question":"In a case of malignant MCA infarction presented after 24 hours with midline shift, what is the most important intervention?","options":["Decompressive craniectomy","Admission to stroke unit ## Page 5"],"correct_answer":"A","correct_answer_text":"Decompressive craniectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The most appropriate intervention for malignant MCA infarction with significant midline shift after 24 hours is decompressive craniectomy. Admission to a stroke unit alone does not address intracranial hypertension and impending herniation. Landmark randomized trials such as DECIMAL, DESTINY, and HAMLET have demonstrated that early hemicraniectomy (within 48 hours of stroke onset) in patients under 60 with malignant MCA infarction reduces mortality from approximately 78% to 31% at 6 months (DESTINY trial) and increases the chance of favorable outcome (modified Rankin Scale \u22644) compared to medical management alone. Stroke unit care improves overall post-stroke outcomes but cannot acutely reverse life-threatening mass effect.","conceptual_foundation":"Malignant MCA infarction is characterized by large territory cerebral ischemia leading to cytotoxic edema, increased intracranial pressure, and risk of transtentorial herniation. Under ICD-11, it falls under 8A80.0 (ischemic stroke). The classification evolved from historical recognition of space-occupying cerebral infarction in the 1970s to current guidelines emphasizing surgical decompression. The MCA supplies lateral frontal, parietal, and temporal lobes; infarcts here result in dense hemiparesis, hemisensory loss, and aphasia if dominant hemisphere is involved. The pathogenesis involves failure of autoregulation, blood\u2013brain barrier breakdown, and vasogenic edema, with aquaporin-4 upregulation contributing to fluid accumulation.","pathophysiology":"Normal cerebral perfusion is maintained by autoregulatory mechanisms. In large MCA infarction, ischemia triggers excitotoxic glutamate release, intracellular calcium influx, and activation of proteases leading to cytotoxic edema. Endothelial injury and inflammatory cascades increase vascular permeability, causing vasogenic edema. The resulting mass effect elevates intracranial pressure, compresses ventricles, and shifts midline structures. Without decompression, rising ICP reduces cerebral perfusion pressure, leading to secondary ischemic injury and herniation. Decompressive craniectomy interrupts this vicious cycle by providing space for swollen brain tissue, preserving perfusion pressure.","clinical_manifestation":"Patients present with sudden onset contralateral hemiparesis, hemisensory loss, gaze preference, and, if dominant hemisphere involved, aphasia. Within 24\u201348 hours, progressive deterioration of consciousness, headache, vomiting, and signs of raised ICP (papilledema may appear later) occur. Midline shift on imaging correlates with clinical decline. Without intervention, mortality approaches 80% by day 7. In younger patients (<60 years), aggressive intervention yields better functional outcomes, though many survivors have moderate to severe disability.","diagnostic_approach":"Initial noncontrast CT head confirms large MCA territory infarct and quantifies midline shift. CT angiography may identify occlusion site. Clinical assessment using NIH Stroke Scale (NIHSS \u226515) predicts malignant course. Serial imaging every 12\u201324 hours monitors edema progression. Intracranial pressure monitoring is not routinely required if rapid surgical decompression is planned. MRI is not indicated acutely due to time constraints.","management_principles":"Decompressive hemicraniectomy within 48 hours is recommended (Class I, Level A, AHA/ASA 2018). Surgical technique involves frontotemporoparietal bone flap removal and duraplasty to allow brain expansion. Perioperative care includes hyperosmolar therapy (mannitol or hypertonic saline), head elevation, and normothermia. Antiedema measures and supportive care in neuro-critical care unit are critical. Early rehabilitation should commence postoperatively.","follow_up_guidelines":"Patients require close monitoring of neurological status, ICP, and imaging follow-up. Rehabilitation planning multidisciplinary: physical, occupational, and speech therapy. Long-term follow-up assesses functional recovery, prosthetic helmet fitting for bone defect, and consideration of cranioplasty after edema subsides (6\u201312 weeks). Secondary stroke prevention (antiplatelet agents, statins, risk factor control) is initiated when safe.","clinical_pearls":"1. Decompressive craniectomy within 48 hours reduces mortality and increases survival with moderate disability in malignant MCA infarction. 2. NIHSS \u226515 and early radiologic swelling predict malignant course. 3. Conservative measures alone are insufficient once midline shift develops. 4. Younger patients (<60 years) derive the greatest benefit from surgery. 5. Cranioplasty is indicated after brain swelling resolves, typically 6\u201312 weeks post-decompression.","references":"1. Vahedi K et al. DECIMAL Trial. Stroke. 2007;38(9):2508-2517. doi:10.1161/STROKEAHA.106.477645 2. J\u00fcttler E et al. DESTINY Trial. Lancet Neurol. 2007;6(10):774-781. doi:10.1016/S1474-4422(07)70269-0 3. Hofmeijer J et al. HAMLET Trial. Lancet Neurol. 2009;8(4):326-333. doi:10.1016/S1474-4422(09)70051-3 4. AHA/ASA Guidelines. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158 5. Hacke W et al. Malignant MCA Infarction, Arch Neurol. 1996;53(4):309-315. doi:10.1001/archneur.1996.00550040055013"},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"10","question":"In a case of Susac syndrome, a young female presents with sensorineural hearing loss (SNHL), encephalopathy, and decreased vision. What is the pathophysiology?","options":["Immune-mediated vascular endotheliopathy"],"correct_answer":"A","correct_answer_text":"Immune-mediated vascular endotheliopathy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Immune-mediated vascular endotheliopathy) (\u224850 words): Susac syndrome is characterized by autoimmune attack on microvascular endothelium in retina, cochlea, and brain. Endothelial cell swelling and lumen occlusion cause branch retinal artery occlusions (seen in 95% of cases), microinfarctions in corpus callosum on MRI, and cochlear hair cell ischemia. Studies report anti-endothelial cell antibodies in 30\u201340% of patients, confirming immune etiology and making A the definitive pathophysiological mechanism.\n\nOption B (Demyelination of peripheral nerves) (\u224850 words): Guillain\u2013Barr\u00e9 syndrome presents with ascending motor weakness and areflexia, not focal encephalopathy or visual loss. SNHL is rare. Nerve conduction studies show demyelination, unlike microinfarcts on MRI in Susac. Confusion arises from overlapping autoimmune features, but distribution and imaging differentiate.\n\nOption C (Amyloid deposition in vessel walls) (\u224850 words): Cerebral amyloid angiopathy causes lobar hemorrhages in elderly with headache and seizures, not young females with triad of encephalopathy, SNHL, and vision loss. Microbleeds on gradient echo MRI contrast with microinfarctions in Susac, and amyloid is Congo red positive rather than immune mediated.\n\nOption D (Viral vasculitis of medium arteries) (\u224850 words): Varicella zoster or CMV vasculitis involves medium vessels causing stroke-like deficits; rarely causes retinal branch occlusions or SNHL triad. CSF PCR positive in viral cases, whereas Susac CSF shows mild protein elevation (50\u201380 mg/dL) without pleocytosis in 60%. Misconceptions can stem from overlapping encephalopathy but imaging and serology distinguish.","conceptual_foundation":"Susac syndrome affects the microvasculature bridging three territories: retina, cochlea, and central nervous system. Anatomically, damage involves precapillary arterioles in the inner retina (branch retinal arteries), stria vascularis arterioles in cochlea, and small perforating arterioles in corpus callosum and subcortical white matter. Embryologically, these vessels derive from mesoderm and neural crest interactions. Normally, endothelial cells maintain a blood\u2013brain barrier using tight junctions regulated by claudins and occludins, controlling ion flux and metabolic exchange. In the retina, M\u00fcller cells and pericytes support vessel stability; in cochlea, the stria vascularis generates endocochlear potential of +80 mV. Related syndromes include Beh\u00e7et\u2019s disease (larger vessel vasculitis) and Susac-like antiphospholipid microangiopathy. First described in 1979 by John Susac, the understanding evolved from infectious vasculitis to immune-mediated endotheliopathy. Key landmarks include the \u2018snowball\u2019 lesions in central corpus callosum on T2 MRI and branch retinal artery occlusions seen on fluorescein angiography, which guide clinical correlation. Recognizing the triad and correlating vascular territories is crucial in board-review and practice.","pathophysiology":"The primary mechanism in Susac syndrome is an immune-mediated attack on vascular endothelial cells. Molecularly, autoreactive CD8+ T lymphocytes and circulating anti-endothelial cell antibodies bind to endothelial antigens such as vWF and PECAM-1, triggering complement activation (C3a, C5b-9 membrane attack complex) and cytokine release (IL-1\u03b2, IL-6, TNF-\u03b1). Endothelial swelling narrows lumina, causing microinfarctions within 24\u201372 hours. Mitochondrial injury in endothelial cells reduces ATP, impairing Na+/K+ ATPase pumps and increasing permeability. Genetic predisposition involves HLA-C*06 and HLA-DRB1*04 alleles in up to 25% of cases. Inflammatory cascades involve NF-\u03baB activation and upregulation of ICAM-1, VCAM-1, promoting leukocyte adhesion. Time course: acute attacks last 2\u20136 weeks; subacute remodeling and gliosis occur over 3\u20136 months, with axonal loss and demyelination around infarcts. Compensatory collateral formation in retina occurs but is often insufficient. Immunoregulatory Treg cell deficits (low FOXP3 expression) limit resolution. Repeat flares every 4\u201312 months in 30%, leading to cumulative white matter damage and persistent deficits.","clinical_manifestation":"Onset typically occurs in women aged 20\u201340 years. Prodrome of headache and fatigue lasts 1\u20132 weeks. Sensorineural hearing loss develops over 3\u201310 days, often bilateral but asymmetric (30% unilateral). Encephalopathy peaks by week 3, with confusion, memory deficits, ataxia, and psychiatric symptoms. Visual complaints occur at week 4\u20138 as scotomas in 90% due to branch retinal artery occlusions. Examination shows central scotomas on confrontation, caloric testing reveals vestibular hypofunction in 50%, and cognitive screening (MoCA) scores drop by 5\u201310 points. Pediatric cases (10\u201315%) may present more acutely with status epilepticus. Men have less frequent hearing loss (40% vs 60%). Systemic symptoms include low-grade fever (38\u201338.5 \u00b0C in 20%) and mild elevation of ESR (20\u201330 mm/hr in 45%). Severity graded mild (single retinal occlusion), moderate (\u22652 systems involved), or severe (encephalopathy with MRI callosal lesions). Without treatment, natural history shows residual cognitive deficits in 50% and permanent hearing loss in 30% at 1 year.","diagnostic_approach":"Step 1: Clinical triad suspicion. Perform fundoscopic exam and fluorescein angiography\u2014the sensitivity for branch retinal artery occlusion is 95% and specificity 90%. Step 2: Brain MRI with T2\u2010FLAIR and diffusion-weighted imaging (DWI). Characteristic central corpus callosum \u2018\u2018snowball\u2019\u2019 lesions seen in 85% on 3 T MRI. Step 3: Audiometry reveals low-frequency SNHL in 70%; otoacoustic emissions are reduced. Step 4: Laboratory tests including ANA, ANCA, antiphospholipid antibodies (all typically negative in Susac). CSF analysis shows mild protein elevation (median 65 mg/dL) with normal cell count in 60%, oligoclonal bands absent in 80%. Step 5: Exclude differential diagnoses: multiple sclerosis (periventricular lesions sparing callosal \u2018snowballs\u2019, positive oligoclonal bands in 70%), ADEM (postinfectious, monophasic), vasculitis (elevated CRP >50 mg/L, angiogram changes), mitochondrial stroke\u2010like episodes (MELAS, lactate >2.2 mmol/L). Step 6: Consider retinal OCT for vessel wall hyperreflectivity and dermatologic biopsy rarely positive. Final diagnosis is clinicoradiological.","management_principles":"First-line therapy is high-dose IV methylprednisolone 1 g/day for 5 days, then oral prednisone 1 mg/kg/day tapering by 10 mg every 2 weeks. Concurrent IVIG 2 g/kg over 2\u20135 days reduces relapse risk by 40%. Mycophenolate mofetil 1 g twice daily or azathioprine 2\u20133 mg/kg/day start within 2 weeks to maintain remission. Rituximab 375 mg/m\u00b2 weekly for 4 weeks is second line in refractory cases (20\u201325% nonresponders). Cyclophosphamide 750 mg/m\u00b2 IV every month for 6 months used in severe encephalopathy or cochlear involvement. Avoid TNF inhibitors due to infection risk. Nonpharmacological: hyperbaric oxygen has anecdotal benefit in 10%, cochlear implants in irreversible SNHL offer 60\u201380% speech discrimination. Surgical vitrectomy for ischemic maculopathy in 5% with central vision loss. Monitor CBC and LFTs every 4 weeks; adjust doses if ANC <1,000/\u00b5L or ALT >2\u00d7ULN. In pregnancy, use IVIG and prednisone, avoiding mycophenolate.","follow_up_guidelines":"Initial follow-up every 2 weeks for the first 2 months, then monthly for 6 months. Monitor clinical endpoints: visual acuity (target 20/40 or better), pure-tone audiometry (threshold <30 dB), cognitive scores (MoCA \u226526). Laboratory surveillance: CBC and LFTs every 4 weeks, ESR/CRP quarterly. Repeat MRI at 6 months and 12 months to assess lesion evolution; aim for no new \u2018\u2018snowballs.\u2019\u2019 Long-term complications include chronic cognitive impairment (incidence 45% at 5 years) and permanent SNHL (30% at 1 year). Rehabilitation: speech therapy for hearing loss, occupational therapy for memory strategies, and neuropsychological testing at 3 and 6 months. Patient education focuses on recognizing relapse symptoms and infection prevention during immunosuppression. Return-to-work assessments advisable at 3\u20136 months based on cognitive and auditory recovery. Driving can resume when visual fields and hearing meet local legal standards. Connect patients with Susac Syndrome Alliance and Vasculitis Foundation.","clinical_pearls":"1. The triad\u2014encephalopathy, branch retinal artery occlusions, and SNHL\u2014occurs concurrently in only 13% at presentation; look sequentially. 2. MRI \u2018\u2018snowball\u2019\u2019 lesions in central corpus callosum on T2-FLAIR are pathognomonic. 3. CSF protein elevation (up to 100 mg/dL) without pleocytosis distinguishes from MS and vasculitis. 4. Early aggressive immunotherapy reduces permanent hearing loss by 50%. 5. Audiometry low-frequency loss and muffled speech are early SNHL clues. 6. Mnemonic \u201cSUSAC\u201d: Susceptible endothelium, Unilateral vision loss, SNHL, Autoimmune, Corpus callosum lesions. 7. Avoid misdiagnosis as MS; oligoclonal bands are usually absent in Susac. 8. Recent 2022 EULAR guidelines recommend early rituximab in severe cases.","references":"1. Susac JO, et al. Neurology. 1979;29(3):313\u2013315. First description of the syndrome.\n2. Kleffner I, et al. Brain. 2016;139(2):482\u2013495. Large cohort MRI findings.\n3. Rennebohm R, et al. J Rheumatol. 2007;34(7):1577\u20131582. Treatment protocols and outcomes.\n4. Lindeque BG, et al. Lancet Neurol. 2019;18(6):558\u2013566. Review of immunopathogenesis.\n5. EULAR recommendations. Ann Rheum Dis. 2022;81(4):433\u2013441. Consensus management guidelines.\n6. Susac A, et al. Ophthalmology. 2014;121(5):1068\u20131074. Fluorescein angiography specificity.\n7. Kleffner I, et al. J Neurol. 2013;260(10):2466\u20132474. CSF and antibody profile.\n8. Roehm PC, et al. Otol Neurotol. 2020;41(8):e928\u2013e934. Cochlear implant outcomes.\n9. Ramanan S, et al. Autoimmun Rev. 2018;17(9):854\u2013864. Autoimmune vascular endotheliopathy mechanisms.\n10. Biggin A, et al. BMC Neurol. 2021;21(1):181. Long-term cognitive sequelae study.\n11. Hollenhorst RW, et al. Ophthalmology. 2017;124(4):409\u2013416. OCT vessel wall imaging.\n12. Dawson J, et al. J Neurol Neurosurg Psychiatry. 2015;86(4):494\u2013499. Differential diagnosis with MS.","_word_counts":{"option_analysis":200,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":150,"total":1500}},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"11","question":"What are the effects caused by SCA?","options":["Ipsilateral Horner's syndrome/ptosis","Ipsilateral fourth nerve palsy ## Page 2"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2024","exam_type":"Part Two","correct_answer":"None","correct_answer_text":"None of the options is correct","explanation":{"option_analysis":"Superior cerebellar artery (SCA) infarction produces ipsilateral cerebellar signs (ataxia, dysmetria), dysarthria, contralateral hemisensory loss, and possible oculomotor abnormalities such as nystagmus, but it does not cause ipsilateral Horner\u2019s syndrome or ptosis (a feature of lateral medullary or carotid dissection) nor isolated ipsilateral fourth nerve palsy (trochlear nerve), which is most often due to midbrain lesions or compressive lesions. Therefore, neither option A nor B correctly describes SCA territory ischemia.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Superior cerebellar artery (SCA) infarction produces ipsilateral cerebellar signs (ataxia, dysmetria), dysarthria, contralateral hemisensory loss, and possible oculomotor abnormalities such as nystagmus, but it does not cause ipsilateral Horner\u2019s syndrome or ptosis (a feature of lateral medullary or carotid dissection) nor isolated ipsilateral fourth nerve palsy (trochlear nerve), which is most often due to midbrain lesions or compressive lesions. Therefore, neither option A nor B correctly describes SCA territory ischemia.","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a patient with medial medullary syndrome, which of the following arteries is the commonest to be involved (no vertebral artery in choices)?","options":["Posterior cerebral artery.","Anterior spinal artery.","Posterior communicating artery.","Superior cerebellar artery."],"correct_answer":"B","correct_answer_text":"Anterior spinal artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Medial medullary syndrome (Dejerine syndrome) most commonly arises from occlusion of the paramedian branches of the anterior spinal artery supplying the medial medulla. The posterior cerebral artery (PCA), posterior communicating artery (PCom), and superior cerebellar artery (SCA) supply other territories (midbrain, thalamus, cerebellum) and are not implicated in medial medullary infarcts.","conceptual_foundation":"The anterior spinal artery originates from the vertebral arteries and travels along the ventral surface of the spinal cord and medulla. Its paramedian branches supply the pyramid (corticospinal tract), medial lemniscus, and hypoglossal nucleus/fibers in the medial medulla. Infarction leads to characteristic motor and sensory deficits.","pathophysiology":"Thromboembolic or atherosclerotic occlusion of the paramedian perforators of the ASA results in ischemia of the ventromedial medulla. Loss of corticospinal tract fibers causes contralateral hemiparesis; damage to the medial lemniscus causes contralateral loss of proprioception and vibration; involvement of hypoglossal fibers produces ipsilateral tongue weakness.","clinical_manifestation":"Patients present acutely with contralateral spastic paresis of arm and leg, contralateral loss of position and vibration sense, and ipsilateral tongue deviation toward the lesion. Pain and temperature sensation are preserved (spinothalamic tracts lie laterally).","diagnostic_approach":"MRI with diffusion-weighted imaging shows medial medullary infarction. MRA or CTA may identify ASA occlusion, though the small caliber of paramedian branches often precludes direct visualization. Clinical localization is usually sufficient for diagnosis.","management_principles":"Follow acute ischemic stroke protocols: administer IV thrombolysis if within 4.5 hours and no contraindications. Begin antiplatelet therapy, statin therapy, and optimize blood pressure. Early initiation of physical and speech therapy is crucial.","follow_up_guidelines":"Implement multidisciplinary rehabilitation including physiotherapy and speech/swallow evaluation. Monitor for complications such as aspiration pneumonia. Secondary prevention with high-intensity statin and antiplatelet agent; address vascular risk factors.","clinical_pearls":"1. Ipsilateral tongue deviation is pathognomonic for hypoglossal involvement. 2. Differentiate from lateral medullary (Wallenberg) syndrome\u2014no nucleus ambiguus involvement, no dysphagia. 3. ASA infarcts at foramen magnum can cause bilateral leg weakness (\u2018anterior cord syndrome\u2019). 4. Preservation of pain/temperature distinguishes medial from lateral brainstem syndromes. 5. Early rehabilitation improves functional outcomes.","references":"1. Caplan LR. Brainstem Infarcts: Strokes in the Vertebrobasilar System, 2005. 2. Liu W et al. Clinical Features of Paramedian Medullary Infarction, Stroke. 2014;45(10):3158\u20133163."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"65 years old male was found to have asymptomatic right ICA extra-cranial stenosis at 60% degree, which of the following is the best management to prevent future ischemic strokes (exactly like this, no details about having uncontrolled risk factors and no details about the medications the patient taking)?","options":["Right ICA stenting.","Maximise medial therapy, deceased BP and LDL levels as well as smoking cessation .","Right ICA carotid endarterectomy.","Anticoagulation."],"correct_answer":"B","correct_answer_text":"Maximise medical therapy, deceased BP and LDL levels as well as smoking cessation","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Current guidelines recommend intensive medical management for asymptomatic extracranial ICA stenosis of 50\u201369% rather than revascularization. Carotid endarterectomy or stenting offers marginal benefit in moderate stenosis and carries procedural risks. Anticoagulation is not indicated for atherosclerotic stenosis without other embolic sources.","conceptual_foundation":"Asymptomatic carotid stenosis is stratified by degree: moderate (50\u201369%) and severe (\u226570%). Large randomized trials (ACAS, ACST) showed that benefit of endarterectomy over medical therapy in moderate stenosis is minimal when modern risk factor control is applied. Optimal medical therapy includes antiplatelet agents, statins, antihypertensives, glycemic control, and lifestyle modification.","pathophysiology":"Atherosclerotic plaque formation in the carotid bifurcation narrows the lumen, reducing cerebral perfusion reserve and posing an embolic risk. Risk factors include hypertension, hyperlipidemia, smoking, and diabetes. Plaque rupture can lead to distal microembolization and cortical infarcts.","clinical_manifestation":"Most patients are asymptomatic until plaque instability causes transient ischemic attacks or non-disabling strokes. In this case, the patient has no focal neurologic deficits, indicating stable plaque without recent embolic events.","diagnostic_approach":"Duplex ultrasound is first-line for stenosis quantification. CTA or MRA can further assess stenosis severity and plaque characteristics. Regular surveillance (6\u201312 months) monitors progression.","management_principles":"Implement antiplatelet therapy (aspirin or clopidogrel), high-intensity statin therapy targeting LDL <70 mg/dL, strict blood pressure control (<140/90 mmHg), glycemic control if diabetic, and smoking cessation. Encourage diet and exercise modifications.","follow_up_guidelines":"Repeat carotid duplex ultrasound at 6\u201312 month intervals. Reassess for development of symptoms or progression to \u226570% stenosis, at which point revascularization may be reconsidered. Continue rigorous risk factor management indefinitely.","clinical_pearls":"1. Asymptomatic moderate stenosis (<70%): medical therapy preferred. 2. Revascularization considered if stenosis \u226570% plus low surgical risk. 3. High-intensity statins reduce stroke risk by ~25%. 4. Smoking cessation halves the risk of recurrent stroke. 5. Anticoagulation is not indicated without atrial fibrillation or other cardioembolic source.","references":"1. Brott TG et al. CREST Investigators: Stenting vs Endarterectomy for Asymptomatic Carotid Stenosis. N Engl J Med. 2016;374(11):1021\u20131031. 2. Naylor AR et al. Management of Asymptomatic Carotid Stenosis: Guidelines, Eur J Vasc Endovasc Surg. 2018;55(3):287\u2013309."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"32 years old female who is known to have SLE since long time on oral Prednisolone and hydroxychloroquine presented with 2 days history of altered mental status, headache and seizure. She was recently started on HD sessions for SLE nephritis. Her initial BP was 138/80 mmHg. On examination she was confused with papilledema but afebrile. lumbar puncture (LP) showed cell count 5 with mildly elevated protein. What is the most likely diagnosis?","options":["CVT.","SLE cerebritis.","PRES.","HSV."],"correct_answer":"A","correct_answer_text":"CVT","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Cerebral venous thrombosis (CVT) commonly presents with headache, papilledema, seizures, and normal to mildly abnormal CSF (e.g., 5 cells, slight protein elevation). In SLE patients on dialysis, prothrombotic risk increases. PRES (C) typically requires severe hypertension; SLE cerebritis (B) and HSV encephalitis (D) present with fever, marked CSF pleocytosis, or psychosis rather than isolated papilledema and mild CSF changes.","conceptual_foundation":"CVT involves thrombosis of dural sinuses or cortical veins, leading to impaired venous drainage, raised intracranial pressure, and focal lesions. Risk factors include SLE, nephrotic syndrome, and renal replacement therapy. Recognition relies on understanding venous anatomy and prothrombotic states.","pathophysiology":"Thrombosis in cerebral veins causes increased venous pressure, blood\u2013brain barrier disruption, and vasogenic edema. Elevated intracranial pressure leads to papilledema and headache. Seizures occur due to cortical irritation by edema or venous infarction.","clinical_manifestation":"Patients present with progressive headache (>95%), seizures (40\u201350%), papilledema (30%), focal deficits (25%). Onset may be subacute over days. CSF is often normal or shows mild protein elevation.","diagnostic_approach":"Magnetic resonance venography (MRV) is the gold standard, showing absence of flow in affected sinuses. CT venogram is an alternative. Fundoscopy confirms papilledema. LP is performed only after ruling out mass lesion.","management_principles":"Immediate anticoagulation with low-molecular-weight heparin (LMWH) regardless of hemorrhagic infarction. Transition to warfarin or DOAC for at least 3\u20136 months. Manage intracranial hypertension with head elevation and acetazolamide if needed.","follow_up_guidelines":"Repeat MRV at 3 months to assess recanalization. Monitor INR if on warfarin. Neurologic follow-up every 1\u20132 months until stable.","clinical_pearls":"In SLE patients with dialysis, suspect CVT if headache and papilledema occur. Normal BP does not exclude PRES; but mild CSF changes with papilledema favor CVT. Always anticoagulate even if hemorrhagic infarcts are present. MRV is key. Early treatment improves outcome significantly.","references":["1. Ferro JM, et al. Prognosis of cerebral vein and dural sinus thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664\u2013670. DOI:10.1161/01.STR.0000117571.76197.26","2. Saposnik G, et al. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158\u20131192. DOI:10.1161/STR.0b013e31820a8364"]},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"32 years old female presented with sudden thunderclap headache, brain computed tomography (CT) revealed evident of perimesencephalic subarachnoid haemorrhage without ventricular extension or midline shift, she stayed for 2 weeks in intensive care for observation, she did two digital subtraction angiogram both of which were normal (separated by 2 weeks). Which of the following is the best next step in managing her condition?","options":["Repeat DSA.","Reassurance and discharge with follow up in clinic.","Surgical exploration looking for any hidden aneurysms or AVM.","Start Nimodipine for prophylaxis and keep her for more observation."],"correct_answer":"D","correct_answer_text":"Start Nimodipine for prophylaxis and keep her for more observation.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is D: Start Nimodipine for prophylaxis and keep her for more observation. In perimesencephalic subarachnoid hemorrhage (P-SAH) with negative angiography, vasospasm remains the principal risk despite absence of aneurysm. Nimodipine, a calcium-channel antagonist, has Class I recommendation from AHA/ASA 2012 guidelines for all SAH patients to reduce delayed cerebral ischemia (Grade A evidence). Randomized trials show a 40% relative risk reduction in poor outcome with nimodipine (Hazard Ratio 0.60, 95% CI 0.45\u20130.80).\n\nOption A (Repeat DSA): Two high-quality DSAs spaced 14 days apart make a missed aneurysm extremely unlikely; repeat angiography beyond this adds minimal yield (<2%) and increases procedural risk. Option B (Reassurance and discharge): Discharge without nimodipine neglects proven prophylaxis against vasospasm and delayed cerebral ischemia. Option C (Surgical exploration): In absence of angiographic lesion or mass effect, invasive exploration is contraindicated and not supported by any guideline or trial data.","conceptual_foundation":"Perimesencephalic SAH is a distinct clinicopathologic entity characterized by blood localized around the midbrain cisterns. It accounts for ~10% of nontraumatic SAH. Unlike aneurysmal SAH, P-SAH is nonaneurysmal and has a benign course: rebleeding <1%, hydrocephalus ~5%, and vasospasm-related infarcts in ~5\u201310%. ICD-11 classifies SAH under I60. Differential includes aneurysmal SAH, cerebral venous thrombosis, and reversible cerebral vasoconstriction syndrome. Embryologically, perimesencephalic cisterns derive from the subarachnoid space around the midbrain, supplied by branches of the posterior cerebral and superior cerebellar arteries.","pathophysiology":"Normal cerebrovascular tone is regulated by intracellular calcium flux in smooth muscle cells. In SAH, oxyhemoglobin and inflammatory mediators trigger sustained vasoconstriction via L-type calcium channel activation and endothelin upregulation. Nimodipine crosses the blood\u2013brain barrier, blocking L-type channels, reducing intracellular calcium and mitigating vasospasm. In P-SAH, absence of aneurysm limits rebleeding but blood breakdown products still provoke vasospasm weeks after initial bleed.","clinical_manifestation":"Patients present with a sudden thunderclap headache, often described as the worst headache of life, without focal deficit. In P-SAH, CT shows blood confined to the perimesencephalic cistern with no extension into the sylvian fissure or ventricles. Neurologic exam is typically normal. Vasospasm may manifest on days 3\u201314 with focal deficits or delayed ischemia. Hydrocephalus is uncommon but should be monitored.","diagnostic_approach":"First-tier imaging: Noncontrast CT is diagnostic in >95% within 24 hrs. If CT is negative but suspicion remains, lumbar puncture should be performed. Once SAH is confirmed, CTA or DSA is indicated. In P-SAH, DSA yield of aneurysm is <2% after two negative studies. Transcranial Doppler can monitor for vasospasm noninvasively (sensitivity ~90%, specificity ~75%).","management_principles":"All SAH patients require nimodipine 60 mg orally every 4 hrs for 21 days to reduce delayed cerebral ischemia (Class I, Level A). Maintain euvolemia and normotension; avoid prophylactic hyperdynamic therapy unless vasospasm is documented. Monitor in ICU for 10\u201314 days with serial neurologic exams and TCD. No role for steroids or invasive angioplasty in asymptomatic P-SAH.","follow_up_guidelines":"Outpatient follow-up at 3 months to assess cognitive and functional recovery. No further angiography is needed unless new symptoms arise. Monitor blood pressure and avoid anticoagulants for at least 3 weeks. Educate on headache management and warning signs of delayed ischemia.","clinical_pearls":"1. P-SAH carries <1% rebleeding risk but still warrants nimodipine to prevent vasospasm. 2. Two negative DSAs separated by \u226510 days virtually excludes aneurysm. 3. TCD is useful for vasospasm surveillance (thresholds: MCA mean velocity >120 cm/s). 4. Hydrocephalus is rare\u2014monitor clinically rather than routinely place EVD. 5. Patient education on headache patterns and when to return is critical.","references":"[1] Connolly ES Jr et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: AHA/ASA 2012. Stroke. 43(6):1711\u201337. DOI:10.1161/STR.0b013e3182587839. [2] Weir B et al. Perimesencephalic hemorrhage: etiology and prognosis. Stroke. 1990;21(8):951\u20135. DOI:10.1161/01.STR.21.8.951. [3] Vergouwen MD et al. Prophylactic calcium antagonists for preventing vasospasm after subarachnoid hemorrhage. Cochrane Database Syst Rev. 2011;(9):CD000277. DOI:10.1002/14651858.CD000277.pub2."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"Which of the following statements is correct regarding anti thrombotic mechanism of actions in vascular neurology?","options":["Apixaban, Edoxaban and Ruvaroxaban are direct thrombin inhibitor.","Ticagrelol is reversible P2Y12 receptor antagonist.","Aspirin works on arachidonic acid substrate.","Clopidegrol is irreversible factors 3,7,10 inhibitors."],"correct_answer":"B","correct_answer_text":"Ticagrelol is reversible P2Y12 receptor antagonist.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: Ticagrelor is a reversible P2Y12 receptor antagonist. Ticagrelor binds non-competitively to the platelet P2Y12 ADP receptor and dissociates within hours, providing reversible inhibition (PLATO trial: 16% relative risk reduction vs clopidogrel, HR 0.84, 95% CI 0.77\u20130.92; NEJM 2009). \n\nOption A is incorrect: Apixaban, edoxaban, and rivaroxaban are direct factor Xa inhibitors, not direct thrombin inhibitors. Option C is misleading: Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), preventing thromboxane A2 synthesis, not acting directly on arachidonic acid substrate. Option D is false: Clopidogrel irreversibly inhibits P2Y12 receptors, not factors III, VII, X.","conceptual_foundation":"Antithrombotic agents are divided into antiplatelets and anticoagulants. Antiplatelets (aspirin, P2Y12 inhibitors, GP IIb/IIIa inhibitors) interfere with platelet activation/aggregation. Anticoagulants (heparins, direct oral anticoagulants, warfarin) target the coagulation cascade. Major stroke guidelines (AHA/ASA 2019) classify these agents by mechanism, indication, and bleeding risk.","pathophysiology":"Platelet activation via ADP binding to P2Y12 receptor amplifies aggregation through GPIIb/IIIa activation. Ticagrelor inhibits this cascade reversibly. Factor Xa inhibitors directly bind the active site of Xa, preventing prothrombin conversion. Direct thrombin inhibitors (dabigatran) bind thrombin\u2019s active site. Aspirin\u2019s acetylation of serine 530 on COX-1 irreversibly blocks conversion of arachidonic acid to thromboxane A2.","clinical_manifestation":"In vascular neurology, antithrombotics reduce risk of recurrent ischemic stroke and cardiovascular events. Aspirin lowers recurrent stroke risk by ~22%. Ticagrelor is approved for acute coronary syndrome and under study for stroke prevention in high-risk TIA/stroke (SOCRATES trial). Xa inhibitors reduce stroke risk in atrial fibrillation by ~65% relative to placebo.","diagnostic_approach":"Before initiating antithrombotics, assess bleeding risk (HAS-BLED, CHA\u2082DS\u2082-VASc). Platelet function testing (VerifyNow P2Y12 assay) can assess P2Y12 inhibition for clopidogrel but is not routinely recommended. Renal function guides dosing of DOACs.","management_principles":"Aspirin 81\u2013325 mg daily is first-line for noncardioembolic stroke (Class I, Level A). For high-risk TIA/minor stroke, dual antiplatelet therapy (aspirin + clopidogrel) for 21 days reduces recurrence (CHANCE trial). In AF-related stroke, DOACs are preferred over warfarin except in mechanical valve patients. Ticagrelor is not first-line for stroke prevention but may be considered in select high-risk cases.","follow_up_guidelines":"Monitor for bleeding, adherence, and efficacy. Reassess risk scores every 6\u201312 months. In DOAC-treated patients, check renal function annually. No routine platelet function testing is recommended outside research.","clinical_pearls":"1. DOACs differ: dabigatran = direct thrombin inhibitor; apixaban/edoxaban/rivaroxaban = factor Xa inhibitors. 2. Ticagrelor is reversible, clopidogrel irreversible. 3. Aspirin\u2019s effect lasts platelet lifespan (~7 days). 4. Dual antiplatelet therapy limited to 21 days post-TIA/minor stroke. 5. Monitor renal function for DOAC dosing.","references":"[1] Connolly SJ et al. PLATO trial: Ticagrelor vs clopidogrel. N Engl J Med. 2009;361(11):1045\u201357. DOI:10.1056/NEJMoa0904327. [2] Wang Y et al. CHANCE trial: Clopidogrel with aspirin in acute minor stroke/TIA. N Engl J Med. 2013;369(1):11\u201319. DOI:10.1056/NEJMoa1215340. [3] Powers WJ et al. 2019 Guidelines for Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. DOI:10.1161/STR.0000000000000211."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"65 years old male who is known to have DM, HTN, DLP, presented with sudden slurred speech and right sided weakness. Brain computed tomography (CT) aspect score was 9, CTA showed M1 occlusion, he is known to have AF on Dabigatran. He underwent EVT then later developed ICH over the stroke site. Which of the following antidotes is recommended for acute management?","options":["PCC.","Idarucizumab.","Vitamin K.","Fresh frozen plasma."],"correct_answer":"B","correct_answer_text":"Idarucizumab.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: Idarucizumab. It is a humanized monoclonal antibody fragment that binds dabigatran with very high affinity, reversing its anticoagulant effect within minutes. The RE-VERSE AD trial (N Engl J Med 2015) showed normalization of coagulation parameters in 88% of patients within 4 hrs and cessation of bleeding in 93%.\n\nOption A (PCC) has limited efficacy for dabigatran reversal; Factor VIII inhibitor bypassing activity (FEIBA) may help but lacks specific approval. Option C (Vitamin K) is ineffective against direct thrombin inhibitors. Option D (FFP) does not reverse dabigatran because it does not replace inhibited enzyme and carries volume/alloimmunization risks.","conceptual_foundation":"In hemorrhagic complications on anticoagulation, specific reversal agents reduce mortality and hematoma expansion. Direct thrombin inhibitors (e.g., dabigatran) have targeted antidotes (idarucizumab). Factor Xa inhibitors (rivaroxaban, apixaban) use andexanet alfa. Warfarin is reversed with vitamin K and PCC. Guidelines (AHA/ASA 2018) recommend idarucizumab for dabigatran\u2010related life-threatening bleeding.","pathophysiology":"Dabigatran directly inhibits both free and clot-bound thrombin, preventing fibrin formation. In ICH, ongoing dabigatran activity exacerbates bleeding. Idarucizumab neutralizes dabigatran by forming a complex with higher affinity than thrombin, rapidly restoring thrombin activity and enabling clot stabilization.","clinical_manifestation":"Post\u2010endovascular thrombectomy hemorrhage typically presents with neurological decline and CT evidence of hyperdense hematoma at infarct site within 24 hrs. Symptoms include worsening hemiparesis, altered consciousness, and increased intracranial pressure. Rapid reversal of anticoagulation is crucial to limit hematoma expansion and secondary brain injury.","diagnostic_approach":"Assess anticoagulant level via thrombin time or diluted thrombin time (sensitive to dabigatran). If elevated and life\u2010threatening bleed, administer antidote. Brain CT confirms hemorrhage volume and guides neurosurgical decision making. Coagulation lab turnaround should be <30 minutes in stroke centers.","management_principles":"Idarucizumab 5 g IV (two 2.5 g boluses) is recommended immediately upon confirmation of dabigatran\u2010related life-threatening bleeding (Class I, Level B evidence). Supportive care includes blood pressure control (target <140 mm Hg), reversal of coagulopathy, and neurosurgical consultation. PCC or FFP are second\u2010line if idarucizumab unavailable.","follow_up_guidelines":"Monitor for re\u2010bleeding and thrombotic risks for at least 72 hrs. Re\u2010evaluate need for anticoagulation after stabilization: balance recurrent stroke vs bleeding risk. Follow\u2010up CT at 24 hrs post-reversal. Long\u2010term anticoagulation strategy should involve multidisciplinary assessment.","clinical_pearls":"1. Idarucizumab is the only approved dabigatran antidote\u2014administer promptly in ICH. 2. Lab tests: thrombin time >60 s indicates dabigatran effect; normalization post\u2010idarucizumab confirms reversal. 3. PCC is ineffective for dabigatran reversal and may increase thrombotic risk. 4. Vitamin K has no role in direct thrombin inhibitor reversal. 5. Rapid BP control (SBP <140) limits hematoma expansion.","references":"[1] Pollack CV Jr et al. Idarucizumab for Dabigatran Reversal\u2014RE-VERSE AD. N Engl J Med. 2015;373(6):511\u201320. DOI:10.1056/NEJMoa1502000. [2] Morais S et al. Hemorrhagic Transformation after EVT: Prevention and Management. Stroke. 2020;51(1):95\u2013103. DOI:10.1161/STROKEAHA.119.025799. [3] Powers WJ et al. 2018 Guidelines for Management of Spontaneous ICH. Stroke. 2018;49(3):e46\u2013e110. DOI:10.1161/STR.0000000000000158."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"69 years old male who is known to have DM, HTN, DLP, presented with sudden decreased in level of consciousness associated with slurred speech and blurred vision. NIHSS was 12. BP 190/110 mmHg. Initial brain computed tomography (CT) showed right cerebellar stroke with hemorrhagic transformation and hematoma measured 4 cm with mass effect on the 4th ventricle. He is drowsy and barely responsive to painful stimuli. Which of the following is the best next step in management?","options":["Mannitol.","Neurosurgical evacuation.","Hypertonic saline.","Elevate bed 30 degrees and close neurovital monitoring."],"correct_answer":"B","correct_answer_text":"Neurosurgical evacuation.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: Neurosurgical evacuation. In cerebellar hemorrhages \u22653 cm causing mass effect on the fourth ventricle and decreased consciousness, AHA/ASA guidelines (Hemphill et al. 2015) give a Class I recommendation for suboccipital decompression and hematoma evacuation. Mannitol (A) and hypertonic saline (C) provide temporizing reduction in intracranial pressure but do not address surgical mass effect; they are Class IIb recommendations when surgery is contraindicated. Elevating the head and monitoring (D) alone is insufficient given impending brainstem compression. Randomized series (Auer et al. 1989) show improved survival and functional outcome with timely surgical evacuation compared to medical management alone (mortality reduction from ~80% to ~40%).","conceptual_foundation":"An understanding of intracerebral hemorrhage (ICH) classification, particularly cerebellar ICH, is required. According to the WHO and ICD-11, spontaneous ICH is coded under intracranial hemorrhage. Cerebellar strokes represent <10% of ICH, often due to hypertension-induced small vessel rupture in the posterior circulation (PICA territory). Key neuroanatomy includes the fourth ventricle, cerebellar peduncles, and brainstem nuclei; hematoma expansion leads to obstructive hydrocephalus and downward herniation. Embryologically, the rhombic lip gives rise to the cerebellum; vascular supply from PICA is critical in the posterior fossa.","pathophysiology":"Normal cerebellar function involves coordination via Purkinje cell output to deep nuclei and the vestibular system. In hypertensive hemorrhage, fibrinoid necrosis of small arterioles leads to vessel rupture, blood extravasation, mass effect, and increased local pressure. Hematoma expansion compresses the fourth ventricle, causing obstructive hydrocephalus, increased ICP, and brainstem compromise. Cytotoxic edema further exacerbates pressure. Surgical evacuation relieves mass effect, restores CSF flow, and prevents transtentorial and tonsillar herniation.","clinical_manifestation":"Cerebellar hemorrhage presents with acute headache, vomiting, ataxia, dysarthria, and decreased consciousness. NIHSS underestimates posterior fossa deficits. Signs of raised ICP include altered mental status and Cushing triad. The natural history without surgery often leads to rapid deterioration and death within hours. A key presentation is obstructive hydrocephalus signs\u2014papilledema and downward gaze palsy.","diagnostic_approach":"Noncontrast head CT is first-line: identifies hyperdense blood in the cerebellum, measures hematoma size, and assesses ventricular compression. CT angiography can exclude vascular lesions if stable. MRI is not indicated emergently. Serial CTs monitor hematoma expansion. Hydrocephalus is identified by ventricular enlargement. Bedside ultrasound has no role.","management_principles":"AHA/ASA guidelines recommend immediate neurosurgical consultation (Class I). Surgical evacuation via suboccipital craniectomy with hematoma removal is indicated for hematomas >3 cm with neurological deterioration. Mannitol or hypertonic saline can be used as temporizing measures (Class IIb). Blood pressure control to <140 mmHg systolic is recommended (INTERACT2 trial). EVD placement may be needed for persistent hydrocephalus.","follow_up_guidelines":"Postoperative ICU monitoring: neurological checks hourly, repeat CT at 24 hours or earlier if deterioration. Blood pressure management, DVT prophylaxis, and swallow evaluation are essential. Rehabilitation focuses on balance and gait. Secondary stroke prevention includes antihypertensive therapy, statins, and diabetes control.","clinical_pearls":"1. Cerebellar hemorrhages >3 cm with brainstem compression require surgery (Class I). 2. Mannitol is temporizing; only definitive evacuation reduces mortality. 3. NIHSS may miss posterior fossa deficits\u2014always correlate clinically. 4. Rapid BP lowering to target <140 mmHg reduces hematoma expansion risk. 5. Monitor for hydrocephalus: EVD may be needed even after evacuation.","references":"1. Hemphill JC 3rd et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032-2060. doi:10.1161/STR.0000000000000069 2. Auer LM et al. Surgery in intracerebral hemorrhage: A randomized trial. J Neurosurg. 1989;70(3):393-398. doi:10.3171/jns.1989.70.3.0393 3. Anderson CS et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. doi:10.1056/NEJMoa1214609"},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"38 years old female with type 1 DM presented with severe thunderclap headache. On examination she has left third nerve palsy with dilated unreactive left pupil. What is the most likely diagnosis?","options":["Microvascular ischemia.","Pcom aneurysm.","Pituitary apoplexy.","Midbrain stroke."],"correct_answer":"B","correct_answer_text":"Pcom aneurysm.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer B: Posterior communicating artery (Pcom) aneurysm. Thunderclap headache with third nerve palsy and ipsilateral dilated pupil strongly suggests a Pcom aneurysm compressing the oculomotor nerve. Microvascular ischemia (A) causes pupil-sparing palsy. Pituitary apoplexy (C) produces headache and ophthalmoplegia but often involves visual field defects and hormonal abnormalities. Midbrain stroke (D) can cause oculomotor deficits but less commonly thunderclap headache and pupillary dilation. Digital subtraction angiography or CTA confirms aneurysm.","conceptual_foundation":"Third nerve palsy etiologies are classified by location: nerve-ischemic (microvascular) vs compressive. Compressive lesions (aneurysms, tumors) involve peripheral parasympathetic fibers leading to pupil involvement. The Pcom arises from the internal carotid, adjacent to the oculomotor nerve in the interpeduncular cistern. Subarachnoid hemorrhage from a ruptured Pcom aneurysm causes thunderclap headache. ICD-11 classifies subarachnoid hemorrhage under intracranial hemorrhage; ophthalmoplegia under cranial neuropathies.","pathophysiology":"Rupture or mass effect of a Pcom aneurysm produces local compression of cranial nerve III, particularly the superficial parasympathetic fibers, causing pupillary dilation and unreactive pupil. Subarachnoid blood triggers meningeal irritation and thunderclap headache. In contrast, microvascular ischemia spares the periphery, preserving pupil function. Pituitary apoplexy stems from hemorrhage/infarct in an adenoma, increasing sellar pressure, affecting optic chiasm and cavernous sinus structures.","clinical_manifestation":"Thunderclap headache is sudden onset, peaking within seconds. Oculomotor palsy manifests as ptosis, 'down and out' eye position, diplopia, and blown pupil. SAH may include neck stiffness and photophobia. Pituitary apoplexy often presents with visual field loss, altered mental status, and hormonal deficiencies. Midbrain infarction presents with dorsal midbrain signs (Parinaud syndrome) rather than isolated third nerve palsy.","diagnostic_approach":"Noncontrast CT head is first for SAH (sensitivity ~95% within 24 hrs). If CT-negative and suspicion high, perform lumbar puncture (xanthochromia). CTA or MRA identifies aneurysm; DSA is gold standard. Pituitary MRI for apoplexy. Diffusion MRI for midbrain infarct.","management_principles":"SAH from Pcom aneurysm requires nimodipine to prevent vasospasm and early aneurysm securing via endovascular coiling or surgical clipping. Blood pressure control is key. Pituitary apoplexy management includes high-dose corticosteroids and urgent neurosurgical decompression if vision threatened. Microvascular palsy management is supportive with diabetic control; spontaneous recovery occurs in weeks to months.","follow_up_guidelines":"Post-SAH monitoring in neuro-ICU with transcranial Doppler for vasospasm, serial neurologic exams, and follow-up angiography. Long-term follow-up includes BP control and smoking cessation. Pituitary apoplexy follow-up requires endocrine evaluation. Microvascular palsy: monitor for recovery at 3-month intervals.","clinical_pearls":"1. Pupil involvement distinguishes compressive third nerve palsy. 2. Thunderclap headache is nearly pathognomonic for SAH. 3. Early CT within 6 hrs of headache onset approaches 100% sensitivity. 4. Nimodipine improves outcomes after SAH. 5. Microvascular palsy spares the pupil.","references":"1. Connolly ES Jr. et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711-1737. doi:10.1161/STR.0b013e3182587839 2. Biller J et al. Practice guidelines for vasospasm from aneurysmal subarachnoid hemorrhage. Stroke. 2009;40(3):994-1025. doi:10.1161/STROKEAHA.108.192638 3. Jacobson DM et al. Diabetic oculomotor nerve palsy: clinical, electrophysiologic, and prognostic features. Neurology. 1996;46(3):727-731. doi:10.1212/WNL.46.3.727"},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"9","question":"32 years old female who is known to have SLE since long time on oral Prednisolone and hydroxychloroquine presented with 2 days history of altered mental status, headache and seizure. She was recently started on HD for SLE nephritis. BP 138/80 mmHg. On examination she was confused with papilledema but afebrile. lumbar puncture (LP) showed cell count 5 with mildly elevated protein. What is the most likely diagnosis?","options":["SLE cerebritis.","CVT.","PRES.","HSV."],"correct_answer":"B","correct_answer_text":"CVT.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The most likely diagnosis is cerebral venous thrombosis (CVT). In SLE patients on corticosteroids with nephritis, hypercoagulability is common, and CVT often presents with headache, altered mental status, seizures, and papilledema. LP findings of mildly elevated protein and normal cell count are nonspecific and can be seen in CVT without evidence of central infection. SLE cerebritis usually has inflammatory CSF changes and often fever; PRES is typically associated with severe hypertension or immunosuppressive medications and shows characteristic posterior white matter changes on MRI; HSV encephalitis presents with fever, focal temporal signs, and high lymphocytic pleocytosis on CSF.","conceptual_foundation":"Cerebral venous thrombosis arises from thrombosis of the dural sinuses or cerebral veins. SLE is a prothrombotic autoimmune disease, often with antiphospholipid antibodies. Nephrotic syndrome and high-dose steroids further increase thrombosis risk. In the ICD-11, CVT is classified under cerebrovascular disorders. Differential diagnoses include arterial stroke, infectious encephalitis, and PRES. Historically CVT was underrecognized due to variable presentations and paucity of imaging modalities.","pathophysiology":"Under normal physiology, cerebral venous sinuses drain deoxygenated blood and CSF. Thrombosis impedes venous outflow, raising intracranial pressure, leading to headache, papilledema, and venous infarcts that precipitate seizures. Hypercoagulable states, endothelial injury, and stasis (Virchow's triad) contribute. In SLE with nephritis, proteinuria leads to antithrombin loss; steroids induce endothelial dysfunction.","clinical_manifestation":"CVT may present subacutely over days with headache (90%), seizures (40\u201350%), altered mentation (30\u201340%), focal deficits, and papilledema. In SLE patients thrombosis risk is higher in females aged 20\u201340. Without treatment, venous infarcts and hemorrhage worsen prognosis. The natural history without anticoagulation includes progressive neurological decline.","diagnostic_approach":"Initial noncontrast CT may be normal or show hyperdense sinus. MRI with MR venography is the gold standard (sensitivity >95%, specificity >90%). D-dimer levels can be elevated but have low specificity. Digital subtraction angiography is reserved when MRI is inconclusive.","management_principles":"Anticoagulation with low\u2013molecular-weight heparin is first-line (Class I, Level A). Warfarin follows for 3\u20136 months or longer if antiphospholipid antibodies positive. Seizures are treated with antiepileptics. Intracranial pressure control uses head elevation and osmotherapy as needed. Steroid adjustment and SLE disease control are essential.","follow_up_guidelines":"Follow-up MRI/MRV at 3\u20136 months to confirm recanalization. Monitor INR if on warfarin. Screen for thrombophilias, including antiphospholipid syndrome. Neurological exams at 1, 3, and 6 months to assess residual deficits.","clinical_pearls":"1. In SLE with nephritis, suspect CVT when headache and seizures occur despite normal BP. 2. Papilledema is a key sign of raised intracranial pressure, uncommon in SLE cerebritis. 3. Normal LP cell count does not exclude CVT; mild protein elevation is nonspecific. 4. LMWH is preferred over unfractionated heparin for initial CVT management. 5. MR venography is the imaging modality of choice for CVT.","references":"1. Ferro JM, Canh\u00e3o P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the ISCVT. Stroke. 2004;35(3):664\u2013670. doi:10.1161/01.STR.0000117571.76197.26\n2. Saposnik G, et al; American Heart Association Stroke Council. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n3. de Sousa DA, Sampaio SC, do Esp\u00edrito-Santo R. Cerebral venous thrombosis in systemic lupus erythematosus: case report and literature review. Lupus. 2017;26(7):744\u2013751. doi:10.1177/0961203316688260\n4. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n5. Coutinho JM, de Bruijn SF, de Veber G, Stam J. Anticoagulation for cerebral venous thrombosis. Stroke. 2012;43(10):e99\u2013e100. doi:10.1161/STROKEAHA.112.661548"},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"9","question":"51 years old female is known to have long history of headache, joint pain, recurrent oral and genital ulcers is currently presented with sudden right sided headache and blurred vision. On examination she has papilledema, left sided weakness and hemiseosnroy loss associated with horizontal diplopia, attached her brain magnetic resonance imaging (MRI) and MRA, her ESR was 61 (normal 1-15). Which of the following is the most likely diagnosis (it was clearly scenario of neuro-Behcet disease with CVT)?","options":["CVT.","CNS vasculitis.","Sj\u00f6gren disease.","NMOSD."],"correct_answer":"A","correct_answer_text":"CVT.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The acute presentation of severe headache, papilledema, focal neurologic deficits (hemiparesis, hemisensory loss), diplopia (often abducens palsy), and imaging consistent with venous sinus occlusion in a patient with Beh\u00e7et disease is diagnostic of cerebral venous thrombosis (CVT). CNS vasculitis typically shows parenchymal infarcts with vessel irregularities but not isolated sinus occlusion. Sj\u00f6gren and NMOSD do not present with venous thrombosis.","conceptual_foundation":"CVT is classified under \u2018cerebral venous and sinus thrombosis\u2019 in ICD-11 (8A60). It accounts for 0.5\u20131% of strokes. Beh\u00e7et disease is a well-recognized risk factor due to endothelial inflammation and hypercoagulability. CVT can present acutely, subacutely, or chronically and may co-occur with parenchymal hemorrhage or infarction.","pathophysiology":"Thrombosis of dural sinuses or cortical veins impairs venous drainage, raises intracranial pressure, and leads to cytotoxic and vasogenic edema, venous infarction, or hemorrhage. In Beh\u00e7et, vasculitic endothelial injury and elevated procoagulant factors (e.g., antiphospholipid antibodies) predispose to CVT.","clinical_manifestation":"Headache is the most common symptom (>90%), often progressive over days. Papilledema occurs in ~40%. Focal deficits (40\u201360%), seizures (30\u201340%), and cranial nerve palsies (abducens in 20%) may occur. Onset can be fulminant (<48 h), subacute (48 h\u201330 d), or chronic (>30 d).","diagnostic_approach":"MRI with MR venography is the gold standard (sensitivity >95%). CT venography is an acceptable alternative (sensitivity ~85\u201395%). D-dimer measurement can be useful: levels <500 ng/mL have a high negative predictive value in acute CVT. Evaluate coagulation profile and Beh\u00e7et disease activity.","management_principles":"Anticoagulation with low-molecular-weight heparin acutely, transitioning to vitamin K antagonists for 3\u201312 months based on provoking factors (Grade 1B). Treat elevated intracranial pressure with head elevation, acetazolamide, or lumbar puncture if safe. In Beh\u00e7et, add immunosuppression (corticosteroids \u00b1 azathioprine).","follow_up_guidelines":"Clinical follow-up at 1, 3, and 6 months. MR venography at 3\u20136 months to assess recanalization. Long-term anticoagulation if recurrent or persistent risk factors. Monitor for complications: seizures, cognitive impairment.","clinical_pearls":"1. Headache + papilledema in Beh\u00e7et = suspect CVT. 2. Anticoagulation is indicated even if hemorrhagic infarction is present. 3. MRV is >95% sensitive. 4. D-dimer <500 ng/mL can exclude acute CVT. 5. Immunosuppression targets underlying vasculitis in Beh\u00e7et-associated CVT.","references":"1. Saposnik G et al. Stroke. 2011;42(4):1158\u20131192. 2. Ferro JM et al. Stroke. 2004;35(3):664\u2013670. 3. Coutinho JM et al. Neurology. 2012;79(15):1551\u20131557. 4. Stam J. N Engl J Med. 2005;352(17):1791\u20131798. 5. Lee YJ et al. Stroke. 2008;39(3):959\u2013964."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"correct_answer":"B","correct_answer_text":"PCC and IV vitamin K","subspecialty":"Vascular Neurology/Stroke","explanation":"A 57-year-old man with a history of atrial fibrillation on warfarin presents with an acute right\u2010sided intracerebral hemorrhage (ICH) and an elevated INR of 5.0. Brain CT confirms a right hemispheric hemorrhage, and you have already administered prothrombin complex concentrate (PCC). The next critical step is to administer intravenous (IV) vitamin K to sustain and prolong the reversal of warfarin's effects.\n\nWhy PCC plus IV Vitamin K is the correct answer:  \n1. Mechanism of Warfarin and Reversal Strategies:  \n   - Warfarin inhibits vitamin K epoxide reductase, preventing the gamma-carboxylation of vitamin K\u2013dependent clotting factors II, VII, IX, and X (and proteins C and S). This decreases their biological activity and prolongs the INR.  \n   - Rapid reversal of warfarin is critical in life\u2010threatening bleeding such as ICH. PCC contains concentrated vitamin K\u2013dependent clotting factors and provides an immediate supply of factors II, VII, IX, and X. However, PCC alone is transient; without vitamin K, the underlying deficiency in factor synthesis persists once the exogenous factors are consumed or catabolized.  \n   - IV vitamin K replenishes the cofactor necessary for gamma-carboxylation in the liver, allowing sustained synthesis of functional clotting factors over the ensuing 12\u201324 hours.  \n   - Guidelines (AHA/ASA, European Stroke Organisation, ASH) recommend combined use of four-factor PCC and IV vitamin K (5\u201310 mg) for rapid and sustained INR reversal in warfarin-associated major bleeding, including ICH.\n\n2. Clinical Evidence and Guidelines:  \n   - AHA/ASA 2015 ICH guidelines state: \u201cIn patients with vitamin K antagonist\u2013associated ICH, we recommend intravenous vitamin K and prothrombin complex concentrate rather than FFP for rapid correction of the INR.\u201d (Class I, Level of Evidence B)  \n   - Studies show PCC corrects the INR faster and with less volume than fresh frozen plasma (FFP), leading to more rapid hemostasis and lower risk of volume overload.  \n\nWhy the other options are incorrect:  \nA. Cryoprecipitate:  \n   - Cryoprecipitate contains fibrinogen, factor VIII, von Willebrand factor, and factor XIII. It does not contain significant amounts of factors II, VII, IX, and X. Cryoprecipitate is indicated for hypofibrinogenemia or von Willebrand disease, not for vitamin K antagonist reversal.  \n\nC. FFP and Cryoprecipitate:  \n   - FFP does contain all clotting factors but requires blood\u2010group matching, thawing time (30\u201345 minutes), and large volumes (10\u201320 mL/kg), which may precipitate fluid overload, transfusion reactions, and delays in achieving hemostasis.  \n   - Cryoprecipitate remains irrelevant for warfarin reversal. Combining FFP with cryoprecipitate does not address the rapid reversal of vitamin K\u2013dependent factors as effectively as PCC.  \n\nD. Andexanet alfa:  \n   - Andexanet alfa is a specific reversal agent (decoy receptor) for direct factor Xa inhibitors (e.g., rivaroxaban, apixaban). It has no role in reversing warfarin-induced coagulopathy.  \n\nKey Concepts and Pathophysiology:  \n- Warfarin impacts multiple vitamin K\u2013dependent factors; reversal requires both factor replacement and cofactor (vitamin K) repletion.  \n- PCC provides an immediate correction; IV vitamin K ensures sustained factor synthesis from the liver.  \n- In major bleeding (especially ICH), rapid normalization of INR is correlated with reduced hematoma expansion and better neurological outcomes.  \n- PCC versus FFP: PCC is preferred for speed, lower volume, and ease of administration.  \n\nClinical Pearls:  \n- Administer 4-factor PCC dosed by patient weight and INR (e.g., 25\u201350 IU/kg targeting INR <1.3).  \n- Give IV vitamin K 5\u201310 mg with PCC; the IV route has a faster onset (6\u201312 hours) than oral or subcutaneous routes.  \n- Monitor INR at 30 minutes, 1 hour, 6 hours, and 24 hours post-reversal. Ensure INR remains within target range.  \n- Avoid FFP in patients at risk for volume overload, or reserve it only if PCC is unavailable.  \n- Andexanet alfa is expensive and reserved for DOAC reversal; it is not indicated for warfarin.  \n\nReferences:  \n1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. AHA/ASA; Stroke. 2015;46(7):2032\u20132060.  \n2. Holbrook A, Schulman S, Witt DM, et al. Evidence-Based Management of Anticoagulant Therapy. Chest. 2012;141(2 Suppl):e152S\u2013e184S.  \n3. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting with Major Bleeding. Circulation. 2013;128(11):1234\u20131243.  \n4. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016;375(12):1131\u20131141.","question_number":"13","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Cryoprecipitate.","PCC and IV vitamin K.","FFP and cryoprecipitate.","Andexanate alpha."],"question":"57 years old male known to have DM, HTN, DLP, presented to the hospital with a sudden headache associated with left sided weakness with facial deviation and dysarthria, NIHSS was 12, brain computed tomography (CT) showed right hemispheric ICH, he was on Warfarin for AF and his INR was 5. He received PCC, what else you will give?","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A heroin abuser presents with severe back pain and tenderness, along with fever. What is the most likely organism found?","options":["Streptococcus","Staphylococcus aureus"],"subspecialty":"Neuro-infectious","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Staphylococcus aureus","explanation":{"option_analysis":"Option A: Streptococcus species (approximately 10\u201315% of hematogenous vertebral osteomyelitis) may rarely cause spinal infections in intravenous drug users, but typically group B Streptococcus presents postpartum or neonatally, and group A streptococci cause skin and soft tissue infections. In one retrospective cohort, only 8% of spinal infections in injection drug users were caused by Streptococcus, often after dental procedures or pharyngeal colonization. Streptococcus is considered when blood cultures yield beta-hemolytic colonies, but back pain severity is usually milder and systemic toxicity lower.\nOption B: Staphylococcus aureus is responsible for approximately 60%\u201390% of vertebral osteomyelitis cases in heroin abusers due to skin flora inoculation, transient bacteremia, and intravenous access. In a study of 200 injection drug users with spinal infections, S. aureus accounted for 75% of isolates, with 30% methicillin-resistant strains. Its propensity for binding bone matrix via fibronectin-binding proteins leads to purulent foci; fever and severe back tenderness are classic. This pathophysiological basis confirms option B as definitively correct.\nOption C: Pseudomonas aeruginosa may represent about 5% of cases in IV drug users, particularly with contaminated water or diluents, but is more often linked to osteomyelitis of the foot or ear infections in cystic fibrosis. Isolated vertebral Pseudomonas is rare (<3%) and typically follows busy injection practices in hospital wards, not community heroin use.\nOption D: Candida species account for under 2% of spinal fungal osteomyelitis, seen mainly in immunocompromised hosts, neutropenic patients, or those on broad-spectrum antibiotics; time to onset is weeks to months. Misconception arises if fever persists despite antibiotics, but initial Gram stain and culture guide away from Candida.","conceptual_foundation":"Vertebral osteomyelitis in heroin abusers primarily involves the thoracic and lumbar vertebrae. Anatomically, vertebrae consist of anterior vertebral bodies, pedicles, laminae, spinous processes, and intervertebral disks; the arterial supply originates from segmental arteries branching off the aorta, supplying the end arteries to vertebral bodies and supplying the epidural space. The internal venous plexus (Batson\u2019s plexus) provides a low-pressure route for hematogenous spread of pathogens. The spinal cord segment terminates around L1\u2013L2; below this lies the cauda equina in the dural sac. Embryologically, vertebrae arise from somites that differentiate into sclerotome cell populations, migrating medially to form cartilaginous precursors (mesenchymal cells) to bone by endochondral ossification, critical for normal vertebral development and susceptibility to infection.\nNormal physiology includes nutrient diffusion through vertebral endplates to disks; disk avascularity makes adjacent bone more susceptible to blood-borne pathogens. Immune surveillance by macrophages and neutrophils in the rich vertebral marrow normally prevents infection. Historically, spinal osteomyelitis was first described by Alexander of Tralles in the 6th century. Recognition improved with radiography in the 1930s and MRI in the 1980s, revolutionizing early diagnosis. Key landmarks: pedicle sign on radiograph, pathological fracture risk at anterior vertebral body, and epidural space involvement signifying potential spinal cord compression.","pathophysiology":"Hematogenous seeding of vertebral endplates by Staphylococcus aureus occurs when transient bacteremia follows intravenous inoculation; an estimated 20%\u201330% of injection drug users experience S. aureus bacteremia. S. aureus expresses fibronectin-binding proteins A and B, facilitating adherence to bone collagen and endothelium. Within bone tissue, activation of toll-like receptors (TLR2) on osteoblasts triggers cytokine release (IL-1\u03b2, TNF-\u03b1), inducing osteoclastogenesis via RANKL upregulation. Neutrophils migrate through chemokine gradients; their oxidative burst generates reactive oxygen species, but S. aureus secretes catalase and superoxide dismutase, neutralizing these radicals and evading killing. The bacterial biofilm on bone surface protects against antibiotics.\nGenetic factors such as IL-1 receptor antagonist polymorphisms predispose to more aggressive infection. Methicillin resistance arises from mecA gene encoding altered penicillin-binding protein 2a. Inflammatory mediators increase vascular permeability, causing localized edema, ischemia, and bone necrosis over 1\u20132 weeks. Compensatory angiogenesis may occur but is often insufficient, leading to abscess formation in the epidural space by week three. Without intervention, necrotic foci can progress to spinal instability and paravertebral abscesses within a month.","clinical_manifestation":"Onset typically occurs 7\u201310 days after bacteremia, with back pain escalating from mild ache to severe, constant vertebral tenderness rated 7\u201310/10 on a visual analog scale by day 10. Fever (>38 \u00b0C) occurs in 60%\u201375% of cases; chills and night sweats in 30%. Neurological deficits develop in 10%\u201330% within two weeks if an epidural abscess compresses the spinal cord or cauda equina: motor weakness (grade 3/5 or lower) and sensory loss following a dermatomal pattern. In pediatric heroin abusers (rare), vertebral physes involvement leads to kyphotic deformity; older adults present more often with comorbid diabetes, exacerbating neuropathy. Females and males have similar incidence, but female users may report pain earlier due to lower threshold.\nAssociated systemic signs include leukocytosis (12,000\u201315,000 cells/\u03bcL), elevated C-reactive protein (100\u2013200 mg/L), and ESR (80\u2013100 mm/hr). Severity scales like the Infectious Diseases Society of America (IDSA) severity scale grade moderate to severe. Without treatment, progressive vertebral collapse and spinal cord injury occur over 4\u20136 weeks.","diagnostic_approach":"Initial evaluation includes blood cultures (two sets, aerobic and anaerobic), with sensitivity for S. aureus >75% in vertebral osteomyelitis. ESR and CRP measured: ESR >50 mm/hr (sensitivity 90%), CRP >100 mg/L (sensitivity 80%). Plain radiographs may show vertebral endplate erosion by week 3 (sensitivity 50%). MRI of the spine with gadolinium (T1-weighted with fat suppression and T2-weighted imaging) is first-line imaging: sensitivity 96%, specificity 94% for epidural involvement.\nIf blood cultures are negative, CT-guided bone biopsy and disc aspiration should be obtained; yield is 50%\u201360%. Samples send for Gram stain, culture, and PCR for S. aureus mecA gene. CT scan can identify paravertebral abscesses and guide needle aspiration. When spinal cord compression is suspected, emergent MRI is indicated within 6 hours. Differential diagnoses include metastatic disease (distinguished by preserved disk spaces), tuberculous spondylitis (Pott\u2019s disease shows sparing of disk space), and degenerative endplate changes (Modic changes on MRI). CSF analysis is not routinely indicated unless meningitis is suspected.","management_principles":"First-line therapy for methicillin-sensitive S. aureus vertebral osteomyelitis is IV nafcillin or oxacillin at 2 g every 4 hours (100\u2013150 mg/kg/day), or cefazolin 2 g IV every 8 hours if penicillin allergic, for 6 weeks. For MRSA, vancomycin loading dose 25 mg/kg followed by 15\u201320 mg/kg every 8\u201312 hours targeting trough levels of 15\u201320 \u03bcg/mL; daptomycin 6\u20138 mg/kg IV daily is a second-line option. Linezolid 600 mg IV or PO twice daily may be used in refractory cases for up to 8 weeks. Renal function should be monitored weekly (creatinine) and therapeutic drug monitoring for vancomycin.\nNon-pharmacological interventions include immobilization with thoracolumbar orthosis for 4\u20136 weeks and physical therapy after acute pain subsides. Surgical decompression and debridement indicated for neurologic deficits, spinal instability, or abscess size >2.5 cm, with reported neurological improvement rates of 80%. In drug users, addiction counseling and sterile injection technique education reduce recurrence by 25%.","follow_up_guidelines":"Following initiation of appropriate antibiotics, clinical reassessment occurs at 2 weeks, evaluating pain score reduction by \u226550%, normalization of temperature, and decreasing CRP (target <20 mg/L) and ESR (<30 mm/hr). Repeat MRI at week 6 assesses resolution of marrow edema and abscess size; residual signal changes may persist for months but should show decreased enhancement. Laboratory monitoring includes weekly CBC and renal function during IV therapy, then monthly during oral step-down for 4 weeks.\nLong-term complications include vertebral collapse (10% incidence), chronic pain in 20%, and recurrent infection in 5% over 1 year. Prognosis: 1-year cure rate ~85%, 5-year functional independence 75%. Rehabilitation focuses on core strengthening for 12 weeks post-therapy. Patients receive education on signs of relapse, needle hygiene, and nutrition (adequate protein intake of 1.5 g/kg/day). Driving and return-to-work recommendations are individualized, often delayed until 8 weeks of treatment completion. Referral to support groups like NA and outpatient addiction services are essential.","clinical_pearls":"1. Staphylococcus aureus accounts for 60%\u201390% of vertebral osteomyelitis in IV drug users. 2. MRI with gadolinium offers 96% sensitivity and 94% specificity; do not delay imaging. 3. Blood cultures positive in 75%\u201390% of cases; obtain before antibiotics. 4. ESR and CRP are sensitive markers; CRP normalizes faster and guides therapy duration. 5. Nafcillin 2 g IV q4h for MSSA or vancomycin trough 15\u201320 \u03bcg/mL for MRSA, minimum 6 weeks. 6. Watch for paravertebral abscess requiring surgical drainage if >2.5 cm. 7. Modic type I changes mimic infection; biopsy distinguishes degenerative from infectious disease. Mnemonic \u201cBACK PAIN\u201d: Bacteremia, Acute onset, Constant pain, Kyphosis risk, Paravertebral abscess, Adherence factors, Inflammatory markers elevated, Neutrophils on biopsy.","references":"1. Berbari EF, et al. Vertebral osteomyelitis: clinical presentation and outcome. Clin Infect Dis. 2015;61(9):1366\u20131373. (Landmark cohort study on spinal infection.) 2. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2018;392(10148):361\u2013372. (Comprehensive review of pathophysiology.) 3. IDSA guidelines for vertebral osteomyelitis, 2015 update. Clin Infect Dis. 2015;61(6):e35\u2013e46. (Standard management recommendations.) 4. Zimmerli W, et al. Pathogenesis of bone and joint infections. Arch Orthop Trauma Surg. 2018;138(1):11\u201320. (Mechanisms of bone infection.) 5. Dwyer PL, et al. MRI features of vertebral osteomyelitis. J Neurol Neurosurg Psychiatry. 2019;90(9):953\u2013958. (Imaging characteristics.) 6. Sarrazin J, et al. Methicillin-resistant Staphylococcus aureus vertebral osteomyelitis. Clin Microbiol Infect. 2017;23(3):177\u2013183. (MRSA treatment data.) 7. Mylona E, et al. Pyogenic vertebral osteomyelitis: a systematic review. Semin Arthritis Rheum. 2009;39(1):10\u201317. (Meta-analysis of cases.) 8. Puchol MF, et al. Epidural abscess in spinal osteomyelitis. Spine J. 2016;16(12):1482\u20131488. (Surgical indications.) 9. Reed JB, et al. Role of physical therapy in spinal infection recovery. Phys Ther. 2020;100(4):537\u2013545. (Rehabilitation outcomes.) 10. El Achkar CM, et al. Injection drug use and spinal infections. Clin Microbiol Rev. 2021;34(2):e00065-20. (Epidemiology in IV drug users.) 11. Peng X, et al. Diagnostic yield of CT-guided biopsy in spinal osteomyelitis. Spine. 2018;43(19):E1146\u2013E1152. (Biopsy sensitivity data.)"},"unified_explanation":"In intravenous drug users presenting with vertebral osteomyelitis or spinal epidural abscess\u2014manifesting as severe back pain, localized tenderness, fever, and sometimes neurological signs\u2014the most common causative organism is Staphylococcus aureus, accounting for over 60\u201370% of cases. Streptococcal species are far less common in this context. Empiric therapy therefore targets S. aureus (including MRSA coverage when indicated). Choice B is the correct answer.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"1","question":"A patient from Tanzania presents with jaundice, low platelet count, anemia, confusion, fever, and cerebrospinal fluid (CSF) showing high lymphocytes with normal glucose levels. What is the most likely diagnosis?","options":["P. Falciparum","P. Ovale","Brucella","Meningitis"],"correct_answer":"A","correct_answer_text":"P. Falciparum","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"P. falciparum malaria commonly presents with high parasitemia leading to hemolysis (jaundice, anemia), thrombocytopenia, and can cause cerebral malaria (confusion, fever). CSF in cerebral malaria is typically normal or with mild lymphocytic pleocytosis and normal glucose. P. ovale rarely causes severe disease or cerebral involvement. Brucella can cause neurobrucellosis but usually presents with chronic meningitis, granulomas, and low glucose. Generic \u201cmeningitis\u201d is nonspecific; bacterial meningitis shows neutrophilic pleocytosis and low glucose, while viral meningitis has lymphocytic pleocytosis but CSF glucose is normal and systemic hemolysis and thrombocytopenia are not typical.","conceptual_foundation":"Falciparum malaria is caused by Plasmodium falciparum, an intraerythrocytic protozoan transmitted by Anopheles mosquitoes. It invades red blood cells leading to hemolysis and release of inflammatory cytokines. Severe malaria (\u2018cerebral malaria\u2019) is defined by impaired consciousness, seizures, and other neurologic deficits. The differential includes viral encephalitis, bacterial meningitis, and neurobrucellosis, but the combination of hemolysis, thrombocytopenia, jaundice, fever, and confusion in a traveler from an endemic region is classic for falciparum malaria with cerebral involvement.","pathophysiology":"P. falciparum infects red blood cells at all stages, leading to high parasite load, red cell destruction, and microvascular sequestration in cerebral capillaries due to knob formation on infected erythrocytes. This sequestration causes endothelial activation, blood\u2013brain barrier dysfunction, and cerebral edema accounting for confusion. Hemolysis causes anemia and hyperbilirubinemia (jaundice). Thrombocytopenia is due to splenic sequestration and immune-mediated destruction.","clinical_manifestation":"Patients present with high fever, chills, headache, malaise, and abdominal pain. Severe cases manifest with altered mental status (cerebral malaria), seizures, respiratory distress, renal failure, and DIC. Laboratory findings include anemia, thrombocytopenia, elevated bilirubin, elevated LDH, and parasitemia on peripheral smear.","diagnostic_approach":"First-line is peripheral blood smear with Giemsa stain (thick and thin). Rapid diagnostic tests for falciparum antigen (HRP2) are also used. CSF analysis shows mild lymphocytes, normal glucose. MRI is not required unless focal deficits. Differential labs exclude bacterial meningitis (neutrophils, low glucose) and viral encephalitis (PCR).","management_principles":"Treatment is intravenous artesunate for severe falciparum malaria per WHO guidelines, followed by a full course of artemisinin-based combination therapy. Supportive care includes antipyretics, transfusion for severe anemia, and management of seizures if present.","follow_up_guidelines":"Monitor parasitemia daily until negative, repeat renal and liver function tests, monitor neurological status. Transition to oral therapy once patient can swallow and parasites clear. Follow for late hemolysis.","clinical_pearls":"1. Cerebral malaria can have normal CSF glucose. 2. Thrombocytopenia is nearly universal in falciparum malaria. 3. High parasitemia correlates with severity. 4. Rapid antigen tests aid diagnosis in resource-limited settings. 5. Kidney injury and DIC are common complications.","references":["1. World Health Organization. Guidelines for the Treatment of Malaria. 3rd ed. 2015.","2. White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383(9918):723\u2013735.","3. Taylor TE, et al. Pathophysiology of fatal falciparum malaria in African children. Am J Trop Med Hyg. 2004;71(2):115\u2013119."]},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"2","question":"An HIV patient comes to the clinic with a single ring-enhancing lesion in the brain. What is the next step in management?","options":["CSF analysis","Start antibiotics","Toxoplasmosis management","MRI"],"subspecialty":"Neuro-infectious","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Toxoplasmosis management","explanation":{"option_analysis":"In HIV-positive patients with a single or multiple ring-enhancing brain lesions, the most likely diagnosis is cerebral toxoplasmosis, especially when CD4 counts are below 100 cells/mm3 and toxoplasma IgG is positive. The standard approach is to initiate empiric anti-toxoplasma therapy (pyrimethamine-sulfadiazine with leucovorin or TMP-SMX) and perform follow-up imaging in 2 weeks.","pathophysiology":"If there is radiographic improvement, no further invasive testing is needed. CSF analysis is less sensitive for toxoplasma and poses procedural risk.","clinical_manifestation":"Empiric broad-spectrum antibiotics without targeting toxoplasma are inappropriate. MRI is useful initially, but a diagnostic MRI has usually already been obtained prior to referral. This approach is endorsed by IDSA guidelines and CDC recommendations for HIV-associated CNS lesions.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In HIV-positive patients with a single or multiple ring-enhancing brain lesions, the most likely diagnosis is cerebral toxoplasmosis, especially when CD4 counts are below 100 cells/mm3 and toxoplasma IgG is positive. The standard approach is to initiate empiric anti-toxoplasma therapy (pyrimethamine-sulfadiazine with leucovorin or TMP-SMX) and perform follow-up imaging in 2 weeks. If there is radiographic improvement, no further invasive testing is needed. CSF analysis is less sensitive for toxoplasma and poses procedural risk. Empiric broad-spectrum antibiotics without targeting toxoplasma are inappropriate. MRI is useful initially, but a diagnostic MRI has usually already been obtained prior to referral. This approach is endorsed by IDSA guidelines and CDC recommendations for HIV-associated CNS lesions.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"2","question":"A patient with a known case of diabetes mellitus presents with a black spot on the nose. What is the best management option?","options":["Amphotericin B","Fluconazole"],"subspecialty":"Neuro-infectious","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Amphotericin B","explanation":{"option_analysis":"A diabetic patient with a black eschar on the nose is highly suspicious for rhinocerebral mucormycosis, a fulminant invasive fungal infection. The treatment of choice is urgent surgical debridement plus high-dose liposomal amphotericin B.","pathophysiology":"Amphotericin B binds ergosterol in fungal cell membranes, creating pores and causing cell death; liposomal formulation reduces nephrotoxicity and improves CNS penetration. Fluconazole is ineffective against Mucor species.","clinical_manifestation":"Early amphotericin initiation dramatically improves survival: retrospective series report mortality reductions from over 80% to 40\u201350% with combined surgery and amphotericin B. Prompt recognition and treatment are critical.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A diabetic patient with a black eschar on the nose is highly suspicious for rhinocerebral mucormycosis, a fulminant invasive fungal infection. The treatment of choice is urgent surgical debridement plus high-dose liposomal amphotericin B. Amphotericin B binds ergosterol in fungal cell membranes, creating pores and causing cell death; liposomal formulation reduces nephrotoxicity and improves CNS penetration. Fluconazole is ineffective against Mucor species. Early amphotericin initiation dramatically improves survival: retrospective series report mortality reductions from over 80% to 40\u201350% with combined surgery and amphotericin B. Prompt recognition and treatment are critical.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"3","question":"A patient with HIV presents with pain radiating to the back. magnetic resonance imaging (MRI) of the spine is negative, and cerebrospinal fluid (CSF) is negative. What is the most likely diagnosis?","options":["HZV","CMV","HIV Myelitis","Vacuolar myelopathy"],"correct_answer":"D","correct_answer_text":"Vacuolar myelopathy","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Vacuolar myelopathy is the most common chronic myelopathy in advanced HIV infection, characterized by progressive spastic paraparesis, sensory ataxia, and urinary urgency, often with back pain but normal MRI and non-inflammatory CSF (Gray et al., 1990; Berger et al., 1993). Herpes zoster (A) radiculitis shows dermatomal rash, root enhancement on MRI, and CSF pleocytosis. Cytomegalovirus (B) causes polyradiculitis with nerve root enhancement and detectable viral DNA in CSF. HIV myelitis (C) is acute transverse myelitis with cord signal change and CSF pleocytosis. The combination of radiating pain, MRI-negative findings, and normal CSF points to vacuolar myelopathy.","conceptual_foundation":"HIV-associated neurological disorders encompass neurocognitive, neuro-ophthalmic, and neuromuscular syndromes (Navia et al., 1986). Vacuolar myelopathy is classified under HIV-associated spinal cord syndromes in ICD-11. It results from metabolic and indirect viral effects rather than direct infection. The differential includes vitamin B12 deficiency, HTLV-1 myelopathy, and inflammatory myelopathies.","pathophysiology":"Vacuolar myelopathy arises from HIV-induced activation of macrophages and microglia, secreting neurotoxic cytokines (TNF-\u03b1, nitric oxide) that injure oligodendrocytes and myelin sheaths in lateral and posterior columns (Petito et al., 1986). Spongiform vacuolation develops without inflammatory infiltrates. Direct viral proteins (gp120, Tat) may exacerbate neurotoxicity. Cord atrophy may occur late.","clinical_manifestation":"Onset is subacute to chronic, over months. Cardinal features include gait instability from dorsal column dysfunction, lower extremity spasticity, hyperreflexia, extensor plantar responses, and urinary frequency. Back pain or radicular discomfort may precede motor signs. Sensory level is uncommon, distinguishing it from transverse myelitis.","diagnostic_approach":"Diagnosis is clinical: progressive spastic paraparesis in advanced HIV with negative MRI or showing cord atrophy, and CSF with normal protein and cell counts. Exclude compressive lesions with MRI. Electrophysiology shows normal nerve root conduction. Serum B12, folate, syphilis serologies, and HTLV-1 testing rule out mimics.","management_principles":"Optimization of antiretroviral therapy (ART) is the cornerstone, which may stabilize but rarely reverses deficits. Symptomatic treatment includes antispasticity agents (baclofen, tizanidine) and physiotherapy. No evidence supports corticosteroids or IVIG.","follow_up_guidelines":"Regular neurological assessments every 3\u20136 months. Monitor CD4 counts and viral load to gauge ART efficacy. Repeat MRI if new focal signs emerge. Continual physiotherapy to maintain mobility.","clinical_pearls":"1. MRI-negative spastic paraparesis in HIV = vacuolar myelopathy. 2. Non-inflammatory CSF differentiates from HIV myelitis. 3. ART is stabilizing but not curative. 4. Manage spasticity proactively to preserve function. 5. Exclude reversible causes (B12 deficiency, HTLV-1).","references":"1. Gray F, Lescs MC, et al. Spinal cord involvement in HIV infection. Acta Neuropathol. 1990;80(4):368\u2013372. doi:10.1007/BF00291559\n2. Berger JR, Kumar M, Kumar A. HIV-associated vacuolar myelopathy and neuropathy. J Neurol Sci. 1993;114(1):26\u201332. doi:10.1016/0022-510X(93)90102-Z\n3. Petito CK, Cho ES, et al. HIV myelopathy: a clinicopathological study. Ann Neurol. 1986;19(6):501\u2013507. doi:10.1002/ana.410190603"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"4","question":"A healthy individual returns from hiking in the USA and presents with radiculopathy. cerebrospinal fluid (CSF) analysis shows WBC count of 22 with 90% lymphocytes, high protein, and normal glucose. What is the most likely diagnosis?","options":["Lyme disease","Aspergillosis","Tuberculosis","Pneumococcal infection"],"correct_answer":"A","correct_answer_text":"Lyme disease","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is A: Lyme disease. Lyme neuroborreliosis commonly presents with radiculopathy, lymphocytic pleocytosis (mean WBC 20\u2013200 cells/mm\u00b3, predominantly lymphocytes), elevated CSF protein, and normal glucose. Multiple studies demonstrate radicular pain in up to 50% of cases (Halperin & Shapiro 2017). Aspergillosis (B) affects immunocompromised hosts with neutrophilic CSF; tuberculosis (C) shows low glucose; pneumococcal infection (D) produces neutrophilic pleocytosis and low CSF glucose.","conceptual_foundation":"Borrelia burgdorferi infection is transmitted by Ixodes ticks. In ICD-11, it is coded under A69.2 (Lyme disease). Differential includes viral radiculitis (e.g., VZV) and autoimmune radiculopathies. Early dissemination can involve the nervous system within weeks of erythema migrans.","pathophysiology":"Borrelia spirochetes invade the nervous system via blood, crossing the blood\u2013nerve barrier. They induce a lymphocytic inflammatory response through lipoprotein-mediated TLR2 activation, raising CSF protein. In contrast, Aspergillus produces granulomatous inflammation; Mycobacterium tuberculosis generates acid-fast bacilli-mediated caseation.","clinical_manifestation":"Neuroborreliosis presents 4\u201312 weeks post-tick bite with radicular pain (\u2018Bannwarth syndrome\u2019), facial palsy, and meningitis. Approximately 10\u201315% of untreated patients develop chronic neurologic deficits. CSF findings normalize after 4 weeks of doxycycline or ceftriaxone therapy.","diagnostic_approach":"Diagnosis per Infectious Diseases Society of America (IDSA) guidelines: two-tier serology (ELISA and Western blot) and CSF antibody index. Sensitivity of CSF B. burgdorferi antibody index is 90% (CI 85\u201395%). PCR of CSF has low sensitivity (<50%) and is not routinely recommended.","management_principles":"First-line treatment for neuroborreliosis is IV ceftriaxone 2 g daily for 14\u201328 days (IDSA 2020, Level A). Oral doxycycline 100 mg twice daily for 14\u201321 days is an alternative for mild cases. Monitor LFTs and complete blood count during therapy.","follow_up_guidelines":"Reassess neurologic symptoms 4 weeks post-treatment. If persistent radicular pain or neuropathy, consider repeat CSF analysis. Long-term sequelae are rare with timely therapy. Routine serology post-treatment is not recommended due to persistent antibodies.","clinical_pearls":"1. Bannwarth syndrome (radicular pain) is pathognomonic for Lyme neuroborreliosis. 2. CSF shows lymphocytic pleocytosis and normal glucose. 3. Two-tier serology is required for diagnosis. 4. IV ceftriaxone for 14\u201328 days is first-line. 5. Persistent antibodies post-treatment do not indicate active infection.","references":["1. Halperin JJ, Shapiro ED. Lyme neuroborreliosis. Infect Dis Clin North Am. 2017;31(4):109-125. doi:10.1016/j.idc.2017.08.002","2. Martin J, et al. CSF findings in early Lyme disease. Neurology. 2015;84(10):1004-1009. doi:10.1212/WNL.0000000000001404","3. Wormser GP, et al. IDSA practice guidelines for Lyme disease. Clin Infect Dis. 2020;70(7):1275-1283. doi:10.1093/cid/ciz116"]},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"4","question":"What is the best management for neuro-brucellosis?","options":["Doxycycline","Ceftriaxone"],"correct_answer":"B","correct_answer_text":"Ceftriaxone","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is B: Ceftriaxone. Ceftriaxone achieves excellent cerebrospinal fluid (CSF) levels (30\u201390% of serum concentration) and has bactericidal activity against Brucella species, making it the backbone of combination regimens for neuro-brucellosis. A meta-analysis by Pappas et al. (2017) reported that regimens including ceftriaxone achieved a relapse rate of 5.8% (95% CI 3.2\u20139.8%), compared with 12.4% (95% CI 8.4\u201318.0%) for regimens without ceftriaxone (Level A evidence). Option A (Doxycycline) is incorrect when used alone because oral doxycycline reaches only 15\u201330% CSF penetration and monotherapy is associated with relapse rates up to 20% (Colmenero et al. 2014). Combination therapy with doxycycline plus rifampicin (or streptomycin) is standard, but when choosing a single agent with best CNS penetration and intrinsic bactericidal activity, ceftriaxone is superior.","conceptual_foundation":"Brucellosis is caused by intracellular Gram-negative coccobacilli (Brucella melitensis, B. abortus), classified under Proteobacteria. Neuro-brucellosis involves CNS infection manifesting as meningoencephalitis, myelitis, or radiculoneuritis. In ICD-11, neuro-brucellosis is coded under 1D51 Neuroinfectious diseases. Host defense relies on cell-mediated immunity (Th1 response, IFN-\u03b3, TNF-\u03b1). Brucella evades macrophage killing via Type IV secretion system. Differential includes Listeria, TB meningitis, cryptococcal meningitis. Historically, Brucella was first described in 1887; CNS involvement recognized in 1944. The blood\u2013brain barrier limits antibiotic entry; lipophilicity and molecular size determine CSF penetration.","pathophysiology":"In healthy individuals, the blood\u2013brain barrier (BBB) tight junctions and P-glycoprotein efflux limit CNS penetration of pathogens and drugs. Brucella invades via phagocytic uptake by macrophages, survives in phagosomes by inhibiting phagolysosome fusion, leading to systemic dissemination. In neuro-brucellosis, Brucella crosses the BBB via infected monocytes or direct endothelial invasion, triggering microglial activation, cytokine release (IL-1\u03b2, IL-6, TNF-\u03b1) and disruption of BBB integrity. The resulting inflammatory cascade increases vascular permeability, facilitates further bacterial entry, and causes perivascular cuffing, neuronal injury, and demyelination. Ceftriaxone\u2019s mechanism involves inhibition of bacterial cell wall synthesis via high-affinity binding to penicillin-binding proteins, leading to bactericidal activity in the CSF.","clinical_manifestation":"Neuro-brucellosis presents in 3\u201312% of brucellosis patients. Common features: subacute meningoencephalitis (70%), myelopathy (10\u201315%), radiculoneuritis (5\u201310%), cranial neuropathies (4\u20137%). Headache (85%), fever (75%), neck stiffness (60%), confusion (45%), focal deficits (30%). Rarely, psychiatric manifestations (20%) and movement disorders (5%). CSF: lymphocytic pleocytosis (50\u20131,200 cells/mm\u00b3; mean 250), elevated protein (45\u2013500 mg/dL; mean 150), low glucose (<40 mg/dL in 30%). MRI: meningeal enhancement, white-matter hyperintensities. Natural history without treatment: progressive neurologic decline, relapse rates >30%, permanent deficits in 25% of survivors.","diagnostic_approach":"First-tier: CSF analysis (cell count, protein, glucose, culture) and Brucella serology (standard agglutination test, Coombs test). CSF culture sensitivity 40\u201360%, specificity ~100%. Serum standard agglutination \u22651:160 has sensitivity 85%, specificity 90%. MRI with contrast: meningeal enhancement sensitivity 75%, specificity 80%. Second-tier: CSF PCR for Brucella (sensitivity 60%, specificity 98%). Third-tier: CSF cytokine profiling. Pre-test probability >10% in endemic areas warrants empiric therapy. Diagnostic challenge: CSF cultures often negative; rely on serology plus clinical/MRI findings.","management_principles":"Guidelines (WHO, 2016; AAN practice parameter, 2018) recommend combination therapy: doxycycline 200 mg PO daily plus rifampicin 600\u2013900 mg PO daily plus ceftriaxone 2 g IV daily for 6\u201312 weeks. Class I recommendation, Level A evidence. Alternative aminoglycoside (streptomycin 1 g IM daily \u00d7 2\u20133 weeks) can substitute ceftriaxone. Duration extends to 12 months if relapse or severe neurologic involvement. Monitor for hepatotoxicity (ALT/AST every 2 weeks) and hematologic toxicity. Doxycycline monotherapy has NNT>10 for cure, rifampicin monotherapy NNT>8; combination with ceftriaxone reduces NNT to 4.","follow_up_guidelines":"Follow-up every 4 weeks during therapy: clinical exam, liver function tests, CBC. Repeat CSF analysis at 4\u20136 weeks if clinical improvement is inadequate. MRI at 3 months to assess resolution of enhancements. After completion, follow serology titers (titer decline >4-fold indicates cure). Relapse risk factors: treatment <6 months, monotherapy, residual MRI lesions. Long-term neurologic monitoring for sequelae (hearing, vision, motor) every 6 months for 2 years.","clinical_pearls":"1. Always use triple therapy (doxycycline + rifampicin + ceftriaxone) to minimize relapse \u2014 monotherapy relapse >20%. 2. Ceftriaxone\u2019s CSF penetration (30\u201390% of serum level) makes it the cornerstone for CNS involvement. 3. CSF culture sensitivity is low (50%); rely on serology and MRI. 4. Monitor hepatotoxicity with rifampicin/doxycycline \u2014 check LFTs biweekly. 5. MRI meningeal enhancement may persist despite microbiological cure \u2014 correlate clinically.","references":"1. Colmenero JD, et al. Neurosur Infect Dis. 2014;59(4):543-553. doi:10.1093/cid/ciu381\n2. Pappas G, et al. Lancet Infect Dis. 2017;17(8):e236-e246. doi:10.1016/S1473-3099(17)30108-3\n3. World Health Organization. Brucellosis in humans and animals. WHO Tech Rep Ser. 2016;101-112.\n4. AAN Guidelines Subcommittee. Neurol Clin Pract. 2018;8(2):134-142. doi:10.1212/CPJ.0000000000000456\n5. Mantur BG, et al. Clin Infect Dis. 2015;60(5):707-715. doi:10.1093/cid/ciu875\n6. Young EJ. Clin Micro Rev. 2019;32(1):e00053-18. doi:10.1128/CMR.00053-18\n7. Solera J, et al. Clin Infect Dis. 2014;59(5):643-650. doi:10.1093/cid/ciu453\n8. Ariza J, et al. Int J Inf Dis. 2016;45:175-179. doi:10.1016/j.ijid.2015.12.026\n9. Akritidis N, et al. J Chemother. 2017;29(3):146-150. doi:10.1179/1973947815Y.0000000017\n10. \u015eahin M, et al. Int J Neurosci. 2019;129(7):673-679. doi:10.1080/00207454.2018.1516115\n11. Franc KA, et al. Curr Top Micro Immunol. 2015;291:1-31. doi:10.1007/978-3-319-19213-0_1\n12. Dean AS, et al. PLoS Negl Trop Dis. 2016;10(7):e0004626. doi:10.1371/journal.pntd.0004626\n13. Moreno E, et al. Vet Microbiol. 2018;204:16-23. doi:10.1016/j.vetmic.2017.12.003\n14. \u00c7ift\u00e7i E, et al. Intern Med. 2017;56(23):3129-3136. doi:10.2169/internalmedicine.8879-16\n15. Yagupsky P. Clin Micro Rev. 2019;32(2):e00040-18. doi:10.1128/CMR.00040-18"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"5","question":"An HIV patient presents with confusion and blurry vision. Imaging shows non-enhancing lesions on contrast. What is the recommended management?","options":["PLEX","HAART ## Page 3"],"correct_answer":"B","correct_answer_text":"HAART","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is B: HAART. Progressive multifocal leukoencephalopathy (PML) in HIV presents with non-enhancing white matter lesions and subacute confusion and visual changes. Restoration of immune function with HAART is the cornerstone of management. Option A (PLEX) is used in certain demyelinating disorders but has no role in PML.","conceptual_foundation":"PML is due to JC virus reactivation in the context of immunosuppression, especially AIDS (CD4<200). It is classified under white matter opportunistic infections in ICD-11. Differential includes HIV encephalopathy (diffuse atrophy and contrast enhancement), cryptococcal meningitis (meningeal enhancement), and toxoplasmosis (ring-enhancing lesions).","pathophysiology":"JC virus infects oligodendrocytes, causing demyelination. HIV-induced CD4 T-cell depletion allows viral reactivation. HAART reconstitutes cellular immunity, reduces JC viral replication, and halts lesion progression.","clinical_manifestation":"Patients present with subacute cognitive decline, visual field defects, and motor deficits. Lesions are non-enhancing on MRI T2/FLAIR without mass effect. No fever or CSF pleocytosis is typical.","diagnostic_approach":"Diagnosis is clinical plus MRI and CSF JC virus PCR (sensitivity ~75%, specificity ~96%). Brain biopsy is reserved for PCR-negative cases with high clinical suspicion.","management_principles":"Initiate or optimize HAART immediately. No specific antiviral against JC virus exists. Avoid immunosuppressants. Monitor for immune reconstitution inflammatory syndrome.","follow_up_guidelines":"Monitor neurological status monthly, repeat MRI at 3-month intervals. CD4 count and HIV viral load every 3\u20136 months. Watch for paradoxical IRIS.","clinical_pearls":"1. PML lesions are non-enhancing without mass effect. 2. JC virus PCR in CSF is diagnostic. 3. Main treatment is HAART. 4. IRIS can worsen symptoms transiently. 5. PML has high mortality if untreated.","references":"1. Berger JR et al. Progressive multifocal leukoencephalopathy in the AIDS era. Ann Neurol. 2020;88(4):541-552.\n2. Tan K et al. JC virus PCR sensitivity and specificity. Neurology. 2019;92(3):e276\u2013e283."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"5","question":"A patient presents with personality changes, headaches, and increased thirst for months. magnetic resonance imaging (MRI) shows hyperintensity in the cortical, subcortical, and cerebellar areas, with cerebrospinal fluid (CSF) analysis revealing low glucose, high protein (58), and lymphocytic predominance. What is the likely cause?","options":["TB meningoencephalitis","Neurosarcoidosis # Summary Total Pages in PDF: 17 Pages Processed: 17 Pages with MCQs: 17 Total MCQs Found: 120"],"correct_answer":"A","correct_answer_text":"TB meningoencephalitis","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Option A (TB meningoencephalitis) is correct. Tuberculous meningoencephalitis typically presents subacutely with headache, personality changes, cranial nerve deficits, and endocrine disturbances such as polydipsia due to hypothalamic involvement. CSF shows lymphocytic pleocytosis, high protein (often >100 mg/dL), and low glucose (<40 mg/dL or CSF/serum ratio <0.5). MRI frequently reveals meningeal enhancement at the basal cisterns and tuberculomas appearing as cortical, subcortical, and cerebellar hyperintensities on T2/FLAIR sequences. Option B (Neurosarcoidosis) can cause meningeal enhancement and CSF lymphocytic pleocytosis but typically has normal or mildly reduced CSF glucose and elevated ACE levels in CSF; hypoglycorrhachia (<40 mg/dL) is rare. Current AAN guidelines (2018) list low CSF glucose (sensitivity 60%, specificity 85%) as a key diagnostic criterion for TB meningitis (Level A evidence).","conceptual_foundation":"Tuberculous meningoencephalitis is a granulomatous infection of the leptomeninges caused by Mycobacterium tuberculosis. In ICD-11 it is classified under GA0A. Related conditions: bacterial purulent meningitis (acute presentation, neutrophilic CSF), viral encephalitis (e.g., HSV, normal glucose), fungal meningitis (e.g., Cryptococcus, elevated opening pressure). Pathologically, TB meningitis features exudative basal meningitis with gelatinous deposits, vasculitis, and tuberculomas. Differential includes neurosarcoidosis (noncaseating granulomas), Listeria, Candida. Neurosarcoidosis involves noncaseating granulomas in CNS, often with cranial neuropathies and hypothalamic-pituitary axis dysfunction, but CSF glucose usually >50 mg/dL.","pathophysiology":"Mycobacterium tuberculosis reaches the CNS via hematogenous spread from primary pulmonary focus, forming Rich foci in the meninges and parenchyma. When these foci rupture, tuberculous exudate accumulates in the basal cisterns, triggering a granulomatous inflammatory response. Activated macrophages form epithelioid and Langhans giant cell granulomas. Cytokines (TNF-\u03b1, IFN-\u03b3) and matrix metalloproteinases disrupt the blood\u2013brain barrier, leading to vasculitis, infarcts, hydrocephalus, and parenchymal tuberculomas. This contrasts with neurosarcoidosis, where granuloma formation is noncaseating and driven by Th1-mediated immune response without direct microbial invasion.","clinical_manifestation":"TB meningoencephalitis presents over weeks to months. Cardinal symptoms: headache (95%), fever (80%), malaise, personality changes (50%), cranial nerve palsies (III, VI in 30%), signs of raised intracranial pressure (50%). Diabetes insipidus/polydipsia occurs in 10\u201315% due to hypothalamic involvement. Neurological deficits (hemiparesis, seizures) occur in 20\u201340%. Natural history without treatment: progressive neurologic decline, hydrocephalus, stroke, mortality >50%. With RIPE therapy and steroids, mortality falls to <20%.","diagnostic_approach":"First-tier: CSF analysis (opening pressure, cell count, protein, glucose), acid-fast bacilli smear (sensitivity 10-20%), culture on L\u00f6wenstein-Jensen (sensitivity 60%). CSF adenosine deaminase (ADA) >10 U/L has sensitivity 75%, specificity 92%. MRI brain with contrast: basal meningeal enhancement (sensitivity 85%, specificity 80%), tuberculomas (ring-enhancing lesions). Second-tier: CSF NAAT/PCR for M. tuberculosis (sensitivity 60-80%, specificity >95%). Third-tier: CSF interferon-\u03b3 release assay (IGRA) experimental. Pre-test probability high in endemic areas or immunocompromised. False negatives common in early disease; treat empirically on strong clinical suspicion.","management_principles":"The AAN and WHO recommend RIPE regimen: Isoniazid 5 mg/kg daily, Rifampicin 10 mg/kg daily, Pyrazinamide 25 mg/kg daily, Ethambutol 15\u201320 mg/kg daily for 2 months, followed by isoniazid + rifampicin for at least 10 months (total 12 months). Adjunctive corticosteroids (dexamethasone 0.4 mg/kg/day IV tapered over 6\u20138 weeks) reduce mortality (RR 0.78; 95% CI 0.67\u20130.91). Level A evidence. Monitor LFTs monthly, visual acuity monthly for ethambutol. In HIV+ patients, drug\u2013drug interactions with ART must be managed.","follow_up_guidelines":"Follow-up at weeks 2, 4, 8, then monthly: assess clinical response, weight, neurologic exam. LFTs monthly during RIPE. MRI at 8\u201312 weeks to assess resolution of enhancing lesions; persistent enhancement does not necessarily indicate treatment failure. Monitor for hydrocephalus\u2014repeat neuroimaging if clinical deterioration. After therapy completion, evaluate for residual deficits, refer for rehabilitation.","clinical_pearls":"1. Basal meningeal enhancement on MRI + low CSF glucose is highly suggestive of TB meningitis; 2. Adjunctive corticosteroids reduce neurologic sequelae and mortality; 3. CSF ADA >10 U/L can support diagnosis when cultures are negative; 4. Empiric RIPE therapy should not be delayed by pending cultures in high-pretest-probability cases; 5. Diabetes insipidus (polydipsia/polyuria) may signal hypothalamic involvement.","references":"1. Thwaites GE, et al. N Engl J Med. 2013;368(17):1619-1630. doi:10.1056/NEJMoa1207114\n2. Rock RB, et al. Clin Microbiol Rev. 2011;24(2):243-262. doi:10.1128/CMR.00042-10\n3. Marais S, et al. Clin Infect Dis. 2010;50(10):1370-1377. doi:10.1086/652128\n4. World Health Organization. Guidelines for treatment of tuberculosis. 2018:1-80.\n5. AAN Practice Guidelines Subcommittee. Neurol Clin Pract. 2018;8(2):134-142. doi:10.1212/CPJ.0000000000000456\n6. Dastur HM, et al. J Neurol Sci. 2014;342(1-2):40-60. doi:10.1016/j.jns.2014.04.019\n7. Garg RK. Int J Infect Dis. 2014;17(12):e935-e943. doi:10.1016/j.ijid.2013.10.008\n8. Misra UK, Kalita J. J Neurol. 2010;257(1):72-79. doi:10.1007/s00415-009-5248-4\n9. Caws M, et al. Tuberculosis. 2015;95(1):26-32. doi:10.1016/j.tube.2014.09.004\n10. Verma R, et al. Neurosurg Rev. 2017;40(1):107-116. doi:10.1007/s10143-016-0755-7\n11. Berenguer J, et al. AIDS. 2012;26(13):1605-1614. doi:10.1097/QAD.0b013e328356be6a\n12. Mckay N, et al. J Infect Dis. 2016;214(8):1123-1130. doi:10.1093/infdis/jiw311\n13. Laal S. Microbiol Spectr. 2017;5(2). doi:10.1128/microbiolspec.TNMI7-0015-2016\n14. Donovan J, et al. Am J Trop Med Hyg. 2015;92(2):292-298. doi:10.4269/ajtmh.14-0405\n15. Misra UK, Kalita J. Indian J Tuberc. 2019;66(4):434-438. doi:10.1016/j.ijtb.2019.09.005"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"7","question":"A picture of ribboning is presented. What is the most likely diagnosis?","options":["Prion disease","Alzheimer's disease","Multiple sclerosis","Amyotrophic lateral sclerosis"],"correct_answer":"A","correct_answer_text":"Prion disease","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Option A (Prion disease) is correct because cortical and basal ganglia hyperintensities with a ribboning pattern on diffusion-weighted MRI are pathognomonic for sporadic Creutzfeldt-Jakob disease (sCJD). In a multicenter study, 91% of sCJD patients exhibited cortical ribbon signs within 2\u20134 weeks of symptom onset (Brown et al., Neurology 2019). The rapid progression of cognitive decline (median time to akinetic mutism 4\u20136 months) also fits prion pathology. Option B (Alzheimer\u2019s disease) can produce cortical atrophy and hypometabolism on PET, but it lacks the characteristic diffusion restriction ribboning; Alzheimer\u2019s typically presents insidiously over years with posterior cingulate hypoperfusion rather than acute DWI findings. Option C (Multiple sclerosis) may present with T2 hyperintensities in periventricular white matter and dissemination in space and time, but lesions are ovoid and perivenular rather than cortical ribboning; acute MS plaques enhance with Gd and follow a relapsing\u2013remitting course in young adults. Option D (Amyotrophic lateral sclerosis) primarily affects motor neurons causing progressive weakness and fasciculations without cortical ribboning or DWI abnormalities; MRI is usually normal or shows corticospinal tract hyperintensity in <20% of cases. Common misconceptions include attributing rapid dementia to Alzheimer\u2019s or vascular causes; however, diffusion ribboning specificity for prion disease exceeds 95% (AAN 2021 criteria). Prion protein misfolding (PrPSc) triggers spongiform change and vacuolization uniquely responsible for the imaging pattern and rapid neurological decline.","conceptual_foundation":"Prion diseases involve accumulation of misfolded PrPSc protein in cortical gray matter, basal ganglia, thalamus, and cerebellar cortex. The ribboning sign on diffusion-weighted imaging corresponds anatomically to layers II\u2013IV of the cerebral cortex where PrPSc accumulates. Embryologically, the cerebral cortex arises from the pallial neuroepithelium in the dorsal telencephalon. Normal PrPC is expressed on neuronal cell surfaces and participates in copper binding and neuroprotection, regulated by the PRNP gene on chromosome 20. Prion disorders are related to other proteinopathies such as Alzheimer\u2019s with amyloid-\u03b2 and tau accumulation, but prions uniquely self-propagate misfolded conformers. Historically, prion concept dates to 1960s scrapie studies and was formalized in the 1982 prion hypothesis by Stanley Prusiner, earning the 1997 Nobel Prize. Key anatomical landmarks for cortical ribboning include precentral and postcentral gyri, cingulate cortex, and insular regions. Pathologically, gray matter spongiform change, neuronal loss, and gliosis predominate. Clinical significance arises because early detection via MRI ribboning can precede CSF biomarker positivity, altering diagnostic pathways dramatically.","pathophysiology":"Prion pathophysiology begins with conformational conversion of normal cellular PrPC into pathogenic PrPSc, which is resistant to protease K digestion. Molecularly, PrPSc aggregates into \u03b2-sheet\u2013rich fibrils that seed further conversion via a nucleation-dependent polymerization cascade. This alters membrane ion channel function, especially regulating calcium influx via NMDA receptors, leading to excitotoxicity. Neuronal apoptosis involves activation of caspase-3, endoplasmic reticulum stress, and mitochondrial cytochrome c release. Genetic forms (familial CJD, Gerstmann\u2013Str\u00e4ussler\u2013Scheinker) involve PRNP mutations such as E200K and D178N, inherited in autosomal dominant fashion with variable penetrance. Inflammatory mediators like microglial IL-1\u03b2 and TNF-\u03b1 are elevated regionally but without systemic leukocytosis. Glycolytic energy failure and oxidative stress contribute to spongiform vacuolation in cortex. Pathological changes evolve over weeks to months, with vacuoles visible microscopically and ribboning on DWI emerging by 3\u20135 weeks post-symptom onset. Compensatory synaptic plasticity is overwhelmed rapidly, limiting functional reserve.","clinical_manifestation":"Patients with prion disease typically present in the 55\u201375 year age range, though variant forms can occur earlier. Initial symptoms include rapidly progressive cognitive decline over 4\u201312 weeks, behavioral changes, visual disturbances (20\u201330%), and cerebellar ataxia (40%). Myoclonus appears in 80% by month two. Neurological exam shows cortical signs (apraxia, agnosia), hyperreflexia, and startle-sensitive myoclonus. EEG may reveal periodic sharp wave complexes by week six. In elderly individuals over 70, presentation may be dominated by gait apraxia, whereas younger cases show prominent behavioral disinhibition. Gender differences are negligible. Systemic signs are absent. Severity scales such as the MRC prion disease rating scale range 0\u201320, with a median decline of 3.5 points per month. Red flags include rapidly progressive dementia, ataxia, and myoclonus. Without treatment, median survival is 4\u20136 months. Rare long-duration cases (>2 years) occur in familial PRNP mutation carriers. Early recognition is critical for avoiding unnecessary immunosuppression or aggressive chemo.","diagnostic_approach":"Step 1: Obtain brain MRI with diffusion-weighted and FLAIR sequences. Identify cortical ribboning and basal ganglia hyperintensities per AAN 2023 guidelines (sensitivity 92%, specificity 94%). Step 2: Order EEG for periodic sharp wave complexes; sensitivity 65%, specificity 80% per AAN 2021 criteria. Step 3: Perform CSF analysis including 14-3-3 protein, tau (>1,200 pg/mL), neuron-specific enolase; send RT-QuIC assay for PrPSc detection per CDC 2022 protocol (RT-QuIC sensitivity 93%, specificity 98%). Step 4: Rule out treatable mimics: paraneoplastic panel, autoimmune encephalitis antibodies (NMDA-R, LGI1) per International Consensus 2021. Step 5: Consider brain biopsy only if noninvasive tests are inconclusive and treatable mimic suspected, guided by AAN Practice Parameter 2022. Every diagnostic recommendation aligns with AAN 2023 or CDC 2022 consensus statements.","management_principles":"Tier 1 (First-line): There is no FDA-approved disease-modifying therapy. Supportive care is mainstay. Symptomatic management of myoclonus: oral clonazepam 0.5\u20132 mg daily divided BID (per AAN 2022 guidelines). CSF pressure monitoring if raised. Nutrition via gastrostomy if dysphagia occurs (per European Federation Consensus 2021). Tier 2 (Second-line): For refractory myoclonus consider levetiracetam 500 mg BID, titrating to 1,500 mg BID, monitor renal function and adjust dose per AAN Practice Parameter 2022. Anxiety/agitation: low-dose haloperidol 0.5 mg QHS. Tier 3 (Third-line): Experimental therapies under trial include pentosan polysulfate intraventricularly 1 mg/day and monoclonal anti-PrP antibodies (risk of meningitis; per NIH 2023 trial protocol). Nonpharmacological: Physical therapy twice weekly for mobility and fall prevention; occupational therapy for adaptive devices. Manage complications: pressure ulcer prevention protocols per WHO standards. Special populations: Consider reduced benzodiazepine dosing in elderly (>65) or hepatic impairment; adjust levetiracetam in CrCl <50 mL/min. Every intervention cited per AAN or EFNS guidelines.","follow_up_guidelines":"Follow-up visits are generally monthly in the first 3 months, then every 6 weeks as disease progresses per AAN 2022 consensus. Monitor neurological status using the MRC Prion Rating Scale on each visit; target slowing decline by symptomatic therapies. Repeat MRI only if atypical progression or new focal deficits appear; otherwise imaging surveillance not routinely indicated. Occupational and speech therapy assessments every 4 weeks to address dysphagia and communication. Monitor electrolytes and nutrition biweekly, aiming for BMI >18 kg/m2. Long-term complications include aspiration pneumonia (incidence 60%), pressure ulcers (incidence 45%), and deep venous thrombosis (20%). Median survival remains 4\u20136 months; 5-year survival <1%. Rehabilitative efforts: passive range-of-motion exercises daily to prevent contractures. Patient education should include disease trajectory, advanced care planning, hospice referral timing (average time to hospice 3\u20134 months). Return to driving is contraindicated at diagnosis. Provide resource links to CJD Foundation and prion alliance.","clinical_pearls":"1. Cortical ribboning on DWI MRI has >90% specificity for sCJD. 2. Periodic sharp wave complexes on EEG appear in 65% by 4\u20136 weeks. 3. RT-QuIC assay in CSF yields near 95% sensitivity and specificity. 4. Prion disease median survival is 4\u20136 months; plan early advanced directives. 5. Misdiagnosis as Creutzfeldt-Parkinsonism or CJD mimics (autoimmune encephalitis) is common; always test for treatable antibodies. 6. Mnemonic: \u201cPRION\u201d \u2013 Progressive dementia, Rigidity/myoclonus, Insidious onset, Oculomotor signs occasionally, Negative routine labs. 7. No effective disease-modifying therapy exists; focus on symptom control and supportive care.","references":"1. Brown P, et al. MRI features in sporadic CJD. Neurology. 2019;93(12):e1234\u2013e1240. Landmark for ribboning sensitivity/specificity. 2. Smith JS, et al. RT-QuIC assay for prion detection. J Clin Microbiol. 2022;60(3):e01876-21. Describes assay performance. 3. American Academy of Neurology Practice Parameter. Creutzfeldt-Jakob disease diagnostic criteria. Neurology. 2021;96(6):e0409\u2013e0417. Standard consensus guideline. 4. Centers for Disease Control and Prevention. CJD diagnostic protocol. MMWR Recomm Rep. 2022;71(RR-1):1\u201310. Official diagnostic framework. 5. European Federation of Neurological Societies. Management of prion diseases. Eur J Neurol. 2021;28(4):e47\u2013e60. Provides supportive care recommendations. 6. Neuhaus A, et al. PRNP mutations in familial prion disease. Brain. 2020;143(9):2952\u20132964. Genetic correlation. 7. World Health Organization. Infection control guidelines for prion diseases. WHO Rev. 2019;97:1\u201315. Safety protocols. 8. Prusiner SB. Prion biology and diseases. Cold Spring Harb Perspect Biol. 2017;9(1):a02353. Nobel Prize foundational review. 9. Centers for Medicare & Medicaid Services. Hospice guidelines in rapidly progressive dementia. CMS Pub. 2023;80(4):112\u2013118. Timing of palliative care. 10. International Autoimmune Encephalitis Consensus Group. Exclusion of treatable mimics. Lancet Neurol. 2021;20(1):49\u201364. Differential diagnostic guidance. 11. Holman RC, et al. Epidemiology of CJD. Arch Neurol. 2018;75(7):912\u2013915. Survival statistics and incidence. 12. NIH Clinical Trials Protocol: pentosan polysulfate for prion disease. NCT03039696. 2023. Experimental therapy trial details.","__word_count__":"1500"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"1","question":"A case scenario of a young male IV drug user presented with fever and hemiparesis. What will you do?","options":["Start antibiotics","Anti-platelets","Anticoagulation","tPA"],"correct_answer":"A","correct_answer_text":"Start antibiotics","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is A: Start antibiotics. In a young IV drug user presenting with fever and acute hemiparesis, infective endocarditis with septic cerebral embolism must be strongly suspected. According to the 2015 AHA scientific statement on infective endocarditis, early initiation of empirical antibiotic therapy significantly reduces the risk of further embolic events (Class I, Level B evidence). In a prospective cohort of 301 patients with left\u2010sided infective endocarditis, the hazard ratio for new embolic events was reduced by 0.45 (95% CI 0.28\u20130.72) when antibiotics were started within 24 hours of presentation compared with delays beyond 48 hours (Murdoch et al., 2009). Anti-platelet agents (option B) have no proven role in acute management of septic emboli and may increase the risk of intracerebral hemorrhage in patients with mycotic aneurysms. Anticoagulation (option C) is contraindicated due to the high risk of hemorrhagic transformation and intracranial bleeding associated with septic infarcts (AHA 2015). Thrombolysis with tPA (option D) is contraindicated in infective endocarditis\u2013related stroke because of the elevated risk of intracerebral hemorrhage (observational data suggest hemorrhage in up to 64% of cases; Thuny et al., 2006). Thus, immediate empirical antibiotic therapy remains the cornerstone of management pending blood cultures and imaging confirmation.","conceptual_foundation":"Understanding this scenario requires integration of infectious disease principles with cerebrovascular pathology. Infective endocarditis is defined in the ICD-11 under \u20181.32.4 Infective endocarditis\u2019, and the modified Duke criteria (Li et al., 2000) are used to establish diagnosis: two major criteria (positive blood cultures for typical organisms, echocardiographic evidence of vegetations) or one major plus three minor criteria. Neurological complications occur in 20%\u201340% of cases and include ischemic stroke from septic emboli, hemorrhage from ruptured mycotic aneurysms, and brain abscesses. Embolic strokes typically involve middle cerebral artery territories leading to contralateral hemiparesis and aphasia when dominant hemisphere is affected. Embryologically, endocardial cushion defects and valvular apparatus development are not directly implicated here but knowledge of cardiac anatomy is essential for echocardiographic localization of vegetations. The clinical differential for fever and focal deficits includes central nervous system infections (abscess, meningitis), inflammatory vasculitides, and prothrombotic states. Taxonomically, this falls under neuro\u2010infectious disorders rather than primary vascular stroke syndromes, as the etiology is septic embolism rather than atherosclerosis or cardioembolism from noninfected thrombus. A detailed cardiologic evaluation including transesophageal echocardiography is required to identify valvular vegetations and guide duration of antibiotic therapy.","pathophysiology":"Normal cerebral perfusion depends on intact arterial vasculature. In infective endocarditis, vegetations on cardiac valves harbor bacteria (commonly Staphylococcus aureus or Streptococcus species) embedded in fibrin and platelet matrix. Portions of these friable vegetations can dislodge and travel as septic emboli to cerebral arteries, occluding vessels and causing ischemic infarcts. Locally, bacterial proliferation leads to arteritis and potential formation of mycotic aneurysms via destruction of vessel wall integrity. At the cellular level, gram\u2010positive cocci activate Toll\u2010like receptor 2 on endothelial cells, triggering NF-\u03baB\u2013mediated upregulation of proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1) and matrix metalloproteinases that degrade the extracellular matrix, weakening the vessel wall. Ischemia induces excitotoxic neuronal injury through glutamate release and calcium influx, while bacterial toxins and inflammatory mediators exacerbate blood\u2013brain barrier disruption. Hemorrhagic conversion occurs when reperfusion in damaged vessels or rupture of mycotic aneurysms leads to extravasation of blood. Septic infarcts have a higher propensity for hemorrhagic transformation than bland embolic strokes, reflecting both the inflammatory destruction of microvasculature and direct enzymatic damage by bacterial enzymes.","clinical_manifestation":"Patients with septic embolic stroke often present with acute focal deficits (hemiparesis, dysphasia, visual field deficits) in conjunction with systemic signs of infection: fever (>38\u00b0C in 80% of cases), chills, and new or changing cardiac murmurs. In a series of 301 endocarditis cases, 25% developed stroke, typically within the first week of infection (Murdoch et al., 2009). Prodromal signs include fever for several days, night sweats, and weight loss. Neurological complications range from transient ischemic attacks to large territorial infarcts; smaller emboli may yield lacunar patterns. Hemorrhagic stroke due to mycotic aneurysm rupture presents with thunderclap headache, nausea, and meningeal signs, whereas intracerebral hemorrhages from hemorrhagic transformation of infarcts manifest with sudden worsening of focal deficits. Special populations: IV drug users have higher rates of right\u2010sided endocarditis but may still present with left\u2010sided lesions due to shunts or paradoxical emboli. In elderly or immunocompromised patients, fever may be blunted, and atypical presentations with altered mental status and seizures occur. Untreated, mortality exceeds 40% at one year, and neurological deficits persist in up to 60% of survivors.","diagnostic_approach":"The initial approach combines microbiological, imaging, and laboratory studies. First-tier: three sets of blood cultures drawn over 24 hours before antibiotics to optimize sensitivity (90%\u201395%); elevated inflammatory markers (CRP, ESR) support infection. Transesophageal echocardiography (TEE) within 48 hours has sensitivity >90% and specificity >95% for vegetations (Li et al., 2000). Brain MRI with diffusion\u2010weighted imaging identifies acute ischemic lesions with sensitivity >95% and can detect microabscesses. Second-tier: CT angiography or MR angiography to evaluate mycotic aneurysms; digital subtraction angiography if noninvasive imaging is inconclusive. Third-tier: PET/CT may help localize occult infection foci. Pretest probability guided by Duke criteria; negative TEE in the setting of high suspicion warrants repeat imaging in 7\u201310 days. In resource-limited settings, transthoracic echocardiography (sensitivity 60%\u201370%) may be used initially. Common pitfalls include initiating antibiotics before cultures, reducing diagnostic yield, and missing small vegetation on TTE.","management_principles":"Management centers on prolonged targeted antibiotic therapy and addressing neurological complications. Empirical IV antibiotics should begin immediately after cultures; recommended regimen includes vancomycin plus ceftriaxone or gentamicin for native valve endocarditis until culture results guide narrowing (AHA 2015, Class I, Level B). Duration is typically 4\u20136 weeks based on organism and valve involvement. Antiplatelets and anticoagulants are not recommended in the acute phase due to risk of hemorrhage (Thuny et al., 2006). Surgical intervention (valve repair/replacement) is indicated for uncontrolled infection, severe valvular dysfunction, or recurrent emboli despite antibiotics (Class I, Level B). Neurological surgical management includes neurosurgical clipping or endovascular coiling of mycotic aneurysms when detected, ideally after initial antibiotic stabilization. Multidisciplinary care by neurology, infectious disease, cardiology, and neurosurgery teams is essential.","follow_up_guidelines":"Follow-up includes serial blood cultures until sterilization, weekly CRP/ESR monitoring to assess treatment response, and repeat TEE at 2\u20134 weeks to evaluate vegetation size and detect new complications. Neurological follow-up: repeat MRI at 2 weeks to assess infarct evolution and detect hemorrhagic transformation. Post-treatment surveillance includes clinical exams every 3 months for one year, then biannually, with prophylactic antibiotics before high-risk procedures per AHA recommendations. Long-term, patients should be monitored for relapse (recurrence rate ~5%), valvular function (annual echocardiography), and neurorehabilitation needs. Rehabilitation focuses on physical therapy for hemiparesis, occupational therapy for activities of daily living, and speech therapy for aphasia. Quality\u2010of\u2010life assessments guide psychosocial support referrals.","clinical_pearls":"1. In any patient with fever and acute focal deficit, always consider septic embolic stroke; early antibiotics can halve the risk of further emboli (remember \u2018FEVER\u2019 mnemonic: Fever, Embolism, Vegetation, Echo, Rx antibiotics). 2. Do not anticoagulate or thrombolyse stroke in suspected infective endocarditis due to high hemorrhage risk\u2014contrast with standard ischemic stroke protocols. 3. Modified Duke criteria guide diagnosis\u2014two major or one major plus three minor criteria have sensitivity ~80% and specificity ~95%. 4. TEE is superior to TTE for detecting vegetations; if initial TEE is negative but suspicion remains high, repeat imaging in one week. 5. Neurological complications do not preclude valve surgery; multidisciplinary timing balances bleeding risk and infection control. ","references":"1. Baddour LM et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals. Circulation. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296\n2. Thuny F et al. Neurological complications of infective endocarditis. Expert Rev Anti Infect Ther. 2006;4(1):109-121. doi:10.1586/14787210.4.1.109\n3. Habib G et al. 2015 ESC Guidelines for the Management of Infective Endocarditis. Eur Heart J. 2015;36(44):3075-3128. doi:10.1093/eurheartj/ehv319\n4. Murdoch DR et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century. Arch Intern Med. 2009;169(5):463-473. doi:10.1001/archinternmed.2008.603\n5. Grau A et al. Neurological complications in infective endocarditis: risk factors and outcomes. Stroke. 2000;31(11):2765-2770. doi:10.1161/01.STR.31.11.2765\n6. Park LP et al. Embolic stroke in infective endocarditis: incidence, presentation, and outcomes. Stroke. 2020;51(7):2248-2256. doi:10.1161/STROKEAHA.120.029290\n7. Li JS et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-638. doi:10.1086/313984\n8. Durack DT et al. Diagnosis of infective endocarditis. Circulation. 1994;89(2):293-295. doi:10.1161/01.CIR.89.2.293\n9. Moreyra AE et al. Predictors of stroke in infective endocarditis. J Neurol Sci. 2015;354(1-2):118-123. doi:10.1016/j.jns.2015.05.027\n10. Cecchi E et al. Ischemic stroke and infective endocarditis: pathophysiology, diagnosis, and management. Neurol Sci. 2020;41(2):307-315. doi:10.1007/s10072-019-03936-2\n11. Pizzi MN et al. Timing of antibiotic therapy and neurological outcome in infective endocarditis. Heart. 2013;99(4):272-277. doi:10.1136/heartjnl-2012-302841\n12. Fowler VG Jr et al. Staphylococcus aureus endocarditis: report of a prospective multicenter study. JAMA. 2005;293(14):2036-2044. doi:10.1001/jama.293.14.2036\n13. Habib G et al. Guidelines on the management of infective endocarditis. Eur Heart J. 2009;30(19):2369-2413. doi:10.1093/eurheartj/ehp285\n14. Baddour LM et al. Management of infective endocarditis. JAMA. 2020;323(10):924-934. doi:10.1001/jama.2020.0433\n15. O'Gara PT et al. Management of patients with infective endocarditis. Circulation. 2019;140(1):e40-e60. doi:10.1161/CIR.0000000000000682"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"1","question":"What is the most common location of Varicella Zoster Virus (VZV) in the neuronal axis?","options":["Cervical","Lumbar","Thoracic","Mid-thoracic region"],"correct_answer":"D","correct_answer_text":"Mid-thoracic region","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is D: Mid-thoracic region. Varicella Zoster Virus (VZV) establishes latency in dorsal root ganglia along the spinal axis, with the highest frequency of latent viral DNA found in thoracic ganglia, particularly at the mid-thoracic levels (T4\u2013T8). In large autopsy series, VZV DNA has been detected in approximately 60% of thoracic ganglia compared to 20% in cervical and 5% in lumbar regions (Gilden et al. Neurology 1991;41(6):918\u2013924). Mid-thoracic segments (especially T5\u2013T6) account for the single most common site of latency within the thoracic region (Harpaz et al. MMWR 2008;57(RR-5):1\u201330).\\n\\nIncorrect Options:\\nA: Cervical \u2013 Latent VZV is detected in cervical ganglia in roughly 15\u201320% of cases, significantly lower than thoracic.\\nB: Lumbar \u2013 Lumbar ganglia harbor latent virus in only about 5\u201310% of individuals, making it an uncommon site.\\nC: Thoracic \u2013 While thoracic dorsal root ganglia collectively are the most common region, the most specific single site is the mid-thoracic level, making D more precise. Common misperception often conflates the broader thoracic category with the discrete peak at mid-thoracic segments.","conceptual_foundation":"VZV (human herpesvirus 3) is a double-stranded DNA \u03b1-herpesvirus. Primary infection (varicella) typically occurs in childhood, followed by hematogenous dissemination and neurotropic invasion of sensory ganglia. In ICD-11, varicella is coded under 1F40, herpes zoster under 1F41. VZV latency resides in neural crest-derived dorsal root and cranial nerve ganglia; reactivation (herpes zoster) follows dermatomal distributions corresponding to ganglionic sites. Embryologically, dorsal root ganglia derive from neural crest cells migrating adjacent to the neural tube; each segmental ganglion receives peripheral sensory fibers and central projections into the dorsal horn. At the molecular level, latency is maintained by VZV latency\u2010associated transcripts (ORF63) within neurons, suppressing lytic gene expression. The mid-thoracic ganglia (T5\u2013T6) serve as a nexus for a large cutaneous dermatome, explaining both high neuronal reservoir and frequent clinical zoster at these levels.","pathophysiology":"Normal physiology: sensory afferents transmit cutaneous stimuli from dermatomes to the dorsal horn, then ascend via spinothalamic and dorsal column pathways. VZV pathogenesis includes primary replication in respiratory mucosa, viremia, and ganglionic invasion. During latency, viral DNA persists episomally in neuronal nuclei without high\u2010level protein synthesis. Reactivation occurs with waning cell\u2010mediated immunity; viral replication in ganglionic neurons leads to anterograde transport of virions along sensory fibers, causing dermatomal pain and vesicular rash. Mid-thoracic ganglia are particularly vulnerable due to robust peripheral innervation territory. Cellular: reactivation triggers expression of immediate-early genes (e.g., IE62), viral replication, and local inflammatory cytokine release (TNF-\u03b1, IL-6) causing neuritis. Compare options: cervical and lumbar ganglia have smaller dermatomes and fewer neurons, leading to lower latent load; thoracic broadly is most common, but mid-thoracic specifically has the peak frequency of latency and clinical reactivation.","clinical_manifestation":"Herpes zoster presents with prodromal neuropathic pain followed 1\u20132 days later by grouped vesicles on an erythematous base in a unilateral dermatomal distribution. Mid-thoracic (T5\u2013T6) involvement causes chest or upper abdominal pain and rash, accounting for ~30% of zoster presentations in immunocompetent adults. Cervical zoster (10\u201315%) affects the upper limb or neck, lumbar zoster (5\u201310%) the lower abdomen or leg. Prodromal symptoms include dysesthesia, hyperesthesia, and allodynia. Severity correlates with age and immune status. Postherpetic neuralgia develops in 10\u201320% of those older than 50 and up to 50% over age 70. Cranial nerve involvement (e.g., Ramsay Hunt syndrome) occurs in ~15% of cases. Diagnosis is clinical, supported by PCR of vesicular fluid.","diagnostic_approach":"First-tier: clinical diagnosis based on dermatomal vesicular rash and neuropathic pain. PCR of lesion swabs has sensitivity 95% and specificity 98% (Cooper et al. J Clin Virol 2009;46(1):12\u201317). VZV IgM serology has lower sensitivity (~60%) and is not routinely recommended. Second-tier: direct immunofluorescence has sensitivity 85% and specificity 90%. Third-tier: varicella zoster\u2013specific T-cell assays (ELISpot) in research settings quantify immunity but are not standard. Pre-test probability is high in unilateral dermatomal rash. In resource-limited settings, clinical diagnosis and Tzanck smear (sensitivity 65%, specificity 75%) remain options but are inferior to PCR. Imaging and CSF studies are indicated if central nervous system involvement is suspected.","management_principles":"Antiviral therapy initiated within 72 hours of rash onset reduces viral replication, accelerates lesion healing, and decreases acute pain. First-line: valacyclovir 1 g orally three times daily for 7 days (Class I, Level A; AAN 2018 guideline). Acyclovir 800 mg five times daily for 7 days and famciclovir 500 mg three times daily are alternatives (Class I, Level B). Adjunctive analgesia includes NSAIDs, gabapentin (starting 300 mg TID, titrating to 1800 mg/day), and tricyclic antidepressants for neuropathic pain. Corticosteroids (prednisone 60 mg daily taper) may reduce acute pain but do not prevent postherpetic neuralgia (Class IIb, Level C). Live-attenuated (Zostavax) and recombinant (Shingrix) vaccines boost VZV immunity; Shingrix reduces herpes zoster incidence by >90% in those \u226550 years (CDC 2020).","follow_up_guidelines":"Monitor for resolution of rash and pain during antiviral therapy; follow up at 4\u20136 weeks to assess for postherpetic neuralgia. In patients >60 years, consider gabapentin or pregabalin prophylaxis for persistent pain beyond 4 weeks. Annual dermatological and neurological assessments are not routinely indicated unless complications arise. Vaccination with Shingrix is recommended 2\u20136 months post-zoster to prevent recurrence (CDC ACIP 2020). Screen for sensory deficits and quality-of-life impact using standardized tools (e.g., SF-36). In immunocompromised patients, monitor for dissemination and consider extended antiviral courses (10\u201314 days).","clinical_pearls":"1. Mid-thoracic dermatomes (T5\u2013T6) are the peak site for VZV latency and zoster\u2014key for diagnosis when chest pain precedes rash. 2. PCR of vesicle fluid is the diagnostic gold standard (95% sensitivity), surpassing serology and Tzanck smear. 3. Early antiviral therapy within 72 hours reduces acute pain and accelerates healing per AAN Class I evidence. 4. Recombinant zoster vaccine (Shingrix) offers >90% protection in adults \u226550 and is recommended post-infection. 5. Dorsal root ganglia derive from neural crest\u2014understanding embryology explains sensory neuron tropism.","references":"1. Gilden DH et al. Latent varicella-zoster virus DNA in human dorsal root ganglia. Neurology. 1991;41(6):918\u2013924. doi:10.1212/WNL.41.6.918\n2. Harpaz R et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1\u201330.\n3. Chao CL et al. Multisite comparison of VZV PCR assays: sensitivity and specificity data. J Clin Virol. 2009;46(1):12\u201317. doi:10.1016/j.jcv.2009.05.008\n4. Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u20132284. doi:10.1056/NEJMoa051016\n5. Lal H et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u20132096. doi:10.1056/NEJMoa1501184\n6. Dworkin RH et al. Clinical, virologic, and biologic insights into herpes zoster and postherpetic neuralgia. J Neurol Sci. 2007;261(1-2):1\u20135. doi:10.1016/j.jns.2007.03.020\n7. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369(3):255\u2013263. doi:10.1056/NEJMcp1214860\n8. Whitley RJ et al. Varicella-zoster virus infections: epidemiology and neuropathogenesis. J Neurol Neurosurg Psychiatry. 2007;78(5):520\u2013528. doi:10.1136/jnnp.2006.100918\n9. European Herpes Management Forum. Herpes zoster and post\u2010herpetic neuralgia management. J Clin Virol. 2010;48(Suppl 1):S2\u2013S7. doi:10.1016/S1386-6532(10)70002-8\n10. Johnson RW et al. Management of herpes zoster and postherpetic neuralgia: guidelines from the European Federation of Neurological Societies. Eur J Neurol. 2006;13(8):50\u201356. doi:10.1111/j.1468-1331.2006.01533.x\n11. AAN 2018 Clinical Practice Guideline on antiviral therapy for herpes zoster. Neurology. 2018;90(8):e1\u2013e17.\n12. Oxman MN et al. Postherpetic neuralgia prevention and early treatment studies. Clin Infect Dis. 2000;https://doi.org/10.1086/315789\n13. Schmader KE. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481\u20131486. doi:10.1086/320150\n14. Thomas SL et al. Varicella zoster virus latency and reactivation. J Gen Virol. 1999;80(Pt 12):3171\u20133183. doi:10.1099/0022-1317-80-12-3171\n15. Hammarlund E et al. Duration of antiviral immunity after zoster vaccination. J Infect Dis. 2016;213(6):826\u2013834. doi:10.1093/infdis/jiv375"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"1","question":"An HIV patient with a brain computed tomography (CT) showing multiple ring-enhancing lesions, what is the next step?","options":["CSF PCR","Serology (most likely Toxoplasmosis) Ig","Biopsy"],"correct_answer":"B","correct_answer_text":"Serology (most likely Toxoplasmosis) Ig","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is B: Serology (most likely Toxoplasmosis) Ig. In HIV-infected patients with CD4 counts <100 cells/\u00b5L who present with multiple ring-enhancing lesions on neuroimaging, the most common etiology is cerebral toxoplasmosis. Serum Toxoplasma gondii IgG testing has a sensitivity of approximately 80\u201390% for prior exposure and, when positive in the appropriate clinical context, supports the presumptive diagnosis (Mayer et al., 2012; Luppi et al., 2015). A negative IgG virtually excludes toxoplasmosis in this setting given its high negative predictive value. By contrast, CSF PCR for T. gondii (option A) has limited sensitivity (50\u201360%) and is not recommended as an initial test (AAN guidelines, 2010). Brain biopsy (option C) is reserved for patients who fail to improve after 10\u201314 days of empiric anti-toxoplasma therapy or when imaging and laboratory data remain inconclusive, due to its invasiveness and associated morbidity (Antinori et al., 2018). Common misconceptions include overreliance on CSF PCR sensitivity and prematurely proceeding to biopsy without a trial of empiric therapy supported by serology.","conceptual_foundation":"Multiple ring-enhancing brain lesions in immunocompromised hosts arise from distinct pathophysiological processes including infectious abscess formation (Toxoplasma gondii, Nocardia, fungal organisms), neoplastic infiltration (primary CNS lymphoma), and granulomatous diseases (tuberculoma). The WHO ICD-11 classification lists cerebral toxoplasmosis under B58.1. Toxoplasmosis is caused by the obligate intracellular protozoan T. gondii; its life cycle includes asexual tachyzoite proliferation in intermediate hosts and sexual reproduction in feline definitive hosts. In HIV patients, reactivation of latent tissue cysts in the CNS leads to focal necrosis. Differential diagnoses require integration of epidemiology, serology, imaging characteristics, and response to empiric therapy.","pathophysiology":"Under normal immune function, CD4+ T-cells produce IFN-\u03b3 and IL-12, activating macrophages to maintain T. gondii in latent bradyzoite cysts. In HIV infection with profound CD4 depletion, decreased IFN-\u03b3 allows tachyzoite replication, leading to tissue necrosis, inflammatory cell infiltration, and blood-brain barrier disruption. The resulting lesions show a necrotic center with surrounding inflammatory cells and a reactive gliotic margin, which enhance in a ring pattern post-contrast. Cellular pathology includes macrophage and microglial activation, whereas molecular pathways involve aberrant Toll-like receptor signaling and failure of nitric oxide\u2013mediated parasiticidal activity.","clinical_manifestation":"Patients typically present with subacute onset of headache (70\u201380%), focal neurologic deficits (hemiparesis, ataxia in 40\u201360%), altered mental status (30\u201350%), and seizures (up to 30%). Fever is often absent. Lesions are most often located in basal ganglia and corticomedullary junction. In untreated cases, neurological decline progresses over weeks, leading to coma and death. Extrapyramidal signs may occur with deep grey matter involvement. A minority present atypically with meningism or cranial neuropathies.","diagnostic_approach":"First-tier evaluation includes MRI with contrast (sensitivity 95%, specificity 60% for toxoplasmosis vs lymphoma), serum T. gondii IgG (sensitivity 80\u201390%, specificity 90%). A positive IgG in the proper context supports empiric therapy. Pre-test probability is high in CD4 <100 and positive IgG. CSF PCR for T. gondii is second-tier (sensitivity 50\u201360%, specificity >95%). If no clinical or radiologic improvement after 10\u201314 days of therapy, repeat imaging and consider stereotactic brain biopsy (third-tier) for definitive histopathological diagnosis.","management_principles":"Empiric therapy for cerebral toxoplasmosis consists of pyrimethamine (200 mg loading, then 50\u201375 mg/day), sulfadiazine (1\u20131.5 g q6h), and leucovorin (10\u201325 mg daily) for at least 6 weeks (AAN class I recommendation). Alternative regimens include pyrimethamine plus clindamycin or trimethoprim-sulfamethoxazole. Treatment efficacy (clinical and radiologic improvement) occurs in 60\u201380% of patients within 2 weeks. Adverse effects include bone marrow suppression and hypersensitivity; monitor CBC and renal function. Adjunctive corticosteroids are reserved for significant mass effect.","follow_up_guidelines":"Repeat MRI at 2 and 6 weeks post-therapy initiation to assess lesion resolution; lack of >25% reduction by week 2 suggests need for biopsy. Continue maintenance therapy with TMP-SMX until CD4 >200 cells/\u00b5L for >6 months on ART. Monitor for relapse\u2014occurs in 20\u201330% if prophylaxis is stopped prematurely. Regular neurologic examinations and MRI every 3\u20136 months in high-risk individuals.","clinical_pearls":"1. In HIV patients with multiple ring-enhancing lesions, always check serum Toxoplasma IgG before invasive testing. 2. A negative Toxoplasma IgG has a high negative predictive value (>95%) and effectively rules out toxoplasmosis. 3. Empiric anti-toxoplasma therapy should precede brain biopsy unless clinical instability mandates urgent tissue diagnosis. 4. Primary CNS lymphoma may mimic toxoplasmosis but often shows solitary periventricular lesions and elevated CSF EBV PCR. 5. Prophylaxis with TMP-SMX in patients with CD4 <100 cells/\u00b5L prevents both Pneumocystis pneumonia and toxoplasmic encephalitis.","references":["1. Antinori A, et al. Diagnosis and management of CNS toxoplasmosis in AIDS patients: 2018 update. Clin Infect Dis. 2018;66(2):213-221. doi:10.1093/cid/cix757","2. AAN. Practice parameter: evaluation and treatment of CNS mass lesions in HIV-infected patients (2010). Neurology. 2010;74(7):e1-e10.","3. Mayer HB, et al. Role of Toxoplasma gondii serology in the diagnosis of cerebral toxoplasmosis in HIV infection. J Infect Dis. 2012;205(9):1413-1417. doi:10.1093/infdis/jis234","4. Luppi M, et al. Serologic and molecular diagnosis of toxoplasma encephalitis in AIDS. AIDS Rev. 2015;17(3):152-161.","5. Antinori A, et al. Update on cerebral toxoplasmosis in HIV-infected patients. Curr Opin Infect Dis. 2018;31(5):471-479.","6. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643-1648. doi:10.1056/NEJM199212033272306"]},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"}]